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Development of Proteomics Approaches towards Characterizing Oxidative Modifications 
Liqing Gu, Ph.D. 
University of Pittsburgh, 2016 
Mass spectrometry (MS) is an analytical technique allowing the investigation of a single 
protein or the entire complement of proteins from biomatrices for understanding attributes such as 
sequences, modifications, structures, abundances and interactions. Protein oxidative modifications, 
such as carbonylation and cysteine reversible oxidations, have important roles in physiological 
processes, including redox signaling, homeostasis, enzymatic catalysis and protein degradation. 
MS-based redox proteomics can identify and quantify oxidized protein modifications within the 
proteome. However it is challenging to globally investigate cysteine reversible modifications, due 
to the low abundance (~ < 1%) and diversity (e.g., S-nitrosylation, S-glutathionylation, sulfenic 
acid, disulfide bonds) of these modifications. Novel proteomics approaches are needed to better 
understand cysteine-related redox signaling and oxidative stress in disease. 
This dissertation presents studies of protein oxidative modifications using MS-based 
approaches. First, proteomics methodologies to study protein carbonylation and cysteine reversible 
modifications are reviewed, including the relevant applications in neurodegenerative disease. Next, 
a MS-based characterization of a whole protein is described by studying oxidative modifications 
generated through treatment of a model protein with oxidants. Novel methods towards 
characterizing endogenous cysteine oxidations in disease are then presented, including 
inexpensive and high-throughput approaches. The first approach utilizes low-cost isotopic 
dimethyl peptide labeling for comparing two proteome samples. This methodology has the ability 
to isolate and quantify total cysteinyl peptides or oxidized cysteinyl peptides from complex 
samples, and is employed to characterize the liver proteome of an Alzheimer’s disease (AD) mouse 
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model. The second approach is cysteine-selective combined precursor isotopic labeling and 
isobaric tagging (cysteine-selective cPILOT), which incorporates isobaric tags to achieve 12-plex 
multiplexing capability. Cysteine-selective cPILOT is used to isolate total cysteinyl peptides from 
liver proteins and S-nitrosylated peptides from brain proteins of an AD mouse model. Overall the 
novel proteomics approaches developed herein lower experimental costs and improve the 
throughput of cysteine redox proteomics studies. 
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1.0 INTRODUCTION 
1.1 MASS SPECTROMETRY, PROTEIN ANALYSIS AND PROTEOMICS 
Mass spectrometry (MS) is an analytical technique that measures the mass-to-charge (m/z) 
ratio of charged particles in the gas phase1. In the past several decades this technology has been 
widely applied to virtually all areas of life sciences2. One of the major reasons is the development 
of techniques that enable the transfer of large and polar molecules such as proteins from liquid and 
solid states to the gas phase through the process of ionization, such as electrospray ionization 
(ESI)3 and matrix-assisted laser desorption/ionization (MALDI)4. In addition, the continuous 
development of biological sample preparations, multi-dimensional separations, bioinformatics 
tools, as well as the performance of mass analyzers such as the Orbitrap MS5 with high resolution, 
sensitivity and accuracy, have facilitated the applications of MS in whole protein analysis6. 
Moreover, the use of MS for analyzing the entire complement of proteins within a given set of 
cells, tissues or whole organisms (i.e., proteomics) has led to the identification of new proteins, 
quantification of proteins and post-translational modifications (PTMs), discovery of biomarkers 
and therapeutic targets in diseases and elucidation of protein-protein interactions7. The following 
sections in Chapter 1 will discuss the key techniques used in MS analysis of proteins with a focus 
on those employed in this dissertation. 
1.1.1 Orbitrap Mass Spectrometry Instrumentation 
In order to combine different performance characteristics from various types of analyzers 
into one mass spectrometer, hybrid mass spectrometers have been developed. For example the ion 
trap-Orbitrap hybrid mass spectrometer (LTQ-Orbitrap Velos, marketed by Thermo Scientific) 
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possesses high resolution (up to 100,000), high mass accuracy (< 2 ppm) and fast tandem mass 
spectrometry (MS/MS) acquisition (~10 Hz)8, making it an ideal MS platform for both whole 
protein analysis and large-scale proteomics experiments. The LTQ-Orbitrap Velos MS, which is 
used throughout this dissertation, is shown in Figure 1.1. An ESI source is equipped, where the 
analyte molecules from either liquid chromatography separation or direct infusion by a syringe 
pump are ionized and introduced into the MS by applying a high voltage (~1-5 kV). The accurate 
mass of the intact protein or peptide ions are first measured by the Orbitrap MS analyzer (MS scan) 
using high resolution (> 60,000). Simultaneously the peaks of interest are selected (automatically 
or manually) and fragmented in the dual ion trap to generate tandem mass spectra for sequence 
determination (MS/MS scan). MS/MS scans are much faster than MS scans (~0.1 s v.s. ~0.7 s), 
and these two types of scans are often executed simultaneously to maximize the instrument duty 
cycle. 
Data dependent acquisition (DDA) (Chapters 3, 4 - 6) is often employed in high 
throughput proteome analysis by liquid chromatography separation coupled with MS/MS (LC-
MS/MS). DDA is automatic isolation and fragmentation of the top-N most intense ions detected 
from each precursor MS scan. Based on the user’s setting, the N could be lower than 10 but may 
be up to 20, based on different experimental parameters and instrumental platforms. Different 
fragmentation techniques, such as collision induced dissociation (CID), higher energy collisional 
dissociation (HCD), electron transfer dissociation (ETD) and infrared multiphoton dissociation 
(IRMPD), have been developed9,10. CID is used throughout this dissertation for protein/peptide 
sequencing (Chapter 3, 4 - 6). In a typical CID event, the isolated ions are trapped in the ion trap 
and excited by a radio frequency (RF) voltage. Ions with increased kinetic energy collide with 
helium gas and result in the cleaved peptide amide bonds. B-type fragment ions (containing N- 
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Figure 1.1 Schematic of the LTQ-Orbitrap Velos (Thermo Scientific). 
ESI Source Ion Trap C-Trap HCD Collision Cell
Orbitrap Mass 
Analyzer
Quadrupole Octopole QuadrupoleS-Lens
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terminus) and y-type fragment ions (containing C-terminus) ions are detected by MS/MS scan and 
used as the peptide fingerprint for sequence determination by database search. CID is generally 
suitable for small to medium peptides (charge states < 6 and mass < 5 kDa) and can reach efficiency 
up to ~ 80% in ion trap11,12. One limitation of ion trap CID is the low-mass cutoff of MS/MS 
spectra, which is roughly 150 to 300 m/z for most peptide ions13. When it is necessary to detect 
mass tags at as low as 100 m/z in the MS/MS scan, HCD is often used, in which peptide ions are 
fragmented in an octopole HCD collision cell and detected in the Orbitrap14. HCD can also 
generate b- and y-type ions for peptide sequencing and is used exclusively for isobaric tag-based 
quantification in Chapters 4 and 6. 
In a typical 3 hour LC-MS/MS run using DDA, more than 50,000 MS and MS/MS spectra 
can be acquired. Spectral interpretation in this dissertation is performed by database searching 
using the SEQUEST algorithm15, which is integrated in the commercial software Proteome 
Discoverer (Thermo Scientific). SEQUEST compares every theoretical MS/MS spectra based on 
the input protein sequence information, calculates its correlation with the experimental MS/MS 
spectra and assigns the peptide sequence based on the highest correlation. One issue of SEQUEST 
search is the presence of false positive identification due to random matching, which can be 
evaluated and filtered by performing a decoy database search16. False discovery rates (FDR) are 
set to either 0.05 or 0.01 for 95% and 99% confidence, respectively in this dissertation.  
1.1.2 Top-down and Bottom-up Mass Spectrometry 
Proteins can be analyzed as the intact molecules directly by MS (top-down MS)17. As 
shown in Figure 1.2a, the protein sample is directly infused into the MS and the MS scan is 
performed to record the precursor spectra. The peaks of interest are isolated and fragmented to  
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Figure 1.2 General procedures for a) top-down and b) bottom-up MS proteomics analysis. 
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obtain MS/MS spectra for structural determination. An advantage of this approach is the ability to 
retain protein-level information, e.g., multiple proteoforms18. Top-down MS is utilized in Chapter 
3, in which oxidized ubiquitin is directly sprayed and analyzed. Although top-down MS has been 
widely utilized in single protein characterization, including the therapeutic monoclonal antibody 
(~150 kDa), it is still challenging to characterize the whole cell/tissue context due to difficulties in 
protein separation, protein MS/MS fragmentation and MS resolution19; however current state-of-
the-art top-down proteomics studies can achieve identification and quantification of more than 
1,000 low molecular weight proteins (<80 kDa) from human cells20,21. An alternative approach is 
bottom-up MS, in which digests resulting from enzymatic protein digestion are analyzed by LC-
MS/MS. Compared with top-down MS, bottom-up MS exhibits better separations, ionization 
efficiencies and peptide PTM localization, making it an ideal approach for complex sample 
analysis22. The general workflow for bottom-up MS is shown in Figure 1.2b. Proteins extracted 
from tissues or cells are digested by a protease. The most widely used protease is trypsin, which 
cleaves peptides at the carboxyl side of lysine or arginine. Other proteases such as Lys-C and Glu-
C can also be used for generating different peptides and obtaining better sequence coverage 
(Chapter 3). Peptides are separated by LC, in which the reverse phase LC (RPLC) is mostly used 
due to its compatibility with ESI. For complex digest samples, an additional dimension of 
separation prior to RPLC can be used to simplify the MS spectra and improve the peptide 
identification23. For example, strong cation exchange (SCX) is coupled with RPLC to separate 
mouse tissue digests in Chapters 4 and 6. SCX separation is based on the differences of peptide 
charge states on a Polysulfethyl A column (Chapter 4) or a SCX spin tip (Chapter 6). An 
increasing salt gradient is used to elute peptides from the column and several fractions are collected. 
Each fraction is furthered separated by RPLC, which is based on the different hydrophobicities of 
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peptides. Eluted peptides are directly ionized by ESI and the m/z ratios as well as the relative 
intensities are measured and recorded by MS. MS/MS scans are triggered automatically by DDA 
to provide peptide sequence information throughout the RPLC separation period. Bottom-up MS 
is used in Chapter 3 together with top-down MS to provide comprehensive mapping of ubiquitin 
oxidative modifications, and also used in Chapters 4 - 6 for large-scale quantitative proteomics. 
1.1.3 Quantitative Proteomics, Post-translational Modifications and Redox Proteomics 
MS-based quantitative proteomics can be used to understand global protein expression and 
modifications as well as the molecular mechanisms of biological processes in physiological and 
pathological conditions24,25. A number of methods use differential stable isotope labeling to create 
a specific mass tag that can be separated by a mass spectrometer and at the same time provide the 
basis for quantification24,25. These mass tags can be incorporated into proteins or peptides 
metabolically, chemically or enzymatically26. Quantification can also be achieved by label-free 
approaches, in which the spectral counts or peptide peak areas are directly compared among 
multiple sample runs27. The following discussion is focused on label-based quantitative proteomics 
methods employing stable isotopic mass tags, including precursor isotopic labels and isobaric tags. 
Some common techniques are listed in Table 1.1, and discussed below. 
Precursor isotopic labeling acquires relative quantification information from MS scans. In 
a typical experiment, two peptides samples are modified so that the peptides in each sample have 
the same chemical structures but one contains heavy atoms (such as 13C, 2H and 15N). Samples are 
pooled and analyzed by LC-MS/MS. The same peptide from two different samples co-elutes and 
can be discriminated by MS due to the mass difference between the light and heavy mass tags. The 
relative intensities of light and heavy peptide peaks are used for relative quantification. Stable   
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Table 1.1 Representative stable isotope tags for relative quantitation. 
Category Techniques Multiplexa Reactive Sites 
Precursor isotopic labels 
SILAC 3 Arg and Lys 
Acetylation 2 N-term and Lys 
mTRAQ 3 N-term and Lys 
Dimethylation 5 N-term and Lys 
Oxygen 18 2 C-term 
ICAT 2 Cys 
Isobaric tags 
TMT 10 N-term and Lys 
iTRAQ 8 N-term and Lys 
DiLeu 12 N-term and Lys 
iodoTMT 6 Cys 
aNumber of samples that can be compared in a single experiment. 
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isotope labeling with amino acids in cell culture (SILAC) grows cells in normal medium (light) or 
medium containing with stable-isotope-labeled amino acids (i.e., 13C6-arginine and 
13C6-lysine)
28. 
For tissue or bio-fluid samples, a good choice is performing precursor isotopic labeling by 
chemical reactions on the amino side chains such as the amine, sulfhydryl and carboxylic groups. 
Some representative techniques include dimethylation29, acetylation30, mass differential tags for 
relative and absolute quantification (mTRAQ)31, isotope-coded affinity tags (ICAT)32 and 
enzymatic 18O labeling (Table 1.1)33. As shown in Figure 1.3, dimethylation uses formaldehyde 
and sodium cyanborohydride to label the peptide N-terminus and Ɛ-amino group of Lys residues 
via reductive amination reaction29. Heavy labeling reagents can generate peptides with a mass shift 
of +8 Da or +16 Da compared with peptides labeled by light reagents. Moreover, the modified site 
can be limited to N-terminus and leave Ɛ-amino of Lys intact if the dimethylation reaction is 
performed under acidic condition34-36. Due to its pH-based site selectivity, as well as other 
properties such as low cost37, solid phase compatibility38,39 and up to five sample multiplexing 
capability40, dimethylation is attractive and is used in Chapters 4 - 6. However further increasing 
the sample multiplexing may complicate the MS spectra, and result in peak overlapping and 
inaccurate quantification. 
An alternative way to multiplex samples is using isobaric tags, which enable comparison 
of up to twelve samples in a single run41. Some representative examples include tandem mass tag 
(TMT, used in Chapter 6)42, iodoacetyl tandem mass tag (iodoTMT, used in Chapter 4)43, 
carbonyl-reactive tandem mass tag (aminoxyTMT)44, isobaric tag for relative and absolute 
quantitation (iTRAQ)45, deuterium isobaric amine-reactive tag (DiART)46 and dimethyl leucine 
tag (DiLeu) (Table 1.1)41,47,48. A typical isobaric tag consists of three portions (Figure 1.4): a 
reporter ion group, a mass balancer group, and a reactive site that targets a peptide functional group 
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Figure 1.3 Labeling schemes of duplex stable isotope dimethyl labeling at a) high and b) low pH. 
HCHO + NaBH3CN
2H13C2HO + NaB2H3CN
a) pH = 8.5
HCHO + NaBH3CN
2H13C2HO + NaB2H3CN
b) pH = 2.5
m/z
8 or 16 Da
Mix
m/z
8 Da
Mix
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Figure 1.4 Chemical structure for 6-plex TMT and iodoTMT tags and the modified peptide sites are shown. 
Samples are combined for LC-MS/MS analysis resulting in a single peak in MS scan. Isolation and 
fragmentation generates six reporter ion signals in the MS/MS scan. 
S iodoTMT
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*
* * *
SH
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such as amine, sulfhydryl or carbonyl. Each reagent has the same chemical structure, contains the 
same number of heavy atoms (13C and 15N) however these atoms are incorporated into different 
locations within the reporter ion and mass balancer regions. For TMT and iodoTMT tags, reporter 
ions are from m/z 126 through 131, while the respective balancer groups are from m/z 103 through 
98 and 203 through 198. Each peptide from different sample origins co-elutes from the LC and is 
detected as a single peak in the MS scan. However, upon isolation and fragmentation of the peptide 
ion, the TMT and iodoTMT tags cleave between the mass balancer and reporter ion groups and 
result in six unique signals corresponding to the masses of the reporter ions (m/z 126-131 for TMT 
and iodoTMT tags). The intensities of reporter ions are compared for relative quantification. 
Isobaric tagging enables higher multiplexing capability without complicating the precursor spectra. 
However one issue of isobaric tagging-based quantitative proteomics is the ratio compression due 
to the co-isolation and co-fragmentation of target peaks with interfering ions49. Some strategies, 
such as simplifying MS spectra with ion mobility separation50, reducing precursor ion charge 
state51 and performing quantification at the MS3 level52, have been utilized for mitigating this issue. 
The last approach can be easily implemented using the LTQ-Orbitrap Velos MS and is employed 
in Chapters 4 and 6 for quantification using iodoTMT and TMT. 
Further increase of multiplexing ability in quantitative proteomics experiments can provide 
the ability to analyze many samples in one run, resulting in higher throughput, shorter instrument 
time and lower experimental variations. An effective strategy developed in our laboratory is 
combined precursor isotopic labeling and isobaric tagging (cPILOT) method36, which labels 
multiple samples using combined precursor isotopic labeling and isobaric tagging. Briefly, 
peptides are modified with a precursor labeling reagent which generates a mass shift between light 
and heavy peaks in MS. Light and heavy peptides are further modified with isobaric tags. 
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Fragmentation of both light and heavy peptides separately can generate two sets of reporter ion 
spectra and double the original multiplexing capacity of the isobaric tag. This method was initially 
developed for 3-nitrotyrosine modified peptides53, and further expanded for global proteome 
quantification36,54. This dissertation further expands this methodology to achieve enhanced 
quantification of cysteine-containing proteins (Chapter 4) and S-nitrosylation (SNO) PTMs 
(Chapter 6). Other enhanced multiplexing techniques are also reported55-58. 
MS analysis of proteins can also characterize various PTMs on the amino acid side 
chains59,60. PTMs are the covalent modification of proteins during or after protein biosynthesis and 
have significant biological relevance. Oxidative PTMs, such as carbonylation and a variety of 
reversible modifications on cysteine sulfhydryl groups are of interest in this work61. Protein 
oxidative PTMs are formed through a variety of pathways but largely due to the attacks of radical 
oxygen and nitrogen species (ROS/RNS)62, and closely related with diseases61,63. Characterization 
of oxidative PTMs on a single protein can be readily achieved using combined top-down and 
bottom-up MS (Chapter 3). However MS characterization of oxidative PTMs in tissues or cells 
are challenging mainly due to the low abundance and diverse structures64,65. Chapter 2 reviews 
current proteomic techniques to investigate common oxidative PTMs such as cysteine reversible 
modifications and carbonylation. The relevant applications of these methods in aging and 
neurodegenerative diseases are also presented. Chapters 4 - 6 discuss the development of novel 
redox proteomics methods to selectively identify and quantify cysteine reversible modifications 
from Alzheimer’s disease (AD) mouse tissues. 
1.1.4 Cysteine-selective Proteomics Approaches: Challenges and Strategies 
Cysteine is a rare amino acid but present in nearly all proteins, and widely involved in 
biological processes through the formation of a number of reversible modifications (reviewed in 
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Chapter 2). Cysteine-selective proteomics approaches can be used to study biological systems by 
targeting low abundant proteins and/or cysteine reversible PTMs. Existing tools, such as ICAT 
and iodoTMT, have been successfully applied in relevant studies (see Chapter 2). However a 
common challenge in discovery proteomic experiments is the large number of biological 
samples/replicates needed. For example, more than 1,000 plasma samples are used in a clinical 
study for biomarker discovery66. By using existing cysteine-selective tools, numerous experiments 
have to be performed to analyze all samples. As a result, increased tagging cost and instrumental 
time are expected. Towards this end, this dissertation presents two directions. One is developing 
inexpensive proteomic methods using isotopic dimethylation (Chapters 4 and 5), and the other is 
developing cPILOT approaches to compare many samples in a single instrumental run (Chapters 
4 and 6). More importantly, these methods provide the flexibility of quantifying peptides 
containing cysteine, oxidized cysteine and a specific oxidized cysteine PTM. Researchers can 
choose the most appropriate method based on specific studies and laboratory conditions, such as 
the MS instrument, the budget and the time frame. 
1.2 OVERVIEW OF DISSERTATION 
This dissertation employs MS-based approaches to characterize proteins with a focus on 
development of novel strategies to study oxidative modifications in disease. Specifically, Chapter 
2 reviews proteomic approaches to identify and quantify protein oxidative modifications as well 
as relevant applications in neurodegenerative diseases. In Chapter 3 a combined top-down and 
bottom-up MS method is developed to study protein oxidation and demonstrated on a model 
protein. Chapter 4 introduces two cysteine-selective approaches enabling comparison of two or 
twelve proteome samples in a single run. In Chapter 5 a simple method is developed to quantify 
reversible cysteine modification in AD. Chapter 6 presents an optimized 12-plex approach to 
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study SNO in AD. Chapter 7 summarizes the dissertation and discusses current challenges and 
future goals of MS-based oxidative PTM analysis. 
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2.0 REDOX PROTEOMIC APPROACHES TO STUDY OXIDATIVE 
MODIFICATIONS IN AGING AND NEURODEGENERATIVE DISEASES 
(Note that information in this chapter is written based on two review papers61,67: 1) Gu, L.; 
Robinson, R. A. S. Proteomics Clinical Applications 2016, Manuscript in Preparation; 2) 
Butterfield, D. A.; Gu, L.; Di Domenico, F.; Robinson, R. A. S. Mass Spectrometry Reviews 2014, 
33, 277-301.) 
2.1 INTRODUCTION 
Radical oxygen/nitrogen species (ROS/RNS) can be generated endogenously (e.g., 
metabolism in mitochondria and peroxisomes) and exogenously (e.g., ultraviolet light and ionizing 
radiation) in biology62. Antioxidant defense systems (e.g., catalase and superoxide dismutase) are 
activated in the presence of ROS and work to maintain physiological homeostasis62. Many studies 
have indicated that the generation, reaction and disassembly of ROS/RNS are important regulatory 
mechanisms for many cellular activities62. However, an imbalance of ROS/RNS with the cellular 
antioxidant defense mechanism results in oxidative stress, and subsequent post-translational 
modifications (PTMs) on various biomolecules, including DNA, RNA and proteins68.  
One of the most susceptible amino acids to oxidative PTMs is cysteine. Cysteine is a rare 
amino acid with a natural occurrence of 2.26% among all amino acids in the mammalian 
proteome65. The percentage of cysteinyl peptides is only ~15% after in silico digestion of the whole 
human proteome65. Cysteine is highly nucleophilic and redox sensitive compared with other amino 
acid side chains. It is involved in redox homeostasis, enzymatic catalysis, signal conduction, metal 
binding and structural stabilization69,70. The pKa value of the cysteine thiol is ~ 8.0 but can be as 
low as 3.5 in some proteins due to electrostatic interactions and hydrogen bonding71. The low pKa 
results in spontaneous in vivo reactions of cysteine with electrophilic and/or oxidizing molecules72.  
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Common reversible modifications of cysteine include formation of sulfenic acids (SOH), 
S-nitrosylation (SNO), S-glutathionylation (SSG), S-palmitoylation and disulfide bonds73 (Figure 
2.1). It is estimated that only 10% of all cysteine residues are reversibly oxidized in vivo64. These 
reversible PTMs have important biological roles and help maintain homeostasis by preventing the 
formation of irreversible oxidative modifications (e.g., sulfinic and sulfonic acid)74. Specifically, 
SOH is often the intermediate status of the active cysteine site during the catalytic process of redox 
enzymes such as peroxiredoxin75. SNO, resulting from the attack of endogenous NO to free 
cysteine, is often involved in cellular signal transduction pathways76. SSG is the reversible 
formation of protein disulfides with glutathione (GSH) and is found to modulate protein activities. 
In addition, the conversion of SOH and SNO derivatives to SSG followed by glutaredoxin 
reduction is an important mechanism to maintain protein-thiol homeostasis77. S-palmitoylation is 
the covalent lipid modification of cysteine with the 16-carbon fatty acid palmitate 
(CH3(CH2)14COOH), and regulates protein trafficking and subcellular localization
78. Disulfide 
bonds are important for maintaining the protein 3D structures, while recently it is found that 
disulfide bonds are involved in the regulation of protein functions79. Finally, modification of 
cysteine by lipid peroxidation products (e.g., HNE) is reported to inhibit protein disulfide 
isomerase in rat liver mitochondrial80. 
Thiol-based redox regulation is important in metabolism. Dysregulated redox homeostasis 
of thiols have been implicated in aging and diseases, such as cancer, diabetes, cardiovascular and 
neurodegenerative diseases72. Better understanding of thiol redox chemistry can give insight to 
biochemical events that occur in diseases, and may lead to potential biomarkers for disease 
diagnosis and therapy81. Redox proteomics can detect hundreds to thousands of oxidized proteins 
in a single experiment and this is attractive to study redox status of proteins82. Redox proteomics   
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Figure 2.1 Representative oxidative modifications of cysteine by ROS/RNS. Low levels of ROS/RNS lead to reversible cysteine modifications, 
including S-glutathionylation, S-nitrosylation, S-palmitoylation, sulfenic acid and disulfides. These modifications have important roles in various 
cellular activities. ROS/RNS can also oxidize cysteine irreversibly, and result in loss of protein function and cellular damage. 
S-glutathionylation
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approaches have been developed to enrich, identify and quantify cysteine oxidative PTMs in 
complex biological samples and can be gel-based and nongel-based83. Gel-based methods offer 
direct detection of cysteine modifications via electrophoretic gel separation and immunoblotting84. 
In recent years, nongel methods have become more popular due to new technologies for PTM 
enrichment, multi-dimensional chromatographic separations and high-through protein 
quantification by mass spectrometry (MS)24,25,85. Redox proteomic workflows are limited by 1) the 
low abundance and high diversity of cysteine PTMs, 2) the labile and dynamic nature of 
modifications and 3) potentially the small changes in oxidative PTM levels that are not detectable 
between different biological conditions83. More effort is needed to overcome these challenges and 
to develop workflows that are efficient, straightforward, unbiased, high-through, sensitive and 
accurate. 
Aging is a complex biological process accompanied by decline in biological and 
physiological functions of many organs61. Aging is also one of the significant risk factors for 
neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD)86, 
in which the brain undergoes both morphological and functional modifications, accompanied by 
the alteration of motor and sensory systems, sleep, memory and learning61. Elevated oxidative 
stress is present in aging and neurodegenerative diseases and occurs in different organs38,54, tissues 
and fluids82,87. Redox proteomic studies in aging and neurodegenerative diseases have been 
provided insights into the molecular consequences of oxidative stress. However, a detailed 
characterization of redox changes to the thiol proteome across tissues and disease stages does not 
exist. 
In addition to oxidative cysteine modifications, oxidative stress can result in a variety of 
other oxidative PTMs (Figure 2.2). For example, carbonylation is generated by direct oxidation of  
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Figure 2.2 Examples of oxidative modifications other than cysteine oxidation. 
  
a) Methionine oxidation
b) Hydroxylation of tyrosine
c) Deamidation of asparagine
d) Carbonylation of lysine
e) Carbonylation of threonine
f) Histidine open ring reaction
  
21 
 
several amino acid side chains (i.e., Lys, Arg, Pro, Thr, His and others), backbone fragmentation, 
hydrogen atom abstraction at alpha carbons and Michael addition reactions of His, Lys, and Cys 
residues with products of lipid peroxidation causing inactivation, crosslinking or breakdown of 
proteins88. Carbonylation is generally considered as an irreversible modification, and can result in 
protein fragmentation, aggregation and increased susceptibility to proteolysis89-91. Protein 
carbonylation is accepted as a good indicator of the extent of oxidative damage of proteins 
associated with various conditions of oxidative stress, aging and physiological disorders90. 
Methionine residues can be readily oxidized to methionine sulfoxide by incorporating one oxygen 
atom, which is often observed even in physiological conditions. This modification is also a marker 
of oxidative stress and its repair by methionine sulfoxide reductases is related to diseases92. Other 
types of modifications by direct attack of hydroxyl radicals include hydroxylation, deamidation, 
decarboxylation, as well as histidine open ring reactions89,93. Most of these oxidative modifications 
can be identified by MS due to the distinct mass shift after oxidation. However some modifications 
have very small mass shifts, such as + 1 Da for deamidation, and -1 Da for carbonylation of Lys, 
and are challenging to characterize. Strict spectral validation is often required68. Chapter 3 
discusses a study of mapping various protein oxidations by using a model protein. Investigation of 
these modifications on the proteome level often requires affinity enrichment techniques due to the 
extremely low concentrations of these PTMs. 
In this chapter, different quantitative proteomic methods to study cysteine modifications 
and protein carbonylation will be discussed. More emphasis will be focused on nongel-based 
approaches and MS-based quantitative profiling of cysteine PTMs, which is highly related to the 
work in Chapters 4 - 6. Finally, applications of different redox proteomic approaches in aging and 
neurodegenerative diseases will be described.  
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2.2 REDOX PROTEOMIC APPROACHES TO QUANTIFY CYSTEINE 
REVERSIBLE MODIFICATIONS 
Proteomics is able to simultaneously identify and quantify nearly the whole proteome in a 
single experiment94, making it a desirable technique to gain insights into the redox status of 
proteins. In addition, different chemical or biological probes can make the methods selective to 
cysteine oxidized PTMs95. Considering the diverse, labile and dynamic nature of cysteine PTMs, 
differential thiol blocking and selective reduction is frequently used82,83,96,97.The primary steps of 
such workflows are summarized in Figure 2.3. This strategy was initially developed for gel-based 
SNO analysis98, and later it was adapted to study a variety of cysteine reversible modifications in 
gel-based and nongel-based approaches. Regardless of the targeted cysteine modifications and the 
downstream processing, the general principles remain the same. First is the blocking of free thiols 
using N-ethylmaleimide (NEM), iodoacetamide (IAM) or methyl methanethiosulfonate 
(MMTS)97 with typical concentrations from 10 mM to 200 mM99-118. In addition, cysteine-reactive 
mass tags can also be used, such as isotope-coded affinity tag (ICAT) and iodoacetyl tandem mass 
tag (iodoTMT). Thiol blocking is recommended at the earliest stage of sample processing such as 
cell lysis or tissue homogenization, in order to minimize artificial cysteine oxidation83. After 
removal of excess blocking reagents, substrate-specific reductants are added. Widely used 
reducing reagents, including ascorbate, arsenite, glutaredoxin, hydroxylamine and dithiothreitol 
(DTT) or tris(2-carboxyethyl)phosphine (TCEP), can reduce SNO, SOH, SSG, S-palmitoylation 
and all reversibly oxidative modifications, respectively119. Next, the nascent thiols react with 
cysteine-reactive isotopic or isobaric mass labels, affinity resins, biotin-based tags, fluorophores 
or radionucleotides. The following steps are highly diverse, and may include gel- or nongel-based 
separation, Western blot, proteolytic digestion, mass tagging, affinity purification and MS analysis.  
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Figure 2.3 Schematic summary of the principles of differential alkylation for identifying and quantifying 
cysteine reversible modifications in redox proteomics. Endogenously reduced cysteine thiols are first 
blocked by IAM, NEM, MMTS or ICAT (see text). Subsequently, different reducing reagents are used to 
selectively reduce targeted cysteine modifications. S-nitrosylation, S-glutathionylation, S-palmitoylation 
and sulfenic acid can be reduced by ascorbate, glutaredoxin, hydroxylamine and arsenite, respectively. A 
strong reductant such as DTT and TCEP (see text) reduces all reversible modifications. Next, nascent thiols 
are labeled with a variety of reagents for different purposes. Biotin-HPDP and thiol-affinity resin are widely 
used for isolating proteins and peptides containing reversible modifications. CysTMT/iodoTMT/NEM are 
cysteine-reactive mass tags and used for MS-based quantification. Finally, the procedures after labeling of 
nascent thiols are highly diverse. Samples may be separated by gel electrophoresis or chromatography, 
detected by Western blot, labeled by cysteine or amine-reactive mass tags, digested by proteases, purified 
by avidin resin or immunoaffinity, and analyzed by tandem MS. Not all of the steps are necessary, and the 
order of these steps may be switched. Sample mixing may also occur at different stages. 
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The overall objective is to discover redox-sensitive proteins and quantify the differences of site-
specific cysteine modifications across different conditions/treatments.  
 Most of the quantitative redox proteomics approaches can be categorized into gel-based 
and nongel-based methods. In gel-based methods, an antibody towards specific cysteine PTM is 
utilized to detect and quantify redox-sensitive protein spots after gel separation. These gel spots 
are then digested and the protein is identified by MS61. Examples of gel-based redox proteomics 
approaches, such as 2D-Oxyblot, biotin-switch technique (BST) and redox difference gel 
electrophoresis (Redox-DIGE), are shown in Figure 2.4. 2D-Oxybot is a widely used gel-based 
technique to detect various types of modifications, e.g., protein carbonyls120, 3-nitrotyrosine121, 4-
HNE122, SNO123, SSG124, by using different primary antibodies. In this method, after 2D 
electrophoresis separation of lysates, immunoblotting analysis is performed to determine the 
protein spots with significant differences. The spots of interest are excised from the gel, in-gel 
digested and analyzed by MS (Figure 2.4a). This is a relatively low throughput technique, and may 
result in unambiguous identification due to the existence of multiple proteins in the same spot. 
Because all cysteine residues are in native states, 2D-Oxyblot is limited by artificial oxidation and 
thiol exchange reactions that occur during the sample processing85. To overcome these limitations, 
the biotin-switch technique (BST) was developed98, in which free thiols are first blocked by 
MMTS, followed by selective reduction of oxidized cysteine modifications, e.g., SNO (Figure 
2.4b). The newly-formed thiols are labeled with pyridyldithiol-biotin (biotin-HPDP), enriched by 
avidin affinity medium and analyzed by SDS-PAGE/immunoblotting or LC-MS/MS. Avidin 
conjugated horseradish peroxidase (Avidin-HRP) antibody can detect total SNO-modified proteins 
by Western blot, while a second antibody against a protein of interest can be used to detect an 
individual SNO-modified protein (Figure 2.4b). LC-MS/MS analysis of the avidin-enriched  
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Figure 2.4 Gel-based approaches for quantification of cysteine reversible modifications. a) In 2D-Oxyblot 
method first samples are separated by 2D SDS-PAGE separately. Gels are probed by Western blot using 
antibodies which recognize the particular cysteine PTM, such as S-nitrosylation and S-glutathionylation. 
Differentially-expressed protein spots are excised and identified by MS. b) Biotin-switch technique (BST) 
employs differential thiol blocking followed by selective reduction of the cysteine modification. The 
nascent thiols are labeled with biotin-HPDP. The oxidized proteins are then enriched by avidin affinity 
medium and analyzed by SDS-PAGE and Western blot. c) In Redox-DIGE method, different fluorescent 
tags are used to label samples after differential thiol blocking and selective reduction of cysteine 
modifications. Two samples are combined and analyzed on a single gel. The protein spots with differential 
fluorescent signals are excised and analyzed by MS. 
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mixtures allows the site specific identification of the oxidized cysteine without gel separation103, 
which will be further discussed in below. 
Both 2D-Oxyblot and BST approaches have limitations of poor gel reproducibility because 
samples are analyzed and quantified separately. An alternative strategy is redox difference gel 
electrophoresis (Redox-DIGE)125. This method employs a differential sample labeling step that 
uses two fluorescent dyes (e.g., Cy3 and Cy5) for untreated and treated samples. Both samples are 
mixed and separated on the same 2D gel (Figure 2.4c). Fluorescent scanning of the gel reveals the 
oxidized proteins with different levels between untreated and treated, which can be subsequently 
identified by MS. By using this approach, 13 mitochondrial SNO-proteins were identified upon 
treatment of rat mitochondrion with MitoSNO (mitochondria targeted S-nitrosothiol), and they 
were related with inhibition of energy-related metabolic enzymes126. 
Most of the gel-based quantitative approaches uses colorimetric or fluorescent detection to 
determine the protein spots with differential expression, followed by MS identification of the 
respective proteins. However there are other gel-based workflows using the stable isotopic labeling 
(SIL) technique for MS quantification of cysteine redox status. One method is called d-Switch 
127,128, in which light and heavy NEM (d5-NEM) are used to label endogenously reduced and 
oxidized cysteine, respectively. The sample is separated by gel electrophoresis, and the region 
containing the target protein is excised and analyzed by MS to obtain the quantitative information. 
Acrylamide matrix can also be used as the reaction chamber to lower sample loss, which is 
demonstrated in gel-based stable isotope labeling of oxidized cysteine (GELSILOX) approach129. 
In GELSILOX sample preparations can be simplified, which is beneficial for reliable 
quantification and better recovery. The differential O16/O18 labeling of control and treated samples 
allows the MS quantification of oxidized thiols in a duplex experiment.  
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 The general limitations of the gel-based quantitative approaches include the lack of 
sensitivity when analyzing proteins with high or low molecular weight, with highly acidic or basic 
IP values, and with high hydrophobicity. Also the proteome coverage can be lower compared to 
full MS methods, and these approaches heavily rely on good and specific antibodies. Nevertheless, 
gel-based methods are very suitable to give a general visualization of oxidized proteins. 
An effective strategy to overcome the limitations associated with gel-based methods and 
to probe deeper into the redox proteome is to employ nongel-based redox proteomics. Nongel-
based approaches may identify and quantify hundreds to thousands of redox-sensitive cysteine 
residues from complex samples using an integrated shot-gun proteomic workflow. To date, 
numerous approaches have been developed and applied in biological studies, e.g., OxICAT 
(oxidized isotope-coded affinity tag)101, OxiTRAQ (oxidized isobaric tag for relative and absolute 
quantitation)109, SNO-RAC (SNO analysis by resin-assisted capture)100, OxMRM (oxidized 
multiple reaction monitoring)104, CysTMTRAQ (cysteine tandem mass tags and isobaric tag for 
relative and absolute quantification)112 and OxcysDML (Oxidized cysteine-selective 
dimethylation), which was developed in this work (Chapter 5). Most of these methods have three 
distinct steps: 1) differential thiol alkylation and selective reduction (Figure 2.5), 2) affinity 
purification of nascent thiols, and 3) protein/peptide quantification using labeled or label-free 
approaches by MS.  
Affinity purification plays an important role in nongel-based methods due to the low 
occurrence rate (~ 0.1%) of endogenously oxidized cysteine64,65. Enrichment methods reduce the 
complexity of the sample mixture, and can dramatically improve the signal to noise ratios of 
modified peptides in LC-MS/MS analysis. Affinity purification methods are: 1) high efficiency, 2) 
little to no non-specific binding, 3) simple workflow and 4) MS compatibility. Only a few 
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Figure 2.5 Representative workflows using biotin as the purification technique. a) In an ICAT-based 
approach, only one sample is employed. The free thiols are blocked by light ICAT, and the nascent thiols 
after selective reduction are labeled with heavy ICAT. The sample is isolated by avidin affinity medium, 
digested and analyzed by MS. b) In another type of ICAT-based method, free thiol blocking, selective 
reduction and differential labeling of nascent thiols by light and heavy ICAT are performed for two different 
samples separately. After mixing, oxidized proteins are further processed, including enrichment, digestion 
and LC-MS/MS analysis. c) OxiTRAQ or label-free approaches use the biotin-switch technique (BST) to 
label oxidized cysteine sites followed by digestion and affinity purification for each sample. Enriched 
peptides are further tagged by iTRAQ and analyzed by MS, or analyzed by MS directly. d) In SILAC-based 
workflows, cells are grown in medium culture with light or heavy amino acids. Two samples are combined 
and processed using BST. Oxidized peptides are enriched and analyzed by MS. 
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enrichment approaches have been repeated to study oxidative cysteine PTMs: 1) biotin-avidin 
interaction, 2) thiol-affinity solid phase resin and 3) immunoaffinity capture.  
Protein/peptide quantification involved in cysteine redox methods are similar to those 
techniques used in expression quantitative proteomics. For example, samples are differentially 
labeled with specific mass tags that can be recognized in MS analysis for relative quantification. 
These mass tags can be incorporated metabolically or chemically24,25. An alternative to labeling 
approaches is “label-free”. Label-free approaches rely on ion intensity or spectrum counting to 
report on the abundance differences of redox-sensitive cysteine sites. Label-free can generally 
provide higher dynamic range compared to labeling methods, especially with multiple reaction 
monitoring (MRM) mode on a triple quadrupole MS analyzer24.  
Overall, differential thiol alkylation and selective reduction, as well as protein/peptide 
quantification using labeled or label-free methods, are readily transferable across different 
workflows. The following discussion gives more details of different enrichment techniques 
currently utilized. 
2.2.1 Biotin-avidin Interaction 
The high affinity and specificity of interactions between biotin and avidin makes it an ideal 
technique to pulldown the target cysteine-containing peptides, which is mostly achieved by using 
isotope-coded affinity tag (ICAT). The first version of ICAT consisted of a thiol-reactive group 
(iodoacetyl), a deuterium-coded light or heavy linker, and an affinity group (biotin) for capturing 
tagged peptides32. ICAT was originally developed for quantifying protein expression in two 
different complex samples. Because only a small portion of the tryptic peptides have cysteine 
residues, ICAT technique can largely simplify the complex mixture, and enrich proteins with low 
abundance. Due to its inherent capability of cysteine tagging and purification, ICAT was readily 
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adapted into the characterization of reversibly oxidized thiol proteomes. Based on how the 
differential alkylation is performed, ICAT-based redox methods can either quantify the absolute 
oxidation status of each cysteine site in a single sample (termed OxICAT)130-133, or quantify the 
relative abundance ratio of oxidized cysteine sites from two different samples101,134-138.  
OxICAT uses light ICAT as the blocking agent to label the reduced cysteine130-133. After 
reduction, the newly appearing cysteine with free thiol is labeled with heavy ICAT. After 
trypsinization, affinity purification and enrichment of cysteine-containing peptides is performed 
using streptavidin affinity column, followed by LC-MS/MS analysis (Figure 2.5a). The coeluted 
light and heavy-labeled peptides generate peaks in the precursor mass spectra, and the relative 
intensity of peak areas represent the abundances of the reduced and oxidized form for each cysteine 
residue. 
In another ICAT-based approach, the ratio of oxidized cysteine from two samples can be 
compared in a single experiment101,134-138. The blocking step uses a generic thiol blocking reagent 
(e.g., NEM, IAM) for both samples. Upon reduction of reversibly oxidized thiols, nascent thiols 
are labeled with light ICAT for one sample and heavy ICAT for the second sample. The two 
samples are combined, digested, enriched and analyzed by LC-MS/MS (Figure 2.5b). Because 
peptides with reduced cysteine have been depleted, the parent mass spectrum is more simplified 
than the OxICAT method, and the light and heavy peaks in each pair have comparable intensities.  
In addition to ICAT-based methods, biotin-based affinity purification has been coupled 
with other quantification methods, such as label-free, isobaric tag for relative and absolute 
quantitation (iTRAQ) and stable isotope labeling by amino acids in cell culture (SILAC). 
Palmitoylated proteins (S-acylated proteins) are isolated and quantified after free thiol blocking by 
NEM, selective reduction by hydroxylamine and label-free quantitation. This method is based on 
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the classic biotin-switch technique105, and can be expanded to study other types of cysteine 
modifications (Figure 2.5c). ITRAQ has been utilized in biotin-based workflow (termed 
OxiTRAQ)109 (Figure 2.5c), in which up to eight samples can be compared in a single experiment. 
In SILAC, cell samples are labeled by either light or heavy arginine and/or lysine in cell culture 
medium (Figure 2.5d)107. Tryptic peptides carry at least one labeled amino acid resulting in a mass 
increment over the non-labeled counterpart that is equivalent to the number of heavy isotope atoms 
incorporated. SILAC-based redox methods combine two different samples at the level of intact 
cells before affinity purification, resulting in lower sample error and higher accuracy compared 
with other quantitative methods.  
2.2.2 Thiol-affinity Solid Phase Resin 
Thiol-affinity resin was initially used to enrich cysteine-containing peptides from complex 
mixture to improve identification of low abundant proteins139,140. The most widely used affinity 
resin is Thiopropyl sepharose® 6B, in which a reactive 2-thiopyridyl disulfide group is attached 
to sepharose through a chemically stable ether linkage. When mixing the affinity resin with peptide 
digests, cysteinyl peptides are covalently captured through the disulfide bond exchange reaction. 
The unbound, non-cysteinyl peptides and the released 2-thiopyridone are removed by washing. 
The captured peptides can be released by incubating the resin with a reducing reagent (e.g., DTT). 
This enrichment is quantitative and the specificity is ~98-99% based on studies in this thesis 
(Chapters 4 - 6)38,39,141.  
Recently thiol-affinity resin has gained popularity for isolating and quantifying cysteine 
reversible modifications in complex mixtures. Different quantitative MS methods, e.g., isotopic 
labels100,141, isobaric tags99,115,116,119,142, label-free methods143-145, have been coupled with resin-
based enrichment, to quantify SNO100,116,142-144, SSG115,119, S-palmitoylation99,119, and all oxidative 
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cysteine119,135,142,145 (Figure 2.6). Resin-assisted approaches have several advantages. First, it is a 
simple workflow in which peptides are directly captured on the thiol-affinity resin without pre-
derivatization. Second, enriched peptides do not have fragmentable tags that will be generated in 
MS/MS, and no side reaction is expected in the reversible capture and release reaction. Third, 
enriched peptides are linked to the resin through stable covalent bonding, so stringent washing 
steps can be applied to remove non-specific binders. Fourth, resin matrix can serve as a sample 
sorbent to facilitate the on-resin peptide labeling reaction by using different amine-reactive tags, 
e.g., acetylation100, dimethylation39, TMT119,142 and iTRAQ99,115,116. This is very attractive, as no 
more sample cleanup is needed between steps, which is beneficial for minimizing sample loss. The 
cost of this workflow can become high, especially if isobaric tags are employed.  
An alternative way to lower the cost is using inexpensive stable-isotope dimethyl labeling 
on solid phase resin, termed OxcysDML (Chapter 5)39. This technique can achieve peptide on-
resin dimethylation using different isotopomers of formaldehyde and cyanoborohydride. The 
average tagging cost of each sample is ~$1. This inexpensive, efficient and accurate method has 
been applied to study the redox proteome of liver tissues from an AD mouse model (Chapter 5). 
Inspired by our previous cPILOT methodologies36,38,54, our laboratory recently further expanded 
the multiplexing capacity of OxcysDML by employing on-resin cPILOT tagging of cysteinyl 
peptides. This approach, termed oxidized cysteine-selective cPILOT (OxcyscPILOT)141, enabled 
sample multiplexing up to twelve samples in a single run, and has been demonstrated in the study 
of endogenous SNO of brain proteins in an AD mouse model (Chapter 6). 
2.2.3 Immunoaffinity Capture 
Immunoaffinity capture is not widely reported until recent years, and most of these studies 
use cysteine-reactive tandem mass tag (cysTMT) or iodoacetyl tandem mass tag (iodoTMT) as the  
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Figure 2.6 Typical workflows using thiol-affinity resin for purification. Free thiols in each protein sample 
are blocked followed by selective reduction of cysteine modifications. After proteolytic digestion, peptides 
containing nascent thiols are enriched by thiol-affinity solid phase resin. Different amine-reactive tagging 
methods can be performed to label peptides on the resin, including acetylation, dimethylation, TMT and 
cPILOT. Finally enriched peptides are eluted, combined and analyzed by MS. Typical spectra obtained by 
each method is provided.*In the label-free approach, peptides are not tagged on the resin so sample mixing 
is not needed. 
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quantitative mass tag. CysTMT contains a mass reporter group, a mass normalizer moiety and a 
pyridyldithiol cysteine-reactive group. CysTMT-tagged peptides are enriched by anti-TMT resin 
immobilized with an antibody recognizing the mass reporter structure of the mass tag. During the 
LC-MS/MS step, cysTMT-tagged peptides can generate up to six reporter ions between 126 and 
131 Da, the intensities of which are used for relative quantification. IodoTMT works similar to 
CysTMT, except its irreversible reaction with sulfhydryl groups. CysTMT and iodoTMT-based 
approaches have been successfully applied in studying the redox proteome alteration of human 
pulmonary arterial endothelial cells treated with S-nitrosoglutathione111, the NO-mediated 
cardioprotection processes43, and the SNO sites responding to lipopolysaccharide (LPS) 
stimulation in microglial cells113. Recently, a novel iodoTMT-based workflow, termed SNO/SOH 
TMT strategy, has been developed to provide quantitative profiling of SNO and SOH changes 
simultaneously118. Compared with other methods, SNO/SOH TMT strategy uses two channels to 
isolate total cysteinyl peptides for correcting protein abundance changes during sample treatment 
and preparation.  
Although not frequently reported, conventional protein immunoaffinity purification - using 
an immobilized antibody to pull down the targeted protein - can also be coupled with differential 
thiol blocking to quantify the redox status of cysteine residues in specific proteins104. In one study, 
diamide treated human breast cancer cells are differentially alkylated with d0 and d5 NEM for 
reduced and oxidized cysteine, respectively. The target protein p53 and protein tyrosine 
phosphatase-1B (PTP1B) are then serially immunoaffinity-purified and analyzed by MRM. This 
method, termed OxMRM, indicated that Cys182 and Cys215 are the redox-sensitive sites in p53 
and PTP1B, respectively.  
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2.2.4 Non-enrichment Approaches 
When comparing the reversibly oxidized cysteine across multiple samples in one 
experiment, one has to consider the effects of total protein-level changes to the cysteine PTM 
changes. Generally a separate experiment is involved to address the protein turnover issue in the 
course of experiments138. In order to obtain the protein expression and cysteine redox information 
by using a single run, a possible strategy, although not widely used, is to retain the non-redox 
portion of the sample. Cysteinyl peptides help determine the redox changes, while the non-
cysteinyl peptides are responsible for quantifying protein-level changes. In these cases, affinity 
purifications are normally not involved. The previously discussed GELSILOX approach is one of 
the relevant examples129. Another good example is cysTMTRAQ (cysTMT and iTRAQ) method112, 
which uses cysTMT to label protein thiols responsive to a treatment, and uses iTRAQ to label 
peptide amines for analysis of protein-levels changes between different treatments. In tandem MS 
spectra, reporter ions generated by cysTMT tags (m/z 126, 127, 128, 129, 130, 131 for six samples) 
and iTRAQ tags (m/z 114, 115, 116, 117, 119, and 121 for six samples) enable the quantification 
of protein redox and total levels simultaneously.  
2.3 REDOX PROTEOMIC APPROACHES TO STUDY PROTEIN 
CARBONYLATION 
2D-gel based redox proteomics can also be used to study protein carbonylation146,147. After 
treatment with 2, 4-dinitrophenylhydrazine (DNPH) to form a DNP hydrazone adduct, protein 
samples can be resolved by 2D gel and recognized by anti-DNP antibodies. Derivatization can 
occur before or after the gel separation148.  Individual carbonylation signals from the blot are 
normalized to the total protein level present on the gel and compared across different 
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conditions149,150. Despite the extensive usage of DNPH for derivatizing carbonylation it should be 
noted that DNPH is not exclusive for carbonyl groups, as it also reacts with sulfenic acids-oxidized 
thiol groups-under acid catalysis conditions151. Biotin-hydrazide may be used to label carbonyl 
groups with fluorescein or peroxidase linked avidin152,153. A protein carbonyl enzyme immuno-
assay kit has recently become available154.  
Non-gel redox proteomics have been widely applied in the study of protein carbonylation 
and have been reviewed recently146,155,156. A key step in these approaches is the incorporation of 
enrichment procedures for carbonylation which is necessary since the average abundance of 
carbonylated proteins has been reported as ~0.2% in human plasma157. One of the most common 
methods uses avidin affinity chromatography to enrich biotin-hydrazide derivatized carbonylated 
peptides. Derivatization with biotin hydrazide also results in the formation of a Schiff base that 
can be reduced to a more stable C-N bond.  Label-free or isobaric tagging strategies (e.g., iTRAQ) 
can be used for quantifying carbonylation level across different samples158,159. Regnier and 
coworkers have successfully applied biotin/avidin affinity chromatography proteomics to study 
carbonylation in in vitro metal-catalyzed oxidation models, yeast, rat and human plasma tissues, 
and diabetic rats156-161. A similar tag based on biotin/avidin is N’-
aminooxymethylcarbonylhydrazino D-biotin (aldehyde reactive probe, ARP), the hydroxylamine 
moiety of which can form a stable C=N bond, thus further reduction is not necessary162-164. This 
ARP however undergoes substantial fragmentation in MS/MS experiments which decreases 
peptide confidence after database searching due to complex spectra. The development of an 
algorithm which incorporates ARP fragment ions and neutral loss into the database searching has 
enhanced identification of protein carbonylation with ARPs165.  
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However MS-based identification of protein carbonylation is still challenging due to the 
complexity and diversity of modifications as carbonyl groups occur many amino acid side chains 
and the range in mass shifts. In Chapter 3 we demonstrate how iterative database searching and 
manual spectral validation can help solve this problem. 
2.4 APPLICATIONS OF CYSTEINE-SELECTIVE REDOX PROTEOMICS IN 
AGING AND NEURODEGENERATIVE DISEASES 
In aging part of the brain shrink, communication between neurons are reduced, and tiny 
plaques and tangles develop outside or inside neurons166. Neurodegenerative diseases including 
AD, PD and human prion diseases are a group of diseases affecting the central nervous system 
(CNS) with different etiologies. It is accepted that aging is an important risk factor for age-related 
neurodegenerative diseases, and many efforts are filling the gaps in our knowledge about the 
earliest stage of AD61. Studies have shown that the imbalanced defense mechanism of antioxidants 
and oxidative damage to cellular macromolecules such as proteins, peptides and DNA accumulates 
with aging and neurodegenerative diseases167. In the past two decades much effort has been made 
to better elucidate the mechanism of oxidative damage in aging and neurodegenerative diseases, 
including using cysteine-selective redox proteomics. These studies gained quantitative insights 
into the redox-sensitive proteins and specific cysteine residues from human tissues and model 
animals. To date, quantitative studies of aging and neurodegenerative diseases using redox 
proteomics are reported in Table 2.1.  
Surprisingly, most of the aging-related redox proteomics are focused on total cysteine 
oxidations (i.e., the specific PTM is not identified). For example, an analysis of liver cytosolic 
proteins from young (4-6 months) and old mice (26-28 months) revealed 11 proteins (such as 
GAPDH, regucalcin and peroxiredoxin 1) showing a more than two-fold increase in cysteine  
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Table 2.1 Representative redox proteomics approaches to quantify various types of cysteine modifications in aging and neurodegenerative 
diseases. 
Year Sample Disease Method 
Cysteine 
Modification 
Results 
2004 Human brain tissues 
AD & PD 
 
2D gel, 
immunostaining and 
MS 
Sulfonic acid Cys220 of UCH-L1 is oxidized to cysteic acid168. 
2007 
Inferior parietal 
lobule from patients 
AD 2D-Oxyblots and MS SSG 
Deoxyhemoglobin, α-crystallin B, glyceraldehyde 
phosphate dehydrogenase (GAPDH), and α-enolase 
were significantly S-glutathionylated in AD169. 
2008 
Foetal, aged normal and 
advanced nuclear 
cataract lenses from 
human 
Aging 
Gel-free switch 
assay, label-free 
quantification, no 
enrichment 
 
Total oxidized 
cysteine 
Quantified relative amount of reduced form and 
oxidized form of each cysteine site within the same 
biological condition. αA, Cys 142; βA1/3, Cys 52; 
βB3, Cys 39 and Cys 45 had higher oxidized form in 
nuclear cataract and aged normal lenses compared with 
foetal170. 
2009 
Entorhinal cortex from 
patients 
Aging 
2D Western blots and 
MS 
SNO 
Glial fibrillary proteins were nitrosylated in a brain 
tissue from a 78-year-old female, 13 h postmortem 
delay without neurological disease171. 
2010 
Liver tissues from mouse 
at 4-6 and 26-28 months 
Aging 
Fluorescence-based 
2D gel and MS 
Total oxidized 
cysteine 
Global protein disulfide levels increased significantly 
with age in liver cytosolic proteins, an 11 proteins 
showed a more than twofold increase in disulfide 
content with age172. 
2011 
Brain cerebrum tissue 
from 5-month old 
transgenic 
mice (B6Cg-Tg) and WT 
controls 
AD 
 
CE-Laser induced 
fluorescence, switch 
assay 
SNO Transgenic mice brain had higher SNO than control173 . 
Continued on Page 39 
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Table 2.1 Representative redox proteomics approaches to quantify various types of cysteine modifications in aging and neurodegenerative 
diseases. 
Year Sample Disease Method 
Cysteine 
Modification 
Results 
2012 
Brain from 11-month old 
transgenic mice (B6Cg-
Tg) and WT controls 
AD 
2D micro-
electrophoresis 
SNO 
2D profiling of nitrosylated proteins in AD and WT 
brains. AD brain proteins with a MW between 35 kDa 
and 65 kDa were most susceptible to SNO174. 
2012 
Brain tissues and blood 
samples from 1-mon, 5-
mon and 11-mon TG 
mice and controls 
AD 
CE-Laser induced 
fluorescence, switch 
assay, PCA analysis 
SSG 
AD and controls could be differentiated (> 90% 
sensitivity and specificity) based on SSG 
electrophoretic profiling175. 
2014 
Autopsied brain 
specimens 
AD 2D-Oxyblot and MS SNO 
Superoxide dismutase (SOD2) [Mn], fructose-
bisphosphate aldolase C (ALDOC) and voltage-
dependent anion-selective channel protein 2 (VDAC2) 
showed differential S-nitrosylation signal123. 
2014 
Synaptosome of 
transgenic mouse (14-15 
mon) 
AD 
BST, avidin 
enrichment, label-
free quantification, 
gel-free 
SNO 
138 S-nitrosylated proteins were involved in various 
cellular pathways, including: glycolysis, 
gluconeogenesis, calcium homeostasis, ion and 
vesicle transport176. 
2014 Mouse skeletal muscles Aging 
Labeling reduced and 
oxidized cysteine 
using light and heavy 
NEM, respectively. 
Gel-free, non-
enriched 
Total oxidized 
cysteine 
The reversible redox state of specific cysteine residues 
within individual muscle samples was obtained177. 
2015 
Hippocampus from 
patients 
AD 2D-Oxyblots and MS 
Sulfenic acid, 
sulfinic acid and 
sulfonic acid 
Pin1 was identified to be oxidized on Cys113. This 
modification was elevated in human AD brain178,179.  
Continued on Page 40 
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Table 2.1 Representative redox proteomics approaches to quantify various types of cysteine modifications in aging and neurodegenerative 
diseases. 
Year Sample Disease Method 
Cysteine 
Modification 
Results 
2015 
Human cortex and 
cerebellum samples 
Human 
prion 
diseases 
(neurodeg
enerative 
disorders) 
BST, avidin 
enrichment, iTRAQ, 
gel-free 
SNO 
1509 S-nitrosylated proteins (SNO-proteins) were 
identified with differential expressions in many 
pathways180. 
2015 
Amyloid-activated BV2 
cells 
AD 
 
BST, avidin 
enrichment, gel-free 
Total oxidized 
cysteine 
60 proteins changed the redox status of their selective 
cysteine residues upon treatment with the 
amyloidogenic Aβ25-35 peptide181. 
2015 
Drosophila melanogaster 
(heads and thoraces) 
Aging and 
fasting 
OxICAT, gel-free 
 
Total oxidized 
cysteine 
Aging had no impact on cysteine-residue redox state. 
In contrast, fasting dramatically affected cysteine redox 
status182. 
2015 
Old and young Human 
eye tissues, glutathione 
depleted LEGSKO 
mouse lens 
Aging 
 
2D gel and OxICAT 
Total oxidized 
cysteine 
Shift of intramolecular disulfides to intermolecular 
disulfides during aging process was observed. Several 
disulfide formation sites necessitated prior 
conformational changes in γ-crystallin183. 
2016 
Liver tissue from AD 
model mouse 
AD 
Gel-free, 
dimethylation 
Total oxidized 
cysteine 
More than 1000 oxidized cysteine were identified. The 
most dysregulated pathway was metabolism. The over 
oxidized proteins involved in lipid metabolism could 
be linked with oxidative stress in AD liver141. 
2016 
Brain tissue from AD 
model mouse 
AD Gel-free, cPILOT SNO 
135 SNO-modified proteins were identified, and the 
majority of them were involved in metabolism and 
signal transduction. Statistical analysis indicated 12 
SNO-modified peptides had differential levels in AD 
compared with WT141. 
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oxidation content with aging172. In another study using young adult (12 months) and old (25 
months) mouse skeletal muscle, the absolute redox status of each cysteine site could be 
measured177. LC-MS/MS identified 50 and 24 redox cysteine proteins in young adult and old 
samples, respectively. Metabolic proteins (e.g., phosphofructokinase, glucose 6-phosphate 
isomerase, glycogen phosphorylase, phophoglycerate mutase 1, and phosphoglucomutase 2) 
containing oxidized cysteine were only identified in young adult samples, which suggests that 
muscle from adult mice has greater flexibility in the metabolic redox response. However different 
biological models may lead to inconsistent conclusions when using redox proteomics to study 
aging. For example, aging was found to have no impact on cysteine-residue redox status in 
Drosophila melanogaster182. However after 24-hour fasting significant oxidation of cysteine 
residues was observed182. Aging is not always accompanied with elevated oxidative stress, but 
fasting is able to induce major metabolic changes and cysteine oxidation, and serve as the 
organism’s response to fasting. Age-related nuclear cataract (ARNC) is a human eye disease with 
covalent crosslinking of polypeptides and loss of protein thiols184. In order to better understand the 
change of site-specific oxidation of cysteine residues in aging and ARNC, three different types of 
human lenses, including foetal lenses, order normal lenses and nuclear cataract lenses, were 
compared170. Ten cysteine residues were found not sensitive to aging, but they were largely 
oxidized in ARNC. Two cysteine residues in γC-crystallin were not oxidized in ARNC due to 
insufficient exposure to the oxidative environment. Another similar study revealed the shift of 
intramolecular disulfides to intermolecular disulfides during aging183. Redox proteomics using 
ICAT determined several disulfide formation sites necessitating prior conformational changes in 
γ-crystallin, which is consistent with the previous study170. 
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AD is a neurodegenerative disorder characterized by neurofibrillary tangles, senile plaques, 
and loss of synapses185. AD is also the main cause of senile dementia (approximately 75%). 
Oxidative stress has been reported in AD brain186, plasma187, heart188, spleen189 and liver141. These 
studies support the notion that oxidative stress plays a major role in the pathogenesis of AD.  
Cysteine can be oxidized into a variety of PTMs, among them SNO is the most frequently 
investigated in AD. SNO originates from the modification of free cysteine by nitric oxide (NO), a 
signaling molecule mainly formed by NO synthase in the CNS190. Protein nitrosylation and 
denitrosylation controls the activities of proteins and pathways in physiological conditions. For 
example, SNO of N-methyl-D-aspartate receptor (NMDAR) can decrease its enzyme activity to 
facilitate neuroprotection191. Also SNO modification has been linked with protein misfolding, 
mitochondrial fragmentation and subsequent neuronal loss63, and has been considered as a 
therapeutic target for neurodegenerative diseases192. In a study of entorhinal cortex from AD 
patients, although a variety of SNO-modified proteins in human brain tissue were identified, no 
significantly changed proteins in AD were observed171. However glial fibrillary proteins were 
found to be nitrosylated in a brain tissue from a 78-year-old female without neurological disease, 
which may suggest the involvement of SNO in aging process. In another study SNO-modified 
proteins of autopsied brain specimens, including hippocampus, substantia nigra and cortex from 
AD patients were investigated123. A total of 45 proteins were identified with endogenous 
nitrosocysteines. These proteins are involved in metabolism, signaling pathways, apoptosis and 
redox regulation. Three proteins, superoxide dismutase [Mn], fructose-bisphosphate aldolase C 
and voltage-dependent anion-selective channel protein 2, had enhanced SNO in AD compared 
with healthy controls. Elevated SNO of these proteins may result in altered detoxification, 
glycolysis and ion transportation in AD brain. SNO of brain synaptosomal proteins were quantified 
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using wild type and transgenic mice overexpressing mutated human amyloid precursor protein 
(hAPP) at 14 month old, a widely used animal model for AD176. One hundred and thirty-eight 
synaptic proteins were SNO-modified, and 38 of those were differentially SNO-modified in hAPP 
mice. SNO-modified proteins were involved in glycolysis, gluconeogenesis, calcium homeostasis, 
ion and vesicle transport, indicating the wide involvement of SNO in basic cellular pathways. 
Brain tissues from APP/PS1 AD mouse model was also investigated using OxcyscPILOT, in 
which 135 SNO-modified proteins were identified, and the majority of which participated in 
pathways of metabolism and signal conductions (Chapter 6)141. The identified proteins containing 
SNO modification, as well as the quantitative information obtained by this study, had considerable 
agreement with previous studies123,176.  
In addition to SNO, SSG is also an important cysteine reversible PTM with biological 
relevance in neurodegenerative diseases193. SSG was probed in inferior parietal lobule (IPL) and 
hippocampus from AD patients169. This work found deoxyhemoglobin, a-crystallin B, 
glyceraldehyde phosphate dehydrogenase (GAPDH), and a-enolase were significantly modified 
by SSG in AD. More interestingly, GAPDH and α-enolase had reduced activity in the AD IPL.  
Our knowledge of redox-modified proteins involved in the pathogenesis and progression 
of AD is consistently being updated. Proline isomerase Pin1 was significantly carbonylated in AD 
hippocampus with decreased activity both in vivo and in vitro194. Recent studies showed the 
oxidation of Pin1 Cys113 was significantly elevated in human AD brains and AD mouse models178. 
Pin1 oxidation on Cys113 inactivated its activity, but the oxidative inhibition of Pin1 could be 
partially reversed by treatment with dithiothreitol179. Cys113 of Pin1 in AD brain tissue was 
probably oxidized into sulfenic acid, sulinic acid or sulfonic acid. It is challenging to determine 
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the relative abundances of the three PTMs in vivo, which may be solved by using chemical 
derivatization coupled with MS195.  
A new method, which couples capillary gel electrophoresis with laser induced fluorescence 
detection and fluorescence switch assay, is able to differentiate the cysteine-modified proteins 
between different complex samples. This method was applied to differentiate the SNO and SSG 
proteins in AD transgenic mice and age matched WT controls173. 
In addition to SNO and SSG, the total cysteine reversible modifications were also 
examined in AD related studies. For example, the reversibly modified microglial proteome of BV2 
cells after treatment of Aβ25-35, a short peptide known to be able to induce the inflammatory and 
oxidative status on microglia without affecting cell viability, was quantified181. This study 
identified 60 proteins with changed redox status. In another report the redox-regulated liver 
proteins from transgenic AD mouse were examined39. This work identified 1129 reversibly-
oxidized cysteine sites, among which 19 showed significant differences between AD and controls 
(Chapter 5). Proteins involved in lipid metabolism were found in more oxidized form, and is 
correlated with the overwhelmed oxidative stress in AD liver tissue. 
PD is the second most prevalent degenerative disease of the nervous system with the 
accumulation of insoluble proteinaceous deposits such as Lewy bodies61. Ubiquitin carboxyl-
terminal hydrolase L1 (UCH-L1) is associated with familial forms of PD196, and oxidized of 
Cys220, as well as Met124 and Met179 in both AD and PD168. In addition to AD and PD, human 
prion diseases, fatal neurodegenerative disorders characterized by neuronal damage in brain and 
accumulation of misfolded protein deposits in the CNS197, have also been investigated by redox 
proteomics. SNO-modified proteins of human cortex and cerebellum tissues from normal controls, 
sporadic Creutzfeldt-Jakob disease (sCJD), fatal familial insomnia (FFI), and genetic CJD with a 
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substitution of valine for glycine at codon 114 of the prion protein gene (G114V gCJD) were 
compared180. A total of 1509 endogenous SNO-proteins were identified, making it one of the 
relevant studies with the highest proteome coverage. Differentially expressed SNO-proteins were 
mainly involved in metabolism, cell cytoskeleton/structure, immune system, cell-cell 
communication and miscellaneous function protein.  
2.5 APPLICATIONS OF REDOX PROTEOMICS TO STUDY PROTEIN 
CARBONYLATION IN ALZHEIMER’S DISEASE 
Redox proteomics studies can directly identify, from brain, fluids or other biological 
sample, a large number of carbonylation modified proteins potentially involved in the pathogenesis 
and/or progression of AD characterized by increased oxidative stress198,199. Some representative 
studies are listed in Table 2.2.  
Increased carbonylation levels exist in AD inferior parietal lobule (IPL) compared to age-
matched controls200,201. Following studies performed on hippocampal region of AD subject 
compared to CTR demonstrated specific carbonylation of Pin1, phosphoglycerate mutase 1, UCH 
L-1, DRP-2, carbonic anhydrase II, triose phosphate isomerase, α-enolase, and γ-SNAP202. The 
impairment of the functionality of the proteins found oxidized in these studies correlates features 
of AD pathology such as the inhibition of cellular degradation machinery and synaptic failure203. 
Korolainen et al. applied a similar redox proteomics approach to frontal cortex samples of AD 
patients compared to healthy subjects showing a decrease of carbonyls in malate dehydrogenase 
1, glutamate dehydrogenase, 14-3-3 protein ς/δ, aldolases A and C, and increased oxidation of 
carbonic anhydrase204. 
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Table 2.2 Redox proteomics studies of neurodegenerative diseases61. 
Pathology Sample 
Oxidative 
modification 
Oxidatively modified proteins Altered biological functions 
AD 
Human brain 
(hippocampus, 
IPL and 
cortex) 
Carbonylation 
CKBB, GS, UCH-L1, DRP-2, 
ENO1, HSC71, Pin1, PGM1, TPI, 
γ-SNAP, CA, MDH, GDH, 14-3-3 
ς/δ, FBA A/C 
energy metabolism, protein 
degradation, neuron outgrow, 
cell signaling, cell cycle, 
neurotransmission, protein 
transport, molecular 
chaperone194,200-202,204 
Human body 
(CSF and 
plasma) 
Carbonylation 
λ-chain precursor, hemopexin, 
transferrin, fibrinogen λ chain 
precursor, α1 antitrypsin precursor, 
Hp β chain, α2 macroglobulin 
heme transport, iron transport, 
blood coagulation, 
extracellular chaperone205-208 
Synaptosomes 
with Aβ (1-42) 
Carbonylation 
β- and γ- chain, GFAP, ATP 
synthase, SNBP1, GDH, GS, 
EAAT2, DRP-2, EF-Tu 
cell structure, energy 
metabolism, 
neurotransmission, neuron 
outgrow, protein 
biosynthesis209 
Rat brain with 
Aβ (1-42) 
Carbonylation 
GS, tubulin  β chain 15/α, 14-3-3 ς, 
HSP60, β-synuclein, PDH, 
GAPDH, PGM1 
neurotransmission, cell 
structure, cell signaling, 
molecular chaperone, energy 
metabolism210 
C. elegans 
with Aβ (1-42) 
Carbonylation 
medium and short-chain acyl-CoA 
DH, EF-1 γ, MDH, AK, RACK1, 
mlc-1 and 2, actin, ADK, 
nematode specific protein, lbp-6, 
TKT, α and β proteasome subunit, 
GST 
energy metabolism, protein 
biosynthesis, protein 
degradation, axon extension, 
cell structure, cell cycle, 
antioxidant211 
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  In addition to human brain tissues, other models have been used to study protein 
carbonylation in AD. For example, the SAMP8 model (the senescence-accelerated prone mouse) 
exhibits age-dependent learning and memory deficits212, making it a model for studying age-
related cognitive impairments that might lead to AD onset and progression213. Analysis of protein 
carbonylation by redox proteomics show increased levels for LDH-2, DRP2, α-spectrin and CK in 
the brain of 12-month-old SAMP8 mice when compared with the 4-month-old SAMP8 brain. 
Other relevant studies include in vitro treatment of synaptosomes with Aβ (1-42)209 and in vivo 
injection of rat brain with Aβ (1-42)210. Proteins such as actin, GFAP, 14-3-3 ζ and HSP60 were 
significantly oxidized, suggesting the mechanism of neurodegeneration driven by Aβ deposition. 
It is noteworthy to highlight that there are no models which contain all of the characteristics and 
behaviors of AD. When designing new experiments and comparing results from different sources, 
one must be careful of the models as well as potential limitations of their use in studying AD. 
2.6 CONCLUSIONS 
Oxidative protein modifications (including cysteine oxidation and protein carbonylation) 
have been shown to be ubiquitously and dynamically involved in aging and aging-related 
neurodegenerative diseases. The growth of MS-based proteomics, including gel-based and nongel-
based approaches, has led to discovery of new PTMs and their identification and quantification. 
For example in Chapter 3, a MS method was developed to characterize a model protein carrying 
various types of oxidative modifications. We believe that the key for future improvements of redox 
proteomics is development of novel methods with higher sensitivity, accuracy, simplicity and 
throughput, for example, the OxcysDML and OxcyscPILOT approaches that will be discussed in 
Chapters 5 and 6. Continued advances in redox proteomics will further the understanding of aging 
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and aging-related neurodegenerative diseases, especially the redox molecular mechanism, the roles 
of oxidative stress and redox signaling in cellular processing.  
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3.0 MULTIPLE PROTEASES TO LOCALIZE OXIDATION SITES 
(Note that information in this chapter is written based on a published research paper214, Gu, L.; 
Robinson, R. A. S. PloS one 2015, 10, e0116606.) 
3.1 INTRODUCTION 
Reactive oxygen and nitrogen species (ROS/RNS) in cellular environments can result in 
macromolecular oxidative damage215 and lead to loss of protein function62, which have been 
reviewed  in Chapter 293,156,216. Key to understanding the events that affect protein function is the 
ability to characterize the distribution of oxidized proteoforms. 
Techniques for the identification of proteoforms have been recently discussed18,217-220. 
Proteoforms can include molecules that arise due to the same post-translational modification (PTM) 
occurring at different amino acid residue positions in the protein. For example, a protein that 
incorporates a single oxygen atom during a free radical attack from hydrogen peroxide (H2O2) or 
superoxide anion, may exist in multiple locations. One population of the protein molecules can 
incorporate the oxygen at residue “A”, others incorporate at residue “B”, while the remaining 
molecules incorporate at both “A” and “B”. For the molecules with only a single oxygen addition, 
mass spectrometry (MS) measurements of intact protein would only detect a single M+16 Da 
species. Liquid chromatography (LC) or electrophoresis separations may be able to resolve the 
two proteoforms (i.e., A and B), however multiple dissociation methods such as collisional 
activation dissociation (CAD)221, infrared multiphoton dissociation222, electron capture 
dissociation (ECD)223, or electron transfer dissocation  (ETD)224 are necessary to localize the 
modification site.         
Top-down and bottom-up protein analysis provides complementary information regarding 
protein sequence and PTMs218,225-228, especially for identification of oxidation sites229-231.  Top-
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down MS has been employed to characterize four oxidation sites in viral prolyl-r-hydroxylase230 
and for the identification of 250 isoforms of oxidized calmodulin231. Bottom-up proteomics is very 
useful for the verification of PTM types and sites although it can be challenging to identify the 
specific proteoform from which peptides originated. This is because shotgun analysis of all 
proteins extracted will lead to many similar peptides produced from various proteoforms. Because 
fragmentation of peptides is very accessible with CID and other dissociation methods, as compared 
to intact proteins, it is very practical to use bottom-up analyses to localize sites of oxidative 
modification. However, for complex biological samples the number of modification sites that can 
be characterized without extensive enrichment or separation strategies is generally low232,233. 
Therefore, it will be necessary to incorporate enrichment with our strategy of multiple proteases 
and iterative database searching to gain localize oxidative modification sites and obtain insight to 
the complexity of oxidized proteoforms present in complex mixtures. 
Ubiquitin is a low molecular weight protein which has significant roles in protein turnover 
and degradation through its molecular chaperoning activity in the proteasome234. Ubiquitin is 
implicated in oxidative stress and disease235,236. The 76 amino acid sequence of this protein is 
highly conserved amongst eukaryotes, such as bovine and human237. Herein, we aimed to 
characterize the heterogeneity of proteoforms of ubiquitin using moderate oxidizing conditions238 
and bottom-up MS with multiple proteases. Chemical oxidizing conditions using Fenton chemistry 
[Fe(II)/H2O2]
238 rely on the metal serving as an electron donor to catalyze the formation of highly 
reactive hydroxyl radical (·OH) which can result in modification of amino acid side chains216,239. 
Previous studies have investigated oxidized forms of ubiquitin after exposure to peroxynitrite240, 
electrochemical oxidation241,242, and photochemical reactions243 for the purpose of structural 
footprinting. The influence of N-terminal oxidation of Methionine (hereafter referred to as Met1-
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Ox) on protein structures and stabilities were examined by ion mobility spectrometry-mass 
spectrometry (IMS-MS)244 and indicate that oxidation of Met1 can lead to destabilization of the 
native state and result in unfolded structures. Thus simple oxidized proteoforms can have a huge 
influence on protein structure.   
Bottom-up LC-MS/MS of peptides generated from multiple proteases245 allows multiple 
oxidation products of ubiquitin to be identified, including several proteoforms of the M+16 Da 
peak. Under Fe(II)/H2O2 conditions, numerous amino acid modifications are possible
246 and 
include side chain hydroxylation, carbonylation and backbone cleavage. The variety of these 
modifications requires multiple database searches to be performed157. Sample integrity was 
confirmed by using high resolution ESI-MS on an Orbitrap Velos of intact oxidized protein 
mixtures.  
3.2 EXPERIMENTAL METHODS 
3.2.1 In Vitro Oxidation of Ubiquitin 
Bovine ubiquitin was purchased from Sigma-Aldrich (St. Louis, MO).  Protein (10 mg·mL-
1) was dissolved in 10 mM sodium phosphate buffer solution (pH 7.4) and 10 mM H2O2 and 1 mM 
FeCl2 were added and allowed to react at 37 C for 2 hours. The reaction was quenched by flash 
freezing with liquid nitrogen. Protein sample was desalted on an HLB cartridge (Waters; Milford, 
MA) according to manufacturer’s instructions. Solvent was removed by centrifugal evaporation 
and dried protein stored at -80 °C until further analysis.  
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3.2.2 Top-down ESI-MS and MSn Analysis 
Intact oxidized ubiquitin (~30 M) was solubilized in 49:49:2 water:methanol:acetic acid. 
ESI-MS analysis was performed on a LTQ-Orbitrap Velos mass spectrometer (Thermo-Fisher 
Scientific, Waltham, MA) with direct infusion by a syringe pump. The following electrospray 
ionization parameters were used: spray voltage 4.25 kV; capillary temperature 200.00 C and flow 
rate 3 μL·min-1. Orbitrap detector settings included resolving power of 100 k, parent m/z scan 
range 600-2000, 3 scans, and 30 and 100 scans for parent and fragmentation spectra, respectively. 
MS/MS data were recorded in the FT. MS/MS and MS3 settings used an isolation width of 1 m/z 
and normalized collision energy of 35%. 
3.2.3 Protein Digestion 
Purified oxidized ubiquitin (1 g·L-1) was solubilized in a denaturing buffer (0.2 M Tris, 
8 M urea, 10 mM CaCl2, pH 8.0). Tris buffer (0.2 M Tris, 10 mM CaCl2, pH = 8.0) was added to 
dilute urea to 2 M. The solution was separated into three equal volume aliquots and each incubated 
with TPCK-treated trypsin (Sigma), glutamic acid-C [(Glu-C); Princeton Separation, Inc, 
Adelphia, NJ] or lysine-C [(Lys-C); Princeton Separation, Inc] proteases at a 1:50 protein:enzyme 
mass ratio for 24 h at 37 C. Liquid nitrogen was used to quench digestions and samples were 
acidified by adding formic acid, desalted with HLB cartridges and the eluent dried by centrifugal 
evaporation. 
3.2.4 Nanoflow LC-MS/MS 
Online desalting and reversed-phase chromatography was performed with a nanoLC 
system equipped with an autosampler (Eksigent; Dublin, CA). Mobile phases A and B for these 
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analyses were 96.95:2.95:0.1 water:acetonitrile:formic acid and 99.9:0.1 acetonitrile:formic acid, 
respectively. Five μL of each peptide sample (1 g·L-1 in 0.1% formic acid) was loaded on to a 
trapping column [100 μm i.d. × 2 cm; 3 m C18 200 Å stationary phase material (Michrom 
Bioresource Inc.;Auburn, CA)] at 3 μLmin-1 in 3% mobile phase B for 3 min. After desalting, the 
sample was loaded onto a pulled-tip (using a CO2 laser) analytical column (75 μm i.d. × 13.2 cm), 
packed in-house with 3 m C18 100 Å stationary phase material (Michrom Bioresource Inc.). The 
following gradient was delivered at a flow rate of 300 nL·min-1: 0-5 min, 10% mobile phase B; 5-
15 min, 10-30% B; 15-45 min, 30-45% B; 45-50 min, 45-60% B; 50-55 min, 60-80% B; 55-65 
min, 80% B; 65-75 min, 10% B. The LC eluent was introduced into the ESI source with ~1.5-2.0 
kV.  Data-dependent acquisition parameters were: parent Orbitrap MS resolving power 60 k; m/z 
scan range 300-1800; the top eight most intense ions were selected and activated using CID; 
isolation width 3 m/z; normalized collision energy 35%; dynamic exclusion was enabled with a 
repeat count of two for a duration of 60 sec; and, a minimum of 5000 ion counts for MS/MS. 
Samples were analyzed in triplicate. 
3.2.5 Data Analysis 
Top-down spectra were viewed and analyzed by Xcalibur 2.1 software (Thermo). The 
Xtract program (Xcalibur) was used to deconvolute the spectra and calculate protein masses. 
Spectra were manually inspected and the m/z values matched to theoretical b- and y-type ions 
generated by ProteinProspector v5.9.4247. For peptide data, .RAW files were analyzed with 
Proteome Discoverer 1.3 software (Thermo) and MS/MS spectra searched against a .fasta file 
containing the ubiquitin sequence (truncated from the N-terminal region of Uniprot ID P0CH28).  
Sequest search parameters included two maximum enzyme miscleavages; precursor mass 
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tolerance of 10 ppm; fragment mass tolerance of 0.8 Da; dynamic modifications (see Table 3.1) of 
mono oxidation to Lys, Arg, Pro, Thr, Met, His, Tyr, Ala, Asn, Asp, Glu, Gln, Ile, Leu, Phe, Ser 
and Val (Ox, +15.995 Da), dioxidation to Lys, Arg, Pro, His, Tyr, Asn, Asp, Phe and Met (DiOx, 
+ 31.990 Da), carbonylation to Lys, Arg, Pro, Glu, Gln, Leu, Ser, Val and Ile (+13.979 Da), 
deamidation to Gln, Arg and Asn (0.984 Da), decarboxylation to Asp and Glu (-30.010 Da), 
oxidation of His to Asn (-23.0159 Da) or Asp (-22.032 Da) or aspartylurea (-10.032 Da) or ring 
open (4.979 Da), carbonylation of Arg to glutamic semialdehyde (GluSA, -43.053 Da), Lys to 
aminoadipic semialdehyde (AminoAdSA, -1.032 Da) or aminoadipic acid (14.963 Da), Pro to 
pyrrolidinone (-30.010 Da), and Thr to 2-amino-3-oxo-butanoic acid (Oxd’n, -2.016 Da). Only 
peptides with medium ( p < 0.05) and high confidence (p < 0.01) as determined from a reverse 
decoy database search (which in Proteome Discoverer sets appropriate thresholds for XCorr values 
as a function of charge state) were used for initial filtering of the data53,248,249. For final inclusion 
of peptide hits and localization of modification sites, all MS/MS spectra were manually validated.   
3.3 RESULTS AND DISCUSSION 
3.3.1 MS Analysis of Intact Oxidized Ubiquitin 
High-resolution ESI-MS analysis of a solution containing only untreated ubiquitin shows 
an M+16 Da peak that represents < 2% of the total unmodified peak intensity in a deconvoluted 
spectrum (data not shown). Because the untreated sample has very limited sample handling, the 
M+16 Da species could be from the manufacturing and storage of the protein product, or from the 
electrospray ionization, (e.g. solution contact with metal needle or the electrolysis of water under 
high spray voltage. However, utilizing Fenton chemistry, several peaks belonging to oxidized 
ubiquitin are observed (Figure 3.1). The most intense oxidized peak belongs to an M+16 Da  
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Table 3.1 List of all oxidative modifications searched. 
  Modification Mass Change Residues 
  
Mono Oxidation 15.99491 Da 
Lys, Arg, Pro, Thr, Met, His, Tyr, Ala, Asn, Asp, 
Glu, Gln, Ile, Leu, Phe, Ser, Val 
Dioxidation 31.98982 Da Lys, Arg, Pro, His, Tyr, Asn, Asp, Phe, Met 
Carbonylation 13.97926 Da Lys, Arg, Pro, Glu, Gln, Leu, Ser, Val, Ile 
Deamidation 0.98402 Da Gln, Arg, Asn 
Decarboxylation -30.01056 Da Asp, Glu 
Special oxidations of 
 histidine 
His-Asn -23.0159 Da His 
His-Asp -22.0319 Da His 
His-Aspartylurea -10.03198 Da His 
His - Formy Asn 4.97892 Da His 
Special carbonylation 
Lys-AminoAdSA -1.0316 Da Lys 
Lys-Aminoadipic acid 14.9632 Da Lys 
Arg-GluSA -43.0534 Da Arg 
Pro-Pyrrolidinone -30.0105 Da Pro 
Thr-Oxd'n -2.01565 Da Thr 
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species at each charge state measured (i.e., +5 - +13). The inset of Figure 3.1 shows a zoom-in of 
the +12 charge state, whereby two protein isotopic distributions are measured for unmodified and 
oxidized ubiquitin ions. Upon deconvolution of the spectrum it is noted that the M+16 Da species 
constitutes ~20% of the unmodified abundance. This is a factor of ten increase in M+16 Da ions 
in comparison to solutions containing only untreated ubiquitin. The masses of the deconvoluted 
native and M+16 Da peaks are 8564.601 and 8580.592 Da. These values are < 5 ppm of the 
theoretically derived mass values and indicate a mass shift of 15.991 Da.  Notably, this shift 
corresponds to the predominance of monooxygenated proteoforms in the Fe(II)/H2O2-ubiquitin 
mixture. The incorporation of an oxygen atom does not appear to influence the ionization 
efficiencies and hence observed signal intensity of ubiquitin in ESI250, and is directly related to the 
relative abundance of each proteoform. Other proteoforms are observed in the spectrum: M-114 
Da, M-57 Da, M-44 Da, M-16 Da, M+32 Da species, M+48 Da and M+96 Da. However, these 
peaks are low intensity and its possible many proteoforms are not observed in this direct infusion 
experiment. 
3.3.2 Characterizing Methionine Oxidation Proteoform 
Based on the sequence of ubiquitin, we anticipated methionine oxidation. The 
[M+O+12H]12+ protein peak was isolated and fragmented in the linear ion trap with CID. As shown 
in Figure 3.2 many of the b- type fragment ion peaks are shifted in mass from expected fragments 
of unmodified ubiquitin ions by 16 Da. Moderate sequence coverage of the intact protein (Figure 
3.2) was obtained with CID and could be increased using dissociation methods such as ECD and 
ETD251-254. Inspection of the lower mass region (m/z 260-410) of the spectrum in Figure 3.2 
revealed the detection of [b2+O+H]
+ and [b3+O+H]
+ ions, indicating the oxygen atom addition on  
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Figure 3.1 Precursor ion mass spectra of oxidized ubiquitin. In the inset is a zoom-in of the +12 charge 
state that shows unmodified and oxidized ubiquitin species. The observed mass shift between native and 
oxidized ubiquitin is indicated in the figure. 
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Figure 3.2 CID MS/MS spectra obtained upon isolation of +12 charge state oxidized ubiquitin species (m/z 
716.06, isolation window 1 m/z). Zoom-in CID MS/MS spectra of the m/z range 260-410. To the right top 
is the sequence of ubiquitin with observed fragment ions across all z labeled.   
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residue Met-1 or Gln-2. Based on the higher sensitivity of methionine to oxidation89, it is very 
probable that the conversion of the single methionine residue to methionine sulfoxide occurred. 
Multiple proteases allow for enhanced sequence coverage in proteomics as some cleavage 
sites are inaccessible with common enzymes245 and oxidative modification may also hinder 
enzymatic cleavage for some residues (e.g., Lys and Arg)161. Peptide analysis of oxidized ubiquitin 
digests using trypsin, Lys-C, and Glu-C proteases is consistent with an M+16 Da methionine 
sulfoxide proteoform (see Table 3.2). Several oxidized methionine-containing peptides were 
identified in nanoLC-MS/MS analyses including doubly-charged mQIFVKTLTGK, mQIFVK, 
and mQIFVKTLTGKTITLE peptides derived from trypsin, Lys-C, and Glu-C proteases, 
respectively (Figure 3.3). The most predominant peak in the MS/MS spectra of each of these 
peptides is the doubly-charged precursor ion with the loss of methyl sulfoxide [M+2H-CH3SOH]
2+. 
This precursor ion is consistent with the presence of an oxidized methionine residue and has been 
observed by others255,256. For the spectra in Figure 3.3, observed b-ions (including b2 fragments) 
are shifted by 16 Da which localizes the modification site to Met1. While not performed in these 
studies, methionine oxidation can also be tested through enzymatic action with peptidyl 
methionine sulfoxide reductase or by treatment with dithiothreitol257,258.               
3.3.3 Mapping Other M+16 Da Proteoforms 
Figures 3.4a and 3.4b show MS/MS spectra of the tryptic peptide [LIfAGK+H]+ and the 
Lys-C peptide [EGIPPDQQRLIfAGK+2H]2+, respectively. Each of these spectra contains 
fragment ions that localize an oxidative modification to a phenylalanine residue (i.e., Phe45). 
Phenylalanine contains an aromatic ring which upon oxidation can be modified by hydroxyl 
radicals at the para-, ortho-, or meta- positions as shown in Figure 3.4a259,260. Similarly, MS/MS  
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Table 3.2 List of oxidative modifications identified from multiple proteases. 
Sequencea Modificationsb XCorr Charge m/z MH+ (Da) 
Δm 
(ppm) 
tr (min) Protease 
EGIPpDQQRc P38-Oxidation 2.15 2 528.2591 1055.5109 -0.71 16.88 Trypsin 
EGIPpDQQRc P38-Carbonylation 2.39 2 527.2507 1053.4942 -1.73 15.8 Trypsin 
EGIpPDQQRc P37-Carbonylation 1.73 2 527.2507 1053.4941 -1.85 18.43 Trypsin 
EGiPPDQQRc I36-Carbonylation 2.18 2 527.2531 1053.499 2.79 13.43 Trypsin 
EGIPPDQQRLIfAGK F45-Oxidation 3.03 2 842.9547 1684.9022 0.21 22.71 LysC 
ESTLhLVLRc H68-Oxidation 1.77 2 542.3115 1083.6158 0.04 24.09 Trypsin 
ESTLHlVLRc L69-Carbonylation 2.57 2 541.3021 1081.5969 -2.98 21.07 Trypsin 
EStLHLVLRc T66-Oxd'n 2.75 2 533.3046 1065.6019 -3.1 20.55 Trypsin 
ESTLhLVLRc H68-Asp 2.17 2 523.2972 1045.5872 -1.57 20.72 Trypsin 
ESTLHlVlRc L69-Oxidation, L71-Oxidation 2.14 2 550.3061 1099.6049 -5.22 22.16 Trypsin 
ESTLhLVLRc H68-Dioxidation 1.79 2 550.3055 1099.6037 -6.33 20.42 Trypsin 
ESTLhLVLRc H68-Histidine ring open (+5) 2.00 2 536.801 1072.5947 -4.74 22.56 Trypsin 
EstLHLVLRLRGGc S65-Oxidation,T66-Oxd'n 2.32 3 488.949 1464.8325 2.91 28.46 LysC 
EVEPSDTIeNVKAKIQc E24-Decarboxylation 2.63 2 885.465 1769.9227 -3.05 28.22 LysC 
GkQLEDGRc K48-Carbonylation 1.98 2 458.7275 916.4476 -0.78 14.51 Trypsin 
IQDKEGIPpDQQRc P38-Dioxidation 3.67 2 778.389 1555.7707 -0.3 19.16 Trypsin 
IQDKEGiPPDQQRc I36-Carbonylation 2.55 3 513.2579 1537.7591 -0.98 14.3 Trypsin 
LIfAGK F45-Oxidation 1.79 1 664.4038 664.4038 1.31 22.16 Trypsin 
LIfAGKQLEDGRc F45-Oxidation 2.29 3 454.9167 1362.7355 -1.58 16.12 Trypsin 
mQIfVKc M1-Oxidation, F4-Oxidation 2.16 2 399.2154 797.4235 1.1 21.18 LysC 
MQIfVKc F4-Oxidation 1.97 2 391.2171 781.4269 -1.09 22.53 LysC 
mQIFVKc M1-Oxidation 1.77 1 781.4302 781.4302 3.23 22.04 GluC 
Continued on Page 61 
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Table 3.2 List of oxidative modifications identified from multiple proteases. 
Sequencea Modificationsb XCorr Charge m/z MH+ (Da) 
Δm 
(ppm) 
tr (min) Protease 
mQIfVKc M1-Oxidation,F4-Oxidation 2.13 2 399.215 797.4228 0.18 21.01 Trypsin  
MQIfVKc F4-Oxidation 1.79 2 391.2177 781.4282 0.63  22.09 Trypsin 
mQIFVKc M1-Oxidation 1.72 1 781.4271 781.4271 -0.84 12.65 Trypsin 
mQIFVKc M1-Oxidation 1.96 2 391.2167 781.4261 -2.1 13.6 Trypsin 
mQIFVK M1-Oxidation 1.95 2 391.2177 781.4282 0.55 21.27 LysC 
mQIFVKc M1-Oxidation 1.76 1 781.4271 781.4271 -0.84 21.33 LysC 
mQIFVKTLc M1-Oxidation 2.84 2 498.2857 995.5641 4.63 25.08 GluC 
MQIFVkTLTGK K6-AminoAdSA 3.09 2 632.8536 1264.7 2.35 26.95 LysC 
mQIFVKTLTGKc M1-Oxidation 3.05 3 427.9143 1281.7283 3.66 23.55 GluC 
mQIFVKTLTGK M1-Oxidation 3.52 2 641.3641 1281.7209 -2.12 18.11 Trypsin 
mQIFVKTLTGKc M1-Oxidation 2.8 3 427.9117 1281.7207 -2.27 18.12 Trypsin 
mQIFVKTLTGKTITLE M1-Oxidation 4.79 2 920.0217 1839.0362 3.53 26.58 GluC 
mQIFVKTLTGKTITLE
VEPSDTIENVKAKc 
M1-Oxidation 5.18 4 813.1945 3249.756 -2.84 22.06 Trypsin 
NVKAKIQDkeGc 
K33-Oxidation; E34-
Decarboxylation 
3.1 2 608.3413 1215.6752 4.92 18.97 GluC 
NVKAKIQDKEGIPpc P38-Dioxidation 2.54 3 523.6282 1568.8702 3.71 20.44 GluC 
QLEDGRTLSDyNIQK Y59-Oxidation 3.68 2 898.4461 1795.8849 1.55 22.14 LysC 
QLEDGrTLSDYNIQKc R54-GluSA 2.34 2 868.9171 1736.827 -3.94 19.35 Trypsin 
tITLEVEPSDTIENVKc T12-Oxd'n 3.14 2 893.4609 1785.9145 1.54 25.96 LysC 
TITlEVEPSDTIENVKc L15-Oxidation 3.44 2 902.4661 1803.9249 1.42 24.32 Trypsin 
TITLEVEPsDTIENVKc S20-Carbonylation 2.83 2 901.4577 1801.9081 0.83 24.64 Trypsin 
TITLEVePSDTIENVKc E18-Decarboxylation 2.03 2 879.4589 1757.9105 -3.62 22.07 Trypsin 
TLSDYNIQkc K63-Oxidation 2.56 2 549.2772 1097.5472 -0.17 21.3 Trypsin 
Continued on Page 62 
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Table 3.2 List of oxidative modifications identified from multiple proteases. 
Sequencea Modificationsb XCorr Charge m/z MH+ (Da) 
Δm 
(ppm) 
tr (min) Protease 
TLSDYNIqKc Q62-Deamidation 2.17 2 541.7697 1082.532 -4.09 14.47 Trypsin 
TLSDyNIQK Y59-Oxidation 2.61 2 549.2759 1097.5446 -2.51 14.33 Trypsin 
tLSDYNIQKc T55-Oxd'n 2.13 1 1079.5325 1079.5325 -4 19.29 Trypsin 
tLSDYNIQK T55-Oxd'n 1.74 2 540.269 1079.5307 -5.65 20.28 Trypsin 
aLowercase letters represent the amino acid residues that have oxidative modifications.  bPositions of modified residues in the entire ubiquitin sequence 
are shown and are abbreviated as follows: Oxidation indicates an oxygen addition to the amino acid residue, Dioxidation indicated two oxygens addition 
to the amino acid residue, carbonylation indicates formaton of carbonyl group with a mass increase of 14 Da, GluSA indicates the carbonylation of 
arginine to glutamic semialdehyde, AminoAdSA indicates the carbonlyation of lysine to aminoadipic semialdehyde, Oxd'n indicates the carbonlyation of 
threonine to 2-amino-3-oxo-butanoic acid, Asp indicates the oxidation of histidine to aspartic acid, Deamidation indicates the conversion of -NH2 to -OH 
and Decarbonylation indicates the loss of carboxyl group .cMS/MS spectra of each peptide is provided in Appendix A Figure 3.1. 
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Figure 3.3 CID MS/MS spectra of a) [mQIFVKTLTGK+2H]2+ with Met1-Ox as observed by trypsin 
proteolysis , tr=18.11 min, m/z=641.36; b) [mQIFVK+H]2+ with Met1-Ox as observed by Lys-C proteolysis, 
tr=21.27 min, m/z=391.22 and c) [mQIFVKTLTGKTITLE+2H]2+ with Met1-Ox as observed by Glu-C 
proteolysis, tr =26.58 min, m/z=920.02. Note that lowercase letters represent the oxidation of methionine to 
methionine sulfoxide. Ions labeled with asterisks (*) contain modifications. 
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Figure 3.4 CID MS/MS spectra of a) [LIfAGK+H]+ with Phe45-Ox as observed by trypsin proteolysis, 
tr=22.16 min, m/z=664.40; b) [EGIPPDQQRLIfAGK+2H]2+ with Phe45-Ox as observed by Lys-C 
proteolysis, tr=22.71, m/z=842.95; c) [TLSDyNIQK+2H]2+ with Tyr59-Ox as observed by trypsin 
proteolysis, tr=14.33 min, m/z=549.28 and d) [QLEDGRTLSDyNIQK+2H]2+ with Tyr59-Ox as observed 
by Lys-C proteolysis, tr=22.14 min, m/z=898.45.  Note that lowercase letters represent the oxidation of 
phenylalanine and tyrosine. Ions labeled with asterisks (*) contain modifications. 
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spectra of the tryptic peptide [TLSDyNIQK+2H]2+ and Lys-C peptide 
[QLEDGRTLSDyNIQK+2H]2+ tentatively assign oxidation of the Tyr59 residue (Figures 3.4c and 
3.4d, respectively).   
Overall we observe several peptides which contain a monoxygenated residue (Table 3.2).  
Positions of these modifications are: Met1, Phe4, Leu15, Lys33, Phe45, Ser55, Tyr59, Lys63, 
His68, Leu69, and Leu71. It is possible that each of these peptides arise from different molecules 
of intact M+16 Da proteoforms. However, it is also likely that they arise from lower intensity 
M+32 Da or other oxidized proteoforms. Ambiguous identifications include Pro37 which is shifted 
by 16 Da and could correspond to oxygen incorporation or a carbonyl shift to glutamic 
semialdehyde.   
3.3.4 Identification of Other Oxidative Proteoforms 
The most abundant oxidized species that exist in these data arise from the incorporation of 
oxygen to amino acid side chains however other proteoforms are present. Figures 3.5a and 3.5b 
are example MS/MS spectra from trypsin and Lys-C peptides [tLSDYNIQK+2H]2+ and 
[MQIFVkTLTGK+2H]2+, respectively. Fragment ions are present (Figure 3.5a) which locate an 
oxidation site to Thr55. Threonine oxidation results in carbonylation to 2-amino-3-oxo-butanoic 
acid represented by a mass loss of -2.016 Da. Figure 3.5b provides MS/MS fragments which 
identify Lys6 oxidation represented by a mass loss of 1.032 Da. It is noted that this N-terminal 
peptide contains an unmodified methionine residue and thus originates from other oxidized 
proteoforms. Other modifications observed with multiple proteases are provided in Table 3.2 (and 
Appendix A Figure 3.1). It is possible that oxidative modifications present can influence MS/MS 
fragmentation patterns and this is dependent on particular amino acid and modification type .   
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Figure 3.5 CID MS/MS spectra of a) [tLSDYNIQK+2H]2+ with Thr55-Oxd’n as observed by trypsin 
proteolysis, tr=20.28min, m/z=540.27 and b) [MQIFVkTLTGK+2H]2+ with Lys6-AminoAdSA as observed 
by Lys-C proteolysis, tr=26.95, m/z=632.85. Note that lowercase letters represent the carbonylation of 
threonine to 2-amino-3-oxo-butanoic acid and lysine to aminoadipic semialdehyde. Ions labeled with 
asterisks (*) contain modifications. 
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MS/MS spectra were manually inspected to eliminate ambiguous and low confidence assignments. 
Extensive database searches were performed in order to search for many potential oxidative 
modifications that may occur using metal-catalyzed oxidation. In addition to searching for 
hydroxylation and carbonylation of Lys, Arg, Thr and Pro residues, our searches also included 
dioxidation, carbonylation on other amino acids, deamidation, decarboxylation, as well as different 
oxidative products of His (Table 3.1). Examples of new modifications, e.g. ring opening of His68, 
carbonylation of Ser20, Ile36, Leu69, were successfully identified through these additional 
database searches (Table 3.2).  
Fe(II)/H2O2 oxidation of ubiquitin leads to multiple M+16 Da and other proteoforms. The 
most abundant M+16 Da species contains Met1-Ox and is consistent with high oxidation 
reactivity261. M+16 Da and M+32 Da proteoforms were distinguishable using top-down MSn 
however, CID MS/MS – MSn only provided a limited amount of information about modification 
sites. Other dissociation methods such as ECD and ETD may provide more extensive sequence 
coverage and directly localize oxidative modification sites. On the other hand, bottom-up data only 
provide information about peptides that are observed in solution and do not completely reflect the 
specific oxidized proteoforms from which they originate. For example, the tryptic peptide 
mQIFVK could have arisen from an intact M+16 Da ubiquitin molecule or from other oxidized 
proteoforms. The observation of the tryptic peptide mQIfVK with two oxidized residues and the 
variety of modified residues listed in Table 3.2, clearly indicates that many oxidized proteoforms 
are present.  
Thus use of multiple proteases greatly improved our ability to localize oxidative 
modification sites of oxidized ubiquitin. Specifically, six out of 24 modified sites identified by 
trypsin are validated by Lys-C and Glu-C experiments (e.g. Met1 is identified by all three 
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proteases). Modifications to residues such as Lys6, Thr12, Glu24 and Ser65 were only identified 
with Lys-C and Lys33, Glu34 were only identified by Glu-C (See Table 3.2). We note that 
incorporation of an enrichment or tagging step may improve the detection of other oxidized 
proteoforms231-233. The combination of multiple proteases with iterative database searching was 
key to identification of so many oxidized sites and proteoforms of ubiquitin. Due to limitations 
with the number of modifications that can be simultaneously searched with SEQUEST (in 
Proteome Discoverer), we performed iterative database searches by classifying the modifications 
into seven groups (methionine oxidation, non-methionine oxidation, carbonylation (+14 Da), 
deamidation, decarboxylation, histidine oxidation and special carbonylation)157. This resulted in 
each RAW file being searched 22 times. For simple protein mixtures in which one seeks to gain 
knowledge about the complexity of oxidized proteoforms we present this strategy (combination of 
top-down mapping, multiple proteases, and iterative database searching) as an alternative to 
targeted chemistries or enrichment steps. 
3.4 CONCLUSIONS 
This work reports on the detection of oxidized species of Fe(II)/H2O2 oxidized ubiquitin 
molecules using multiple proteases and iterative database searching of oxidative modifications. 
Multiple proteases allowed numerous modification sites to be identified and increased confidence 
in each oxidative site. Multiple proteases also allowed inaccessible sites by trypsin digestion to be 
available with other proteases.  Iterative database searching allowed different types of oxidative 
modifications to be identified, however this also required manual validation of MS/MS spectra 
and extended computing times. Under the mM concentrations of oxidizing reagent used, oxidative 
modifications to ubiquitin included protein carbonylation. The ability to identify distributions of 
proteoforms for simple systems, such as ubiquitin, using multiple proteases in shotgun proteomics 
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can be extended to larger and more complex protein samples. Complex protein samples will benefit 
from additional enrichment steps. The utility of multiple proteases combined with iterative 
database searching of oxidative modifications can be extended to other types of PTMs such as 
glycosylation, cysteine oxidations, and deamidation and has promising applications in 
pharmaceutical industries for the analysis of intact antibodies. In this work only one protein is 
present in the sample, making it possible to characterize oxidations of various amino acid acids by 
MS directly. For complex sample analysis, e.g., cell lysates or tissue homogenates, affinity 
purification is often required to simplify complex matrices and target a specific residue or 
modification. In Chapters 4 - 6, novel workflows were developed to enrich cysteine-containing 
peptides using the solid phase capture technique and study oxidative modifications to cysteine. 
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4.0 SAMPLE MULTIPLEXING WITH CYSTEINE-SELECTIVE APPROACHES: 
CYSDML AND CPILOT 
(Note that information in this chapter is written based on a published research paper38, Gu, L.; 
Evans, A. R.; Robinson, R. A. S. Journal of the American Society for Mass Spectrometry 2015, 
26, 615-630.) 
4.1 INTRODUCTION 
Mass spectrometry (MS) - based quantitative proteomics is an important tool to measure 
relative and absolute protein abundances in order to discover disease biomarkers and to provide 
insight into biological processes. Comprehensive proteome analysis still remains challenging 
however, partially due to heterogeneity associated with biological samples, the wide dynamic 
range of protein concentrations, the presence of protein post-translational modifications (PTMs) 
and proteoforms262. Furthermore, even with considerable advances in MS technology there is still 
a demand for proteomics workflows which are all-inclusive and offer high-throughput, high 
efficiency, and deep proteome coverage. A widely-used strategy to reduce sample complexity and 
improve detection of low-abundance proteins is to isolate cysteinyl-peptides65. Cysteine occurs 
~2.3% among the twenty amino acids in mammals65. According to our in-house calculations ~14% 
of peptides contain cysteine which corresponds to ~96% of proteins in the mouse proteome 
(Uniprot database, 05/21/2014 release, 51344 sequences). This trend is similar for human, yeast, 
and other species65 and suggests that cysteinyl-enrichment can greatly reduce sample complexity 
while affording high proteome coverage. Cysteine is a highly reactive nucleophilic amino acid and 
is implicated in biological processes, such as cell recognition and apoptotic signaling65, cellular 
homeostasis, immune signaling, and redox chemistry263. Cysteine can be subject to a variety of 
covalent oxidative PTMs (e.g. sulfinic acid, disulfide formation, S-nitrosylation, and S-
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glutathionylation) as described in Chapter 285,263 and the study of these oxidation states gives 
insight to cellular redox status.   
Cysteinyl-peptides can be enriched directly via the reactions of sulfhydryl groups, such as: 
solid phase thiopropyl resin99,140,145,264,265, superparamagnetic266 and gold nanoparticles267, 
organomercurial beads268, and aldehyde resin269. Alternatively, cysteine residues may be captured 
indirectly270, through derivatization271, biotin/avidin affinity chromatography272,273, or with 
chemical tagging and antibody enrichment43,113. After the enrichment of cysteinyl-peptides, the 
incorporation of chemical tagging steps with stable-isotopes can be used to design cysteine-
selective quantitative proteomics approaches. The most widely used techniques including 
precursor isotopic labeling such as diemthylation24,25 and isobaric tags such as TMT, iTRAQ and 
DiLeu274, which were introduced in Chapter 1.  
One of the first and most-widely used cysteine-selective quantitative proteomics 
approaches is isotope-coded affinity tag (ICAT)32,275-281, which was reviewed in Chapter 2. In 
addition, enriching techniques such thiol-affinity resin and biotin/avidin can couple with various 
isotope-coded mass tags100,109,116,119,139,282-285 for either cysteine subproteome characterization or 
cysteine redox quantification (Chapter 2). Recently, iodoTMT - a cysteine-reactive TMT reagent 
- was applied to map and quantify nitrosylation43,111,113. While there are attractive features to many 
of these approaches, few cysteinyl-based quantitative proteomics workflows provide all the 
following features: 1) effective cysteinyl-peptide enrichment; 2) simple and straightforward 
sample processing; 3) moderate sample multiplexing (at least > 2-plex and up to 8-plex or higher); 
and 4) cost-effective reagents. 
Herein we developed two novel cysteine-based quantitative proteomics workflows. The 
first method is cysteine-selective precursor dimethyl labeling (CysDML). In this workflow, 
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cysteinyl-peptides are captured on a commercially available Thiopropyl Sepharose 6B resin and 
captured peptides are labeled on resin with either light (-C2H6) or heavy (-
13C2
2H6) dimethyl tags
29. 
CysDML appears to be a convenient, efficient, accurate, and affordable cysteine-selective 
quantitative proteomic technique. However, this approach is limited to a maximum of two samples 
in this report thus we sought to develop another approach which could significantly improve on 
sample multiplexing capabilities. Higher multiplexing capacity is useful for reducing sample 
preparation and analysis time, minimizing errors, and allowing a readout of differences in relative 
protein abundances from a variety of sample types, conditions, time points, etc. Recently, our 
laboratory developed combined precursor isotopic labeling and isobaric tagging (cPILOT), a 
method that increases multiplexing capabilities of isobaric tags to 12 and 16 samples for TMT and 
iTRAQ, respectively. We36,53 and others55,56 have used enhanced multiplexing to study global and 
PTM specific protein abundances in complex mixtures. To-date, there is no report of a cysteine-
selective enhanced multiplexing method. The second approach that we present is a cysteine-
selective cPILOT approach using a 12-plex experiment. This novel technique relies on cysteinyl-
peptide enrichment and on-resin isotopic dimethyl labeling, in combination with iodoTMT6 
reagent tagging. The combination of duplex dimethyl labeling and 6-plex iodoTMT6 tagging 
results in twelve channels available for sample multiplexing in a single experiment. We note that 
this method could be extended to 16 or 20 samples if cysteine-reactive iTRAQ or TMT10 286 
reagents were available. Both CysDML and cysteine-selective cPILOT workflows were 
benchmarked relative to each other and applied to liver tissues from an Alzheimer’s disease (AD) 
mouse model. The performance of these methods and results from the application are discussed.   
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4.2 EXPERIMENTAL 
4.2.1 Animal Husbandry 
Fourteen-month old APP/PS-1 male mice [B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, 
stock number 005864, genetic background C57BL/6J express the chimeric mouse/human (Mo/Hu) 
APP695swe (i.e., K595N and M596L) and a mutant human PS1-dE9] and the genetically 
heterogeneous wild type (WT) (stock number 000664, genetic background C57BL/6J) were 
purchased from Jackson Laboratory. Mice were housed in the Division of Laboratory Animal 
Resources at the University of Pittsburgh and fed standard Purina rodent laboratory chow ad 
libitum on a 12 hour light/dark cycle. APP/PS-1 (hereafter referred to as AD) and WT mice (N = 
6 for each genotype) were euthanized using CO2. Liver tissues were harvested immediately and 
stored at -80°C until further experiments. Animal protocols were approved by the Institutional 
Animal Care and Use Committee at the University of Pittsburgh.    
4.2.2 Liver Homogenization and Protein Digestion 
Liver tissues were homogenized in an ice-cold phosphate buffer saline (PBS) solution 
containing 8 M urea with 100 passes of a Wheaton homogenizer. Homogenate solution was 
collected, sonicated, and centrifuged at 13000 rpm for 10 minutes (4°C). Supernatants were 
collected, aliquoted into ~50 µL portions, and stored at -80°C. Protein concentrations were 
determined using the BCA assay according to the manufacturer’s instructions (Pierce Thermo; 
Rockford, IL). Liver proteins (100 µg and 75 µg) were digested for each sample in CysDML and 
cPILOT experiments, respectively. After dilution to 1 µg/µL, the liver proteins were denatured 
and reduced in 50 mM Tris buffer (pH = 8.2), 8 M urea, 10 mM dithiothreitol (DTT) for 1 hour at 
37°C. The resulting protein mixture was diluted 10-fold with 20 mM Tris buffer (pH = 8.2). TPCK-
  
74 
 
treated trypsin from bovine pancreas (Sigma; St. Louis, MO) was added to each sample in a 4% 
w/w enzyme/protein ratio and incubated at 37°C for 18 hours. Samples were acidified with 0.5% 
formic acid, cleaned using Waters Oasis HLB C18 cartridges, and lyophilized.  
4.2.3 Cysteinyl-Peptide Enrichment 
All solutions used in the following steps were degassed to prevent oxidation of thiols. 
Tryptic digests were reduced with 5 mM DTT in 20 µL of 50 mM Tris buffer (pH = 7.5) with 1 
mM EDTA (coupling buffer) for 1 hour at 37°C, after which the samples were diluted to 100 µL 
by adding coupling buffer. Thiopropyl Sepharose 6B thiol-affinity resin (35 mg each) was 
prepared from dried powder per the manufacturer’s instruction (Sigma, St. Louis, MO). Briefly, 
the dried powder was rehydrated in 1 mL water for 15 minutes, suspended and transferred to spin 
columns (Pierce Thermo; Rockford, IL), and washed with 0.5 mL water six times. Next, the slurry 
was washed with 0.5 mL coupling buffer ten times. Reduced peptide samples were incubated with 
the resin for 1.5 hours at room temperature with a shaking speed of ~800 rpm, and the unbound 
portion (non-cysteinyl peptides) was removed by centrifugation. The resin was washed in the spin 
column sequentially with the following solutions: 0.5 mL of 50 mM Tris buffer (pH = 8.0) with 1 
mM EDTA (washing buffer), 2 M NaCl, 80% acetonitrile/0.1% TFA, and 100 mM 
tetraethylammonium bromide (TEAB). Each wash was repeated six times.  
4.2.4 On-Resin Stable-Isotope Dimethyl Labeling  
Washed samples were contained in spin columns and 100 µL of 100 mM TEAB was added. 
Then, 11.2 µL of 4% CH2O/
13C2H2O (98% 
2H and 99% 13C) and 11.2 µL of 0.6 M 
NaBH3CN/NaB
2H3CN (96% 
2H) were added to the sample for light and heavy labeling, 
respectively. In the CysDML experiments, WT samples were labeled with light (-C2H6) dimethyl 
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tag and AD samples were labeled with heavy (-13C2
2H6) dimethyl tag. In the cPILOT experiment, 
randomly selected WT and AD samples (N = 3 each) were labeled with the light dimethyl tag and 
heavy dimethyl tags (N = 3 each). Samples were incubated for 1 hour at room temperature while 
mixing at a speed of ~800 rpm. The reaction was terminated by adding ammonia to a final 0.2% 
(v/v) concentration and after, formic acid to a final 0.3% (v/v) concentration. Buffer and reagents 
were removed by centrifugation, and the resin was washed with 0.5 mL 100 mM TEAB (three 
times) and 0.5 mL washing buffer (six times). The captured and labeled cysteinyl-peptides were 
released by incubating the resin with 100 µL of washing buffer with freshly prepared 20 mM DTT 
at room temperature for 30 minutes while shaking. The above step was repeated two more times 
with shorter 10 minute incubations followed by a final incubation with 80% acetonitrile. Flow-
through fractions were collected and combined. In CysDML experiments, the released peptides 
were further alkylated with 80 mM of iodoacetamide (IAM) for 1 hour at room temperature in the 
dark. AD and WT samples were pooled, concentrated, acidified, desalted using C18 cartridges, and 
lyophilized. CysDML samples were stored at -80°C for LC-MS/MS. In the cPILOT experiment, 
the released peptides were concentrated, acidified, desalted using C18 tips (Pierce Thermo; 
Rockford, IL), and lyophilized. 
4.2.5 IodoTMT Tagging 
In cPILOT experiments, light and heavy labeled AD and WT samples were labeled with 
iodoTMT6 reagents according to the manufacturer’s protocol (Pierce Thermo; Rockford, IL) with 
modifications. Briefly, each peptide sample was dissolved in 10 µL of degassed washing buffer 
containing 5 mM DTT, reduced for 1 hour at 37°C, and diluted by adding 65 µL washing buffer. 
Each iodoTMT6 reagent was solubilized with 10 µL of MS-grade methanol and transferred to the 
peptide mixture. After 1 hour incubation at 37°C in the dark, the reaction was quenched by adding 
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20 mM DTT. All tagged samples were pooled into a single cPILOT sample, concentrated, acidified, 
desalted using C18 cartridges, and lyophilized. 
4.2.6 Offline SCX Fractionation 
SCX fractionation of the cPILOT sample was carried out on a PolySulfoethyl A 100 mm 
× 2.1 mm, 5 µm, 200 Å column (The Nest Group, Inc.; Southborough, MA) with buffers as follows: 
mobile phase A was 5 mM monopotassium phosphate (25% v/v acetonitrile, pH 3.0), and mobile 
phase B was 5 mM monopotassium phosphate, 350 mM potassium chloride (25% v/v acetonitrile, 
pH 3.0). Dried sample was resuspended in 300 µL of mobile phase A and injected onto the SCX 
column. The gradient for SCX was 0-5 min, 0% B; 5-45 min, 0-40% B; 45-90 min, 40-80% B; 90-
100 min, 80-100% B; 100-110 min, 100% B; 110-121 min, 0% B. One-minute fractions were 
collected into a 96-well-plate and pooled into a final eight fractions which were desalted using a 
C18 tip. 
4.2.7 LC-MS/MS Analysis 
Online desalting and reversed-phase chromatography was performed with a Nano-LC 
system equipped with an autosampler (Eksigent; Dublin, CA). Mobile phases A and B were 3% 
(v/v) acetonitrile with 0.1% formic acid and 100% (v/v) acetonitrile with 0.1% formic acid, 
respectively. Sample (5 µL) was loaded onto a trapping column (100 µm i.d. × 2 cm), which was 
packed in-house with C18 200 Å 5 μm stationary phase material (Michrom Bioresource Inc.; 
Auburn, CA) at 3 µL/min in 3% mobile phase B for 3 min. The sample was loaded onto an 
analytical column (75 µm i.d. × 13.2 cm), which was packed in-house with C18 100 Å 5 µm 
stationary phase material (Michrom Bioresource Inc.; Auburn, CA). The following gradient was 
used for both CysDML and cPILOT experiments: 0-5 min, 10% mobile phase B; 5-40 min, 10-
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15% B; 40-90 min, 15-25% B; 90-115 min, 25-30% B; 115-130 min, 30-60% B; 130-135 min, 60-
80% B; 135-145 min, 80% B; 145-150 min, 80-10%B; 150-180 min, 10%B. The LC eluent was 
analyzed with positive ion nanoflow electrospray using a LTQ-Orbitrap Velos mass spectrometer 
(Thermo-Fisher Scientific; Waltham, MA).  
CysDML samples were analyzed by employing three gas phase fractionations (GPF). 
Specifically, each sample was injected seven times and subject to different MS scans:  1st injection) 
precursor scan over the m/z range 350-1700, 2nd – 4th injections) m/z 350-800, m/z 785-975 and 
m/z 960-1700, respectively, and the 5th – 7th  injections were repeats of the 2nd – 4th injections. GPF 
mass ranges were determined from a preliminary analysis of the full m/z range scan and optimized 
to generate similar numbers of PSMs in each GPF. The following data-dependent acquisition 
(DDA) parameters were used in each injection: the MS survey scan in the Orbitrap was 60,000 
resolution; the top 15 most intense peaks in the MS survey scan were isolated and fragmented with 
CID at an isolation width of 3 m/z; CID was performed in the ion trap with normalized collision 
energy 35%. The maximum fill time for MS and MS/MS is 500 ms and 50 ms, respectively. A 
complete duty cycle timing is ~3 sec. 
SCX fractions of the cPILOT sample were injected three times and subject to various top 
ion acquisitions. The MS survey scan in the Orbitrap was 60 000 resolution over m/z 350-1700. 
The first injection included the top five ions for DDA. The second and third injections included 
the 6th to 10th and 11th to 15th most intense peaks in the MS survey scan for DDA, respectively. 
DDA parameters were as follows: precursor ions were isolated with a width of 3 m/z and 
normalized collision energy of 35%, the most intense CID fragment ion over the m/z range 400-
1300 was selected for HCD-MS3. The HCD fragment-ion isolation width was set to 4 m/z, the 
normalized collision energy was 60%, and HCD resolution was 7500 in the Orbitrap. The 
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maximum fill time for MS, MS/MS and MS3 is 500 ms, 50 ms and 250 ms, respectively. The total 
duty cycle timing is ~2.4 sec. 
4.2.8 Database Searching and Data Analysis 
RAW files were analyzed using the SEQUEST HT search engine with Proteome 
Discoverer 1.4 software (Thermo-Fisher Scientific; Waltham, MA) and searched against the 
Uniprot mouse database (05/21/2014, 51344 sequences). SEQUEST HT search parameters of 
CysDML data are as follows: precursor mass tolerance 15 ppm; fragment mass tolerance 1 Da; 
static modifications light dimethyl/+28.031 Da (Lys) or heavy dimethyl/+36.076 Da (Lys), 
carbamidomethyl modification/+57.021 Da (Cys); dynamic modifications light dimethyl/+28.031 
Da (N-terminal) or heavy dimethyl/+36.076 Da (N-terminal), oxidation/+15.995 Da (Met). Decoy 
database searching was employed to calculate false discovery rate (FDR). Only peptides with 
medium confidence (<5% FDR) were used further analysis287. Proteome Discoverer 1.4 provided 
peak area information for light and heavy labeled peptides and protein ratio calculations. Protein 
ratios were normalized based on the protein median ratio in each biological replicate experiment 
for CysDML. SEQUEST HT search parameters of cPILOT data are the same as CysDML data 
except the static modification on cysteine is iodoTMT6/+329.226 Da. The reporter ions (i.e., m/z 
126-131) were identified with the following parameters: centroid with smallest delta mass, 30 ppm 
for reporter ion mass tolerance. The isotope correction was employed according to the 
manufacturer’s data sheet (Pierce Thermo; Rockford, IL). The median reporter ion intensity of 
each channel was calculated across all peptide spectral matches (PSMs). The median of all reporter 
ion channels (from light and heavy) was used to normalize reporter ion intensities. Peptide ratios 
were calculated and finally, protein ratios were determined from peptide median ratios. 
Noncysteinyl-peptides were excluded from quantification.  
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4.2.9 Statistics 
Normalized AD/WT ratios were transformed to log2 scale and subject to permutation. 
Permutation testing calculates p-values by randomly enumerating all possible permutations. The 
null hypothesis is 𝐻0:µ = 0 with alternative of 𝐻1:µ ≠ 0. The p-value was calculated as 𝑝 = (1 +
𝑏)/(1 + 𝑚), where b is the number of times in the 10,000 permuting counts, m, that tpermuted  (test 
statistics in permutation test) is larger than tobserved (observed test statistic)
288-290. Calculations were 
performed in MATLAB R2014a. A p < 0.05 was considered statistically significant. Stringent 
filter criteria were applied to generate a list of statistically significant differentially expressed 
proteins as follows: 1) protein must be quantified in N = 6 biological replicates; 2) for CysDML, 
AD/WT ratios < 0.78 or > 1.20 and for cPILOT, AD/WT ratios < 0.72 or > 1.4054 and 4) standard 
deviation < 0.5 for protein AD/WT ratios across all biological replicates. 
4.3 RESULTS AND DISCUSSION 
Here we present two novel multiplexing approaches based on the enrichment of cysteinyl-
peptides termed: CysDML and cPILOT. Both strategies are depicted in Figure 4.1 and were used 
to compare differences in the liver proteomes of AD and WT mice. First, twelve liver protein 
samples (i.e., six WT and six AD) were serially digested by trypsin. Next, cysteinyl-peptides were 
enriched using a Thiopropyl Sepharose 6B resin. On resin, captured peptides were labeled with 
either light (-C2H6) or heavy (-
13C2
2H6) dimethyl tags on primary amines such as the N-termini 
and Lysine residues. The CysDML approach relies on precursor labeling to quantify relative 
protein abundances between WT and AD samples. Because CysDML is a duplex experiment it 
was necessary to repeat six independent times to accommodate all biological replicates. On the 
other hand, the cPILOT approach is a 12-plex experiment and dimethylation is used to double the  
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Figure 4.1 Schematic representation of cysteine-selective proteomics workflow. Mouse liver peptides are 
enriched by a thiol-affinity resin. Samples are labeled with either light (-C2H6) or heavy dimethyl (-13C22H6) 
tags on resin. In the CysDML experiment: a) WT and AD samples are tagged with light and heavy dimethyl 
groups, respectively; b) peptides are eluted from the resin with 20 mM dithiothreitol (DTT); c) 
iodoacetamide is used to alkylate free cysteines; and d) WT and AD samples are combined, desalted and 
analyzed by LC-MS/MS. In the cPILOT experiment: a) WT and AD samples are tagged with light or heavy 
dimethyl groups on resin; b) after elution with DTT, iodoTMT6 reagents are added to each sample; c) all 
12 samples are combined, cleaned, fractionated and analyzed by LC-MS3. 
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number of channels accessible with the TMT isobaric tagging method. Here, three WT and three 
AD samples were labeled with the light dimethyl group whereas the remaining samples in each 
group were labeled with the heavy dimethyl group. After precursor labeling steps, peptides were 
released from the resin using DTT. CysDML samples were alkylated, six WT and AD pairs were 
pooled independently, and analyzed using gas-phase fractionation (GPF)291 and LC-MS/MS. 
CPILOT samples were cleaned, tagged with iodoTMT6 reagents, and the twelve samples were 
pooled into a single mixture that was analyzed using LC-MS/MS and HCD-MS3.  
4.3.1 Optimization of On-Resin Dimethylation Reaction Conditions 
Stable-isotope dimethylation is an attractive precursor isotopic labeling technique because 
(1) the tag is inexpensive25, (2) it offers up to five sample channels40, (3) the reaction is versatile 
and can be performed in solution or on resin292, and (4) the reaction is pH-dependent and site- 
selective34. In order to minimize sample loss we performed dimethylation on the Thiolpropyl 
Sepharose 6B resin. Initially, we achieved an ~90% labeling efficiency (Figure 4.2a) using starting 
conditions that mimicked in-solution labeling conditions (i.e., 25 mM NaBH3CN, 55 mM CH2O, 
and one hour incubation). Significant improvement of the labeling efficiency to >98% was 
achieved with a longer incubation time (i.e., 24 hours). Because we are interested in maximizing 
the overall throughput of multiplexing experiments we sought to reduce the reaction time while 
maintaining high efficiency. This was made possible by increasing the reagent concentrations ~2.5 
fold (60 mM NaBH3CN, 145 mM CH2O) with a one hour incubation period (Figure 4.2b). These 
conditions are consistent with dimethyl labeling performance on solid phase hydrazide beads293 
and were used for remaining CysDML and cPILOT experiments. Because NaBH3CN is a much 
weaker reducing regent than NaBH4, it will not affect aldehydes, ketones as well as disulfide 
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Figure 4.2 Optimization of on-resin dimethylation. a) Plot of on-resin dimethylation labeling efficiency 
(calculated based on spectral counts) of N-terminal and Lys residues using various reaction times; b) 
labeling efficiency of N-terminal and Lys residues using 25 mM NaBH3CN and 60 mM NaBH3CN with a 
one-hour incubation time. 
  
0%
80%
100%
60mM NaBH3CN
 N-Terminal
 -Lys
99%
97%
L
ab
el
in
g
 E
ff
ic
ie
n
cy
Reagent Concentration (mM)
90%
90%
89%
25mM NaBH3CN
1h 3h 5h 24h
0%
80%
100%
89%
L
ab
el
in
g
 E
ff
ic
ie
n
cy
Reaction Time (h)
 N-Terminal
 -Lys
90%
95%
94%
97%
95%
99%
98%
a)
b)
  
83 
 
between peptides and resin294. We also did not observe any change to the physical property of the 
resin after dimethyl labeling, indicating the presence of intact disulfide bonds295. 
4.3.2 Evaluation of Quantification Accuracy and Resin Loading Range for CysDML 
CysDML is a novel precursor dimethylation technique. Thus we assessed the quantitative 
accuracy and linear dynamic range using tryptic peptides from WT mouse liver. The first 
experiment evaluated quantitative accuracy of a mixture of 1:1 light:heavy labeled tryptic peptides 
that were separated using a three hour LC gradient. A total of 689 proteins were identified and 424 
of these were quantified (i.e., proteins had reported ratios for light and heavy peptides from 
Proteome Discoverer report). The average heavy/light ratio for the quantified proteins is 0.98±0.21 
(mean±standard deviation) as shown in Figure 4.3a; this error is consistent with other reports296. 
More than 95% of the proteins have ratios falling within two standard deviations of the mean and 
thus fits a normal distribution. To understand the effects of resin loading amount on quantitative 
accuracy, we varied the sample loading on resin as follows: six CysDML samples contained a 
fixed amount (100 µg) of peptides prior to resin loading, while the heavy channel varied from 12.5 
µg, 25 µg, 50 µg, 100 µg, 200 µg to 400 µg. When the sample loading amount was between 25 µg 
to 200 µg, accurate heavy/light ratios were obtained (Figure 4.3b). However, on the low and high 
ends the ratios were skewed. We attribute this to dilute samples on the low end that result in an 
overall minimal capture of cysteinyl-peptides. On the high end, inefficient capture on the resin 
occurred as the amount of DTT concentration was not increased to accommodate higher 
concentrations of peptide thiols. Excessive DTT concentrations are damaging to the Thiolpropyl 
Sepharose 6B resin. The measured dynamic range is 8-fold which is comparable to other 
reports145,297, and the maximum standard deviation was ~0.5. Results of these experiments were 
used to establish appropriate criteria for determining differential expression of proteins. 
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Figure 4.3 On-resin loading capacity of CysDML experiment. a) Scatter plot of protein ratios measured in 
CysDML experiment designed to have theoretical ratios of 1:1 for light and heavy labeled peaks. Horizontal 
lines represent average±2×standard deviation (µ±2σ) and the numbers of quantified proteins within each 
region are labeled. b) Box plot of measured ratios in CysDML dynamic range experiment. The amount of 
peptide labeled with the light tag is fixed at 100 µg, while the amount of peptide labeled with the heavy tag 
varies as follows: 12.5 µg, 25 µg, 50 µg, 100 µg, 200 µg and 400 µg. The theoretical ratios of light and 
heavy labeled peaks are designed to 0.125, 0.25, 0.5, 1, 2 and 4. 
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4.3.3 Application of CysDML to the Liver Proteome of an AD Mouse Model 
A tradeoff that must be considered in any proteomics experiment is proteome depth or 
coverage versus sample preparation, acquisition, and analysis time. We wanted to minimize the 
number of sample handling steps (and potential sample loss) while maintaining adequate proteome 
coverage, because each CysDML sample is only ~40 µg. Thus GPF was used as a fractionation 
step for CysDML samples291. Figure 4.4 provides example base peak chromatograms of seven 
GPFs for one of the pooled AD/WT sample pairs. The first injection was analyzed with a full m/z 
range of 350-1700. Six subsequent injections were collected over the m/z ranges of 350-800, 785-
975 and 960-1700 such that each fraction was not analyzed back-to-back. An overlapping window 
of 15 m/z was used between adjacent GPFs to ensure that light and heavy pairs were detected 
within the same spectrum. Comparisons of GPF to a single LC-MS/MS analysis over the full m/z 
range of 350-1700, indicate that GPF increases protein and peptide identifications by 79% and 
75%, respectively (data not shown). Furthermore, the replicate injections are highly reproducible. 
Figure 4.5a displays several example spectra containing light (m/z = 974.03) and heavy (m/z = 
982.07) pairs of the doubly charged peptide [V(dimethyl)AVVAGYGDVGK (dimethyl)GC 
(IAM)AQALR+2H]2+ from protein adenosylhomocysteinase. The observed spacing (Δm = 16 Da) 
between the peaks is consistent with two dimethyl groups being present on the peptide. Also, the 
diversity in peptide levels across the six biological replicates is apparent. An M+7 Da species, 
which has a relative abundance of ~10%, is observed for heavy dimethylated peaks consistent with 
other reports37,292. The presence of this peak could be from use of isotopically pure reducing 
reagent however does not have significantly influence on quantitative accuracy and precision 
(Figure 4.3a and 4.3b). Overall, the average number of spectral counts, peptides, proteins 
identified, and proteins quantified across the replicates is 14005±2125, 1823±238, 850±92, and  
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Figure 4.4 Base peak chromatograms for an example CysDML experiment (one biological replicate). 
Samples are injected a total of seven times. The first injection is analyzed with a full m/z range of 350-1700. 
The subsequent injections use gas phase fractionation (GPF) such that data are acquired over the m/z ranges 
of 350-800, 785-975 and 960-1700, and repeated twice. The top 15 most intense ions are selected and 
fragmented in each run. 
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Figure 4.5 Example CysDML MS spectra for: a) pair of light (m/z = 974.03) and heavy (m/z = 982.07) 
peaks assigned to the doubly charged peptide V(dimethyl)AVVAGYGDVGK(dimethyl)GC(IAM)AQALR 
of adenosylhomocysteinase in each biological replicate (BR); b) scatter plot of normalized protein ratios 
(AD/WT) measured in CysDML experiment for each BR.   
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594±65, respectively (Table 4.1). In total, 2085 unique proteins were identified from CysDML 
experiments. A large number of the spectral counts (~98%) and peptides (~91%) identified in each 
CysDML experiment can be attributed to cysteinyl-peptides. Thus, the CysDML approach is very 
efficient at enrichment and detection of cysteinyl-peptides. When assessing the AD/WT ratios for 
proteins quantified in each of the six CysDML experiments, we find that they are very similar 
across biological replicates (Figure 4.5b). Many proteins have ratios that fall outside of an AD/WT 
ratio of one. We used permutation testing and conservative filtering criteria (see Experimental) 
and identified 54 proteins that are differentially-expressed in the AD mice from CysDML 
experiments (Table 4.2).  Twenty-three of these proteins have higher levels in AD mice, whereas 
31 proteins have lower levels in AD mice relative to WT. Differentially-expressed proteins are 
involved in various biological processes which will be briefly discussed below. 
4.3.4 Application of cPILOT to the Liver Proteome of an AD Mouse Model  
Previously our laboratory has demonstrated enhanced multiplexing using global36 and 3-
nitrotyrosine53 specific cPILOT approaches. The combination of precursor isotopic labeling with 
isobaric tagging methods can increase the number of sample multiplexing channels by a factor of 
two to three times. Capabilities afforded by enhanced sample multiplexing include increasing 
biological replication, the ability to examine many tissues, sample types, environmental stimuli, 
longitudinal studies, etc. in a single analysis, and minimizing biases caused by multiple sample 
preparation steps and LC and MS acquisitions. We note that because cPILOT involves post-
digestion chemical labeling, errors introduced prior to sample pooling are still inherent in the final 
ratios reported. In order to increase sample multiplexing capabilities, simplify the protein mixture, 
assay (Figure 4.1) and benchmarked its performance against the CysDML method. Compared with 
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Table 4.1 Summary of CysDML and cPILOT experiments. 
  CysDML 
cPILOT 
  BR1 BR2 BR3 BR4 BR5 BR6 Average Sdc 
Total PSMs 16800 15513 12627 10766 13991 14334 14005 2125 3748 
Total Peptides 2175 1963 1649 1499 1783 1867 1823 238 414 
Cysteine PSMs 16469 15238 12412 10574 13778 14125 13766 2080 3318 
Cysteine Peptides 1972 1772 1492 1354 1624 1716 1655 217 245 
%Enrichmenta 98.0 98.2 98.3 98.2 98.5 98.5 98.3 0.2 88.5 
 %Enrichmentb 90.7 90.3 90.5 90.3 91.1 91.9 90.8 0.6 59.2 
Proteins Identified 982 908 769 728 840 871 850 92 330 
Proteins Quantified 690 625 533 510 593 611 594 65 151 
aEnrichment efficiency is calculated by PSMs (cysteine PSMs count/total PSMs count)  bEnrichment 
efficiency is calculated by unique peptides (unique cysteine peptide count/total unique peptide count). 
cStandard deviation across six biological replicates. 
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Table 4.2 Differentially expressed proteins quantified from CysDML experiment. 
Acc.no.a Protein name AD/WTb Sdc p-valued 
Q61838 Alpha-2-macroglobulin 1.64 0.28 0.0001 
Q3UEJ6 Phosphorylase 1.58 0.45 0.0138 
P54869 Hydroxymethylglutaryl-CoA synthase, mitochondrial 1.54 0.38 0.0001 
Q7TMF3 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 1.52 0.46 0.0006 
Q9CQC9 GTP-binding protein SAR1b 1.45 0.45 0.0130 
P20918 Plasminogen 1.41 0.48 0.0008 
P16332 Methylmalonyl-CoA mutase, mitochondrial 1.40 0.21 0.0002 
P80313 T-complex protein 1 subunit eta 1.37 0.31 0.0120 
Q9D0S9 Histidine triad nucleotide-binding protein 2, mitochondrial 1.36 0.46 0.0011 
Q571F8 Glutaminase liver isoform, mitochondrial 1.31 0.36 0.0127 
Q8BWT1 3-Ketoacyl-CoA thiolase, mitochondrial 1.29 0.36 0.0476 
O35718 Suppressor of cytokine signaling 3 1.28 0.27 0.0001 
Q3UT49 Cytochrome P450 2C29 1.28 0.30 0.0408 
Q9QZD8 Mitochondrial dicarboxylate carrier 1.27 0.26 0.0456 
P97742 Carnitine O-palmitoyltransferase 1, liver isoform 1.26 0.19 0.0125 
Q8VDN2 Sodium/potassium-transporting ATPase subunit alpha-1 1.26 0.38 0.0454 
Q9QXD6 Fructose-1,6-bisphosphatase 1 1.26 0.17 0.0001 
P68040 Guanine nucleotide-binding protein subunit beta-2-like 1 1.23 0.22 0.0004 
F2Z459 Protein Acat3 1.22 0.14 0.0004 
P51881 ADP/ATP translocase 2 1.22 0.13 0.0001 
Q4LDG0 Bile acyl-CoA synthetase 1.22 0.22 0.0460 
J3QNG0 MCG15755 1.22 0.11 0.0008 
Q3UXD9 Peroxisomal trans-2-enoyl-CoA reductase 1.21 0.21 0.0001 
F6T930 Enoyl-CoA hydratase, mitochondrial (Fragment) 0.77 0.09 0.0001 
Q8BWF0 Succinate-semialdehyde dehydrogenase, mitochondrial 0.75 0.15 0.0006 
P60335 Poly(rC)-binding protein 1 0.75 0.18 0.0001 
D3YXF4 14-3-3 protein zeta/delta (Fragment) 0.75 0.24 0.0480 
P14094 Sodium/potassium-transporting ATPase subunit beta-1 0.74 0.07 0.0008 
A2A815 Protein DJ-1 (Fragment) 0.73 0.07 0.0015 
P27659 60S ribosomal protein L3 0.73 0.07 0.0002 
A2AD25 MCG49690 0.73 0.12 0.0001 
P08228 Superoxide dismutase [Cu-Zn] 0.72 0.18 0.0120 
Q8BGD8 Cytochrome c oxidase assembly factor 6 homolog 0.72 0.14 0.0003 
Q99PG0 Arylacetamide deacetylase 0.72 0.25 0.0124 
Q9DBW0 Cytochrome P450 4V2 0.71 0.25 0.0134 
F8WIT2 Annexin 0.71 0.13 0.0001 
Q8BP47 Asparagine--tRNA ligase, cytoplasmic 0.69 0.08 0.0008 
A2AVJ7 Ribosome-binding protein 1 0.69 0.28 0.0138 
Q9CXS4-2 Isoform 2 of centromere protein V 0.69 0.20 0.0008 
A2AKV0 ATP synthase subunit gamma, mitochondrial (Fragment) 0.68 0.11 0.0001  
Continued on Page 91 
  
91 
 
Table 4.2 Differentially expressed proteins quantified from CysDML experiment. 
Acc.no.a Protein name AD/WTb Sdc p-valued 
B1AXY0 DnaJ homolog subfamily A member 1 (Fragment) 0.68 0.18 0.0005  
Q91ZA3 Propionyl-CoA carboxylase alpha chain, mitochondrial 0.68 0.33 0.0128 
B1ASE2 ATP synthase subunit d, mitochondrial (Fragment) 0.67 0.08 0.0001 
P63276 40S ribosomal protein S17 0.67 0.21 0.0001 
E9Q2H8 Hydroxyacylglutathione hydrolase, mitochondrial (Fragment) 0.65 0.16 0.0001 
Q99P30-5 Isoform 5 of Peroxisomal coenzyme A diphosphatase NUDT7 0.65 0.28 0.0005 
D3Z5M2 Protein gm10110 0.64 0.14 0.0001 
D3Z6C3 40S ribosomal protein S3a 0.62 0.33 0.0468 
Q9D0E1-2 Isoform 2 of heterogeneous nuclear ribonucleoprotein M 0.60 0.25 0.0002 
Q8BGY2 Eukaryotic translation initiation factor 5A-2 0.59 0.09 0.0001 
D3Z0E6 3'(2'),5'-bisphosphate nucleotidase 1 0.56 0.19 0.0010 
Q60991 25-hydroxycholesterol 7-alpha-hydroxylase 0.55 0.44 0.0165 
Q8R164 Valacyclovir hydrolase 0.49 0.14 0.0002 
E9Q1R2 4-hydroxy-2-oxoglutarate aldolase, mitochondrial 0.45 0.23 0.0006 
 
aAccession number provided from the Uniprot mouse database (05/21/2014, 51344 sequences). bAverage ratio of 
AD/WT. cStandard deviation. dp-value calculated from permutation test.  
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CysDML, cPILOT used iodoTMT to replace iodoacetamide at the last step. Before iodoTMT 
tagging, excess DTT (~20 mM) was depleted by C18 cleanup according a relevant report 298. In 
order to reduce any possible oxidized thiols, right before using iodoTMT tag, a low level of DTT 
(5 mM) was applied. After dilution and adding iodoTMT tag, our calculation indicated that the 
remaining DTT will not quench all iodoTMT, and the active tag amount (~4 mM) was sufficient 
for reaction according to manufacturer’s protocol (Pierce Thermo; Rockford, IL). We tested this 
process by using iodoacetamide and iodoTMT0 before applying to WT/AD samples. We believe 
Tris(2-carboxyethyl)phosphine (TCEP) can be used as a substitute for DTT. 
Data-dependent acquisition was employed on a LTQ-Orbitrap Velos MS such that the top 
five most intense ions were subject to CID MS/MS and the most intense fragment ion (over the 
m/z range 400-1300) was further subjected to HCD-MS3. MS3 has been demonstrated to address 
co-isolation and ratio suppression issues of isobarically-tagged peptides52. Figure 4.6 provides 
example MS spectra for a tryptic peptide detected in the cysteine-specific cPILOT experiment. 
The precursor MS scan (Figure 4.6a) displays a light (m/z = 693.02) and heavy (m/z = 698.39) pair 
of peaks that arise from a triply-charged ion. In independent CID MS/MS scans, both the light and 
heavy peaks were isolated and fragmented to provide the MS/MS spectra shown in Figure 4.6b. 
The fragmentation patterns for the light and heavy labeled precursor ions are very similar and the 
fragment peaks only differ by the masses of the heavy isotope atoms from the dimethyl tag.  Based 
on the MS/MS spectral information, the peptide sequence has been assigned to the peptide 
[T(dimethyl)SAC(iodoTMT6)FEPSLDYMVTK(dimethyl)+3H]3+ that belongs to the protein 
carbamoyl-phosphate synthase. We applied a relatively large isolation width (3 m/z) in precursor 
selection for better sensitivity in MS3 quantification. We also analyzed the distribution of charge 
state and m/z spaces between light and heavy species across all PSMs. Although 35.4% of PSMs 
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Figure 4.6 Example cPILOT MS spectra for: a) pair of peaks assigned to the peptide 
T(dimethyl)SAC(iodoTMT6)FEPSLDYMVTK(dimethyl) of carbamoyl-phosphate synthase; b) CID 
MS/MS spectra of the peaks with m/z = 693.024 and m/z = 698.387 from a). The most intense peaks (*) 
within the m/z range of 400-1300 were further selected and fragmented to give the HCD MS3 spectra shown 
in c), which are zoomed-in over the reporter ion region. 
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have charge states more than three, only 5.5% of PSMs have m/z gap less than 2.7, and these PSMs 
may have co-isolation issue (see Figure 4.7). However, the following MS3 isolation and 
fragmentation could alleviate it. Isolation and HCD fragmentation of the most intense peaks in the 
CID spectra (i.e., the b6
2+ ion at m/z = 498.97 for light and m/z = 503.04 for heavy), result in the 
MS3 spectra shown in Figure 4.6c. The low m/z region of the spectra are shown and two sets of 
reporter ions (m/z 126-131) are detected for the light and heavy labelled fragment ions. Relative 
abundances of the reporter ion peaks for WT and AD samples indicate that this peptide has an 
overall lower level in AD liver relative to WT.  When considering the average reporter ion AD/WT 
ratio (i.e., AD/WT=0.81, p=0.015) for this protein, it is excluded according to filter criteria (see 
Experimental) for differential expression.   
There was a total of 3318 spectral counts and 245 peptides that are specific to cysteinyl 
peptides in the cPILOT experiment.  Overall, this total number results in 330 identified proteins in 
which 151 proteins were quantified. It is clear that the performance of the 12-plex experiment 
compared to the CysDML duplex experiment is lower with regards to total proteins identified and 
quantified. A very possible reason for this difference is that cPILOT analysis employed slower 
HCD MS3 data acquisition. Using the same DDA duty cycle timing (~3 sec), the number of isolated 
and fragmented parent ions for CysDML and cPILOT is 15 and 7, respectively.  Another major 
reason is the sample loss arising from multistep sample handling and cleanup in the cPILOT 
experiment. In lieu of GPF with the cPILOT experiment, we performed offline SCX separations. 
We believe that with the additional condensed phase separation sample loss occurred as another 
sample clean-up step is necessary between SCX fractionation and final LC-MS3 analysis. 
Furthermore, the detection of reporter ions relies on the generation of intense fragments that 
contain the iodoTMT tag.  Based on the location of the cysteine residue relative to the N-terminus,   
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Figure 4.7 Distribution of a) m/z spaces and b) charge states between light and heavy species of all PSMs 
in cPILOT experiment. 
a)
b)
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we observe that only half of HCD-MS3 spectra result in reporter ions when the cysteine is within 
three positions relative to the N-terminus. Also, it appears that the enrichment efficiency of 
cysteinyl- peptides is lower for cPILOT (88.5% PSMs) compared to CysDML (98.3%). However, 
because we are reporting efficiency after derivatization of thiols with iodoTMT or IAM, it is 
possible that the labeling efficiency of cysteines with iodoTMT is also less. Detection of lower 
numbers of cysteinyl-peptides with cPILOT could be attributed to sample loss and lower MS3 duty 
cycle. The latter occurred because excess iodoTMT reagent eluted throughout the course of the 
reversed-phase LC run and these contaminant ions were selected and fragmented numerous times. 
Finally, we noticed many instances whereby non-iodoTMT-tagged fragment ions were further 
selected for HCD-MS3. As the most intense ions are selected for HCD-MS3 this suggests that the 
instrument spent a great deal of time on ions that could not generate reporter ions.  In the future 
we plan to remove these excess reagents as well as include these ions on a reject list and develop 
potentially more selective ion53 or incorporate multinotch MS3 299 approaches. After application 
of stringent criteria, eleven proteins have statistically significant differential expression in liver 
from AD mice relative to WT from cysteine-selective cPILOT (Table 4.3).   
4.3.5 Comparison of CysDML and cPILOT   
Both the CysDML and cPILOT approaches described herein, are novel methods to quantify 
cysteinyl-proteins in multiple samples simultaneously. The CysDML, duplex experiment, resulted 
in 2.5× more identified and quantified proteins in comparison to the cPILOT, 12-plex experiment. 
Although similar amounts of starting material where used for each experiment, the number of 
sample handling and sample cleanup and wash steps is substantially greater in the cPILOT 
approach. From the proteins identified with each method, 156 overlap and 1929 and 174 are unique 
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Table 4.3 Differentially expressed proteins quantified from cPILOT experiment. 
Acc.no.a Protein name AD/WTb Sdc p-valued 
A2A848 Acyl-coenzyme A oxidase (Fragment) 1.57 0.47 0.0006 
P05202 Aspartate aminotransferase, mitochondrial 0.71 0.24 0.0011 
H3BLB8 Paraoxonase 1, isoform CRA_c 0.70 0.27 0.0136 
Q9DBJ1 Phosphoglycerate mutase 1 0.68 0.18 0.0005 
Q91Y97 Fructose-bisphosphate aldolase B 0.68 0.24 0.0001 
L7N451 Interferon-induced very large GTPase 1 0.68 0.23 0.0140 
G3UX44 Estradiol 17-beta-dehydrogenase 8 (Fragment) 0.66 0.31 0.0439 
P15105 Glutamine synthetase 0.65 0.19 0.0009 
G3UYR8 Alpha-aminoadipic semialdehyde dehydrogenase 0.63 0.19 0.0001 
P99029-2 Isoform cytoplasmic+peroxisomal of peroxiredoxin-5, mitochondrial 0.52 0.18 0.0001 
J3QPZ9 Enolase (Fragment) 0.40 0.14 0.0001 
 
aAccession number provided from the Uniprot mouse database (05/21/2014, 51344 sequences). bAverage ratio of 
AD/WT. cStandard deviation. dp-value calculated from permutation test.  
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to the CysDML and cPILOT experiments, respectively. Thus there is good agreement in the 
proteins identified from both methods, however each approach can give new information not 
reported in the other method.  Also, CysDML is more advantageous for deeper proteome coverage 
compared to cPILOT. Six CysDML experiments were completed compared to a single cPILOT 
experiment. However, if one is interested in generating a short list of starting candidates in a quick 
analysis, the cPILOT approach would be more beneficial.   
Next, we compared the correlation in AD/WT ratios from CysDML and cPILOT 
experiments for all proteins quantified in six biological replicates regardless of p-values from 
statistical testing (Table 4.4) to better assess the performance of each method. In a majority of the 
cases, the AD/WT ratios are in good agreement (e.g., within ~20% error) between CysDML and 
cPILOT experiments. However, based on the results of statistical testing some proteins may not 
be considered as differentially-expressed in one or both methods. Furthermore, there exists a 
handful of proteins in which the AD/WT ratios are different between the CysDML and cPILOT 
experiments. In these cases, there are high standard deviation (>0.5) values across peptide ratios, 
differences in peptides detected and number of PSMs used for quantitation, and errors associated 
with variations in selection of peaks for MS/MS and HCD-MS3 during data-dependent acquisition.  
There are other considerations for sample multiplexing with CysDML or cPILOT.  First, 
the number of necessary sample channels is important for determining if it is appropriate for a 
researcher to perform multiple duplex experiments or a single 12(or higher)-plex experiment. It 
could become rather cumbersome and time consuming to perform multiple combinatorial 
experiments to compare differences from more than two sample types with the CysDML approach. 
Whereas, with the cPILOT experiment every sample can be analyzed simultaneously with the 
noted tradeoff in breadth of proteome coverage. Incorporation of additional separation steps and 
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Table 4.4 Proteins quantified in both experiments. 
Acc. No.a Protein Name 
CysDML cPILOT 
AD/WTb Sdc p-valued AD/WTb Sdc p-valued 
A2A848 Acyl-coenzyme A oxidase (Fragment) 1.46 1.04 0.4223 1.57 0.47 0.0006 
D3YZ54 2-hydroxyacyl-CoA lyase 1 1.09 0.23 0.4181 1.14 0.27 0.2848 
D3Z041 Long-chain-fatty-acid--CoA ligase 1 1.04 0.15 0.7297 1.00 0.24 0.7662 
E9Q484 5-oxoprolinase (Fragment) 0.90 0.13 0.1184 1.66 0.93 0.0146 
F8WIT2 Annexin 0.71 0.13 0.0001 0.85 0.24 0.1311 
G3UX44 Estradiol 17-beta-dehydrogenase 8 (Fragment) 1.00 0.28 0.7931 0.66 0.31 0.0439 
G3UYR8 Alpha-aminoadipic semialdehyde dehydrogenase 0.90 0.13 0.1251 0.63 0.19 0.0001 
H3BJI7 Protein Mettl7a2Higd1c 0.88 0.13 0.0494 0.81 0.18 0.0130 
O09173 Homogentisate 1,2-dioxygenase 1.02 0.14 0.8964 1.62 1.35 0.4210 
O35490 Betaine--homocysteine S-methyltransferase 1 0.90 0.28 0.3071 0.72 0.22 0.0003 
O88844 Isocitrate dehydrogenase [NADP] cytoplasmic 1.04 0.14 0.5231 1.08 0.27 0.6399 
P05202 Aspartate aminotransferase, mitochondrial 1.29 0.56 0.2907 0.71 0.24 0.0011 
P07724 Serum albumin 0.84 0.15 0.0136 2.02 1.78 0.0448 
P08228 Superoxide dismutase [Cu-Zn] 0.72 0.18 0.0120 1.10 1.26 0.4258 
P08249 Malate dehydrogenase, mitochondrial 1.08 0.34 0.9507 0.84 0.16 0.0601 
P15105 Glutamine synthetase 0.82 0.33 0.1204 0.65 0.19 0.0009 
P24549 Retinal dehydrogenase 1 1.12 0.30 0.4699 0.97 0.34 0.6036 
P26443 Glutamate dehydrogenase 1, mitochondrial 1.18 0.12 0.0001 0.86 0.23 0.1965 
P28474 Alcohol dehydrogenase class-3 1.03 0.18 0.7972 0.75 0.18 0.0134 
P55264-2 Isoform short of adenosine kinase 1.27 0.52 0.2909 0.81 0.30 0.1686 
P63038 60 kDa heat shock protein, mitochondrial 1.03 0.48 0.7183 0.88 0.24 0.2474 
P68368 Tubulin alpha-4A chain 1.09 0.30 0.6392 0.75 0.23 0.0136 
P97872 Dimethylaniline monooxygenase [N-oxide-forming] 5 1.13 0.37 0.6649 0.81 0.26 0.1176 
P99028 Cytochrome b-c1 complex subunit 6, mitochondrial 1.11 0.69 0.7878 0.98 0.37 0.6367 
P99029-2 Isoform cytoplasmic+peroxisomal of peroxiredoxin-5, mitochondrial 0.92 0.22 0.3163 0.52 0.18 0.0001 
Q01853 Transitional endoplasmic reticulum ATPase 1.04 0.15 0.5979 0.80 0.35 0.0492 
Q3V0K6 Kynurenine 3-monooxygenase 3.67 6.01 0.2498 0.83 0.18 0.0414 
Continued on Page 100 
  
100 
 
Table 4.4 Proteins quantified in both experiments. 
Acc. No.a Protein Name 
CysDML cPILOT 
AD/WTb Sdc p-valued AD/WTb Sdc p-valued 
Q63880-2 Isoform 2 of carboxylesterase 3A 1.27 0.47 0.2585 0.80 0.23 0.0509  
Q6P3A8-2 Isoform 2 of 2-oxoisovalerate dehydrogenase subunit beta, mitochondrial 1.59 0.63 0.0473 1.04 0.43 0.8616 
Q6XVG2 Cytochrome P450 2C54 1.18 0.57 0.5609 0.85 0.25 0.1228 
Q8BGT5 Alanine aminotransferase 2 1.30 0.55 0.2580 1.18 0.45 0.5155 
Q8BH00 Aldehyde dehydrogenase family 8 member A1 1.19 0.23 0.1230 0.80 0.18 0.0132 
Q8BMS1 Trifunctional enzyme subunit alpha, mitochondrial 1.01 0.18 0.9541 0.82 0.14 0.0001 
Q8C196 Carbamoyl-phosphate synthase [ammonia], mitochondrial 0.90 0.14 0.0842 0.81 0.21 0.0151 
Q8QZR5 Alanine aminotransferase 1 1.66 1.19 0.0117 0.93 0.30 0.4005 
Q8VBW8 Tetratricopeptide repeat protein 36 1.36 0.41 0.0766 0.75 0.29 0.0001 
Q8VCH0 3-ketoacyl-CoA thiolase B, peroxisomal 1.25 0.28 0.0581 1.21 0.32 0.1415 
Q91X91 Nicotinate-nucleotide pyrophosphorylase [carboxylating] 1.07 0.44 0.9982 1.13 0.36 0.6188 
Q91XD4 Formimidoyltransferase-cyclodeaminase 1.06 0.35 0.9856 0.73 0.15 0.0001 
Q91Y97 Fructose-bisphosphate aldolase B 1.52 1.12 0.3734 0.68 0.24 0.0001 
Q922D8 C-1-tetrahydrofolate synthase, cytoplasmic 1.09 0.22 0.3899 1.17 0.30 0.2486 
Q93092 Transaldolase 1.00 0.15 0.8608 0.86 0.15 0.0543 
Q99KI0 Aconitate hydratase, mitochondrial 1.03 0.14 0.6775 0.77 0.17 0.0110 
Q99LB7 Sarcosine dehydrogenase, mitochondrial 1.03 0.15 0.6957 0.74 0.24 0.0006 
Q9CZ13 Cytochrome b-c1 complex subunit 1, mitochondrial 1.29 0.92 0.9196 1.06 0.39 0.9881 
Q9D8E6 60S ribosomal protein L4 1.01 0.18 0.9990 1.19 0.64 0.9857 
Q9DB77 Cytochrome b-c1 complex subunit 2, mitochondrial 1.03 0.32 0.9991 0.75 0.14 0.0003 
Q9DBJ1 Phosphoglycerate mutase 1 0.99 0.29 0.7038 0.68 0.18 0.0005 
Q9DBM2 Peroxisomal bifunctional enzyme 1.18 0.21 0.0522 0.72 0.14 0.0001 
Q9DCW4 Electron transfer flavoprotein subunit beta 1.28 0.54 0.4343 0.67 0.38 0.0780 
Q9EQ20 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial 1.11 0.27 0.4578 0.77 0.21 0.0120 
Q9QXF8 Glycine N-methyltransferase 1.23 0.27 0.0568 0.93 0.10 0.1363 
aAccession number provided from the Uniprot mouse database (05/21/2014, 51344 sequences). bAverage ratio of AD/WT from six biological replicates. 
cStandard deviation. dp-value calculated from permutation test. 
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improvements to the cPILOT workflow to reduce sample handling steps and minimize sample loss, 
could significantly improve the proteome breadth of this approach. CysDML is a fairly 
inexpensive approach compared to cPILOT which involves the purchase of commercial isobaric 
tagging reagents. We maximized commercial reagents by using each iodoTMT6 reagent vial to 
label two samples (75 µg for light and 75 µg for heavy dimethyl peptides). The use of isobaric 
reagents that could be synthesized in-house such as DiLEU tags50,274 could help to reduce the cost 
of a cPILOT experiment while maintaining enhanced sample multiplexing capability. The 
CysDML sample preparation steps can be carried out in less than 24 hours while the 
cPILOTapproach can take up to two or three days. Overall, the cPILOT approach ends up taking 
less total experiment time as there is only one sample used for fractionation and smaller numbers 
of samples for MS acquisition. A major drawback to the CysDML approach is the limited amount 
of multiplexing capability that it has even with recent reports of five sample multiplexing with 
dimethyl labeling40. Currently we have demonstrated 12-plex analyses with cPILOT however note 
that further multiplexing is possible with the use of iTRAQ8 reagents or TMT10 286 reagents and 
additional stable-isotope precursors. The errors that arise from independent LC-MS/MS 
experiments in CysDML experiments are not present in cPILOT experiments, where all twelve 
samples are subject to the same exact MS conditions.   
It must be noted that the enrichment of cysteine-containing peptides introduces additional 
sample handling steps that can increase variation in the workflow. In control CysDML experiments 
(Figure 4.3), accurate quantitation was obtained. Care was taken to ensure samples were treated 
similarly prior to the pooling steps. Normalization55 of reporter ion signals was performed to help 
account for errors introduced from sample handling.  
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In both experiments, analysis of only cysteinyl-peptides dramatically simplifies precursor 
MS spectra relative to global dimethylation and cPILOT experiments. This simplification affords 
less spectral interference from closely-spaced precursors that are likely to be co-isolated and 
fragmented in global assays. 
Shi et al. have identified one thousand proteins from mouse liver proteome in a single-run 
LC Orbitrap MS analysis300. Our analyses of liver tissue without enrichment generate similar 
results (data not shown). While enrichment of cysteine-containing peptides should allow for the 
same depth of proteome coverage, lower numbers of proteins are identified140,264. This could be 
attributed to several factors including minimal number of cysteine-containing peptides after 
enrichment for a given protein, peptides not being selected during a DDA experiment, and sample 
loss that can occur during the sample preparation steps as additional clean-up is necessary.  
4.3.6 Differentially-Expressed Proteins in the Liver Proteome of an AD Mouse Model 
Herein CysDML and cPILOT methods identified 65 differentially-expressed proteins in 
liver tissue from an AD mouse model relative to WT controls. AD is a progressive 
neurodegenerative disorder and the most common form of dementia. Little is reported about 
changes in the liver proteome of AD patients or animal models. However, it is suggested that liver 
may be a major contributor to amyloid-β accumulation in the brain301. Liver has a wide range of 
functions including metabolism, biosynthesis of proteins and small molecules, as well as 
detoxification, however below the most interesting changes we have observed revolve around 
metabolism.  
Several proteins have similar trends in differential-expression in AD in liver as compared 
to previously reported studies in AD brain and plasma: alpha-2-macroglobulin302 and 
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hydroxymethylglutyaryl-CoA synthase303 are higher in AD whereas ATP synthase subunit 
gamma304,305, 14-3-3 zeta/delta305,306, sodium/potassium-transporting ATPase subunit beta-1 
(Na+/K+-ATPase)304,305,307, phosphoglycerate mutase 1, enolase, and fructose-bisphosphate 
aldolase B304,306,307 are lower in AD. One protein, superoxide dismutase [Cu-Zn] changes 
differently in liver tissue compared to brain for AD subjects. In liver, superoxide dismutase is 
lower in AD whereas in brain it has higher levels in AD304,308. Superoxide dismutase is a major 
protein targeted under oxidative stress in AD, and the Cys146 residue is irreversibly oxidized to 
cysteic acid309. In CysDML experiments, we detected a tryptic peptide containing Cys146 however 
it was unmodified.  Oxidized cysteine residues are likely to be lost during the enrichment steps.  
Thus, while we observe lower levels of the unmodified peptide in AD mice, it is possible that our 
ratios would be different with detection of the oxidized version of the peptide. 
The reactome pathway database310 was used to provide biological processes related to the 
differentially-expressed proteins and here we focus on a few key aspects of metabolism.  
First, carbohydrate metabolism appears to be altered in AD mouse liver.  Phosphorylase, a 
protein involved in glycogenolysis is higher in AD mice relative to WT.  Enzymes involved in 
glycolysis: fructose biphosphate aldolase, phosphoglycerate mutase, and enolase are lower in AD 
mice relative to WT. In the liver, glycogen synthesis and degradation regulate blood glucose levels. 
Higher phosphorylase suggests that high levels of glucose are generated in the liver, however, 
altered glycolysis implies that the glucose is not being utilized efficiently in this tissue. 
Hyperglycemia is a major risk factor for vascular injury associated with AD 311 and diabetes is 
also a risk factor for AD312, and it is well known that lower glucose metabolism occurs in the brains 
of AD patients166. 
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Second, our data suggest that lipid metabolism is augmented in AD mice. For instance, 
methylmalonyl-CoA mutase and acyl-CoA oxidase, enzymes involved degradation of long-chain 
fatty acids, are higher in AD mice. Changes in this pathway are consistent with other studies in 
our laboratory that have utilized global cPILOT methods to compare liver tissues in AD54. Another 
interesting finding is the increased level of ketogenesis. In AD brain, higher levels of ketone bodies 
were observed with the decrease of brain glucose uptake313. We observed higher levels of 
hydroxymethylglutaryl-CoA synthase in AD mice. This enzyme catalyzes the synthesis of 
acetoacetate, a major ketone bodies produced in ketogenesis. Ketone bodies migrate from the liver 
and enter the circulatory system. Ketone bodies have been suggested as alternative fuel for AD 
brain166 and as a possible therapeutic approach of AD314.  
Finally, it appears that higher levels of ammonia that occur in the blood and brain of AD 
patients315,316 may be linked to our observation of decreased consumption of ammonia by key 
enzymes in the liver. Aspartate aminotransferase and glutamine synthetase, involved in ammonia 
regulation, have lower levels in AD mice relative to WT. These lower levels suggest that ammonia 
is not being consumed by the liver and thus correlates well with reported higher levels of ammonia 
in blood and brain of AD subjects315,316. Hyperammonemia in the liver links to cognitive 
impairment in a model animal study317.  
4.4 CONCLUSIONS 
Two novel cysteine-selective quantitative proteomics approaches were presented in this 
work: CysDML and cPILOT. These are two approaches that allow moderate and high levels of 
sample multiplexing in proteomics workflows. Based on our results, CysDML allows higher 
proteome coverage as compared to cysteine-selective cPILOT. However, cysteine-selective 
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cPILOT offers a more high-throughput approach to study many samples simultaneously.  There 
are direct advantages and limitations to perform multiple duplex experiments or single 12-plex 
experiments, as we have thoroughly discussed.  It is up to the researchers to design which approach 
is most suitable for their given research questions.  Our application of both CysDML and cPILOT 
to the liver proteome from an AD mouse model resulted in identification of more than 2200 
proteins, in which 65 were differentially-expressed in the AD model relative to WT controls.  
These are the first studies to report on changes in the liver proteome for this AD mouse model and 
AD in general. Many interesting findings, especially involved in metabolism occur in the liver of 
AD mice. A potential advantage of cysteine-selective proteomic approach is that it can couple with 
different thiol blocking and reducing techniques to study cysteine reversible modifications in 
complex samples. Cysteine is widely involved in many types of biological activities by forming 
different types of reversible modifications endogenously as described in Chapter 2. 
Characterization of the cysteine redox status using proteomic tools will benefit our understanding 
of neurodegenerative diseases, especially discovering the dysregulated molecular mechanisms 
involved. In Chapters 5 and 6, novel redox proteomics methods were developed based on the 
demonstrated CysDML and cPILOT methodologies. These methods provide quantitative 
information about cysteine reversible modifications in an AD mouse model. 
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5.0 A SIMPLE ISOTOPIC LABELING METHOD TO STUDY CYSTEINE 
OXIDATION IN ALZHEIMER'S DISEASE: OXIDIZED CYSTEINE-
SELECTIVE DIMETHYLATION (OXCYSDML) 
(Note that information in this chapter is written based on a published research paper39, Gu, L.; 
Robinson, R. A. S. Analytical and Bioanalytical Chemistry 2016, 408, 2993-3004.) 
5.1 INTRODUCTION 
Proteins can be oxidized into a variety of post-translational modifications (PTMs)318 and 
these oxidative PTMs have important biological relevance in both physiological and pathological 
conditions68,74, which have been extensively reviewed in Chapter 2. Cysteine is one of the most 
susceptible amino acids and is subject to various oxidative PTMs96. These PTMs are involved in 
various cellular activities64,319 and help maintain homeostasis under conditions of oxidative 
stress320-322 as described in Chapter 2. Cysteine PTMs are of importance for fully understanding 
the physiological role of these cysteine in aging and disease96.  
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by neurofibrillary 
tangles, senile plaques, and loss of synapses185. It has been widely accepted that oxidative stress 
plays an important role in AD pathogenesis323. Proteomic methods coupled with 2D gel 
electrophoresis and affinity enrichment have identified brain proteins that are significantly S-
glutathionylated169 or S-nitrosylated123,171,176 in AD patients or transgenic mouse models relative 
to controls (more details about these studies were reviewed in Chapter 2). These modifications 
are likely due to elevated oxidative stress and are involved in various cellular pathways, such as 
glycolysis, calcium homeostasis and vesicle transport169,171,176. More recently, Cys113 oxidation 
of proline isomerase, Pin1, in postmortem AD brain has been associated with catalytic inactivity178. 
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Gel-based and gel-free proteomic approaches have been applied in cysteine oxidative PTM 
characterization (Chapter 2)324. Briefly, due to some inherent limitations of gel-based approaches, 
gel-free approaches such as ICAT32,101,138, iodoTMT43,113,118 and resin-assisted mass 
tagging99,100,119 are increasingly popular and can isolate and quantify cysteine PTMs from various 
biological samples with enhanced sensitivity. 
On the other hand, multiplexing analysis of cysteine oxidation heavily relies on expensive 
isotope-coded reagents such as ICAT, TMT, and iodoTMT, which have been commercialized 
recently for the enrichment and detection of S-nitrosylation (SNO) from complex samples43. 
Because there are limited isotopic reagents that can be economically synthesized274, there is still a 
demand to develop novel proteomic workflows to isolate, label, and quantify oxidized cysteines 
efficiently and cost-effectively. In this chapter we describe a new redox proteomic approach, 
oxidized cysteine-selective dimethylation (OxcysDML), an extension of our previous reported 
cysteine-selective dimethylation (CysDML) method in Chapter 438, to quantify cysteine oxidative 
modification levels from complex proteome samples. By using the CysDML method, 54 out of 
2085 identified proteins exhibit significant alterations in AD liver tissue, and suggest dysregulated 
metabolic processes occur in AD, especially in carbohydrate metabolism, lipid metabolism, amino 
acid metabolism and ammonia regulation38. OxcysDML employs differential thiol labeling 
followed by thiol-affinity resin enrichment of cysteinyl peptides and on-resin stable-isotope 
dimethyl labeling. The thiol-affinity resin approach has superior enriching efficiency over biotin107 
or iodoTMT113 techniques (>98% by spectral counts38), while solid-phase dimethyl labeling makes 
the workflow inexpensive and easy to perform25. To demonstrate its applicability to disease studies, 
we applied this method to quantify cysteine oxidation status in liver proteins from an AD mouse 
model and wild-type (WT) controls. Specifically, our approach first blocked unmodified cysteine 
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thiols with N-ethylmaleimide. After that proteins were treated to reduce total reversible cysteine 
modifications, which could be further captured by the thiol-affinity resin after tryptic digestion. 
Because a strong reducing reagent dithiothreitol is used prior to enrichment, all types of cysteine 
reversible modifications, e.g., S-nitrosylation (SNO), S-glutathionylation (SSG), S-palmitoylation, 
sulfenic acid and disulfide bonds are reduced to free thiols followed by resin capture. Irreversible 
modifications, including sulfinic and sulfonic acid, should not be enriched by this method. The on-
resin isotopic dimethyl labeling enabled the relative quantification of site-specific cysteine 
modifications between WT and AD samples. The quantified ratios were normalized to protein 
expression abundances from our previously reported CysDML experiment (Chapter 4)38. After 
normalization, this method identified 828 in vivo oxidized cysteine residues from 527 liver proteins. 
Among them nineteen cysteine sites from seventeen proteins had significantly different cysteine 
oxidation levels in AD compared to WT. To the best of our knowledge, this is the first report of 
dimethylation-based methods to quantify cysteine oxidation from complex protein samples, and 
the first study to globally assess cysteine redox status in a peripheral organ system related to AD.  
5.2 MATERIALS AND METHODS 
5.2.1 Animals, Materials and Reagents 
Liver tissues from fourteen-month old amyloid precursor protein/presenilin-1 (APP/PS-1) 
double transgenic mice (AD) and wild type controls (WT) (N = 6 for each genotype) were used in 
this study (see 38 for more details). Animal protocols were approved by the Institutional Animal 
Care and Use Committee at the University of Pittsburgh. Sodium cyanoborohydride (NaBH3CN), 
formaldehyde (HCHO), formaldehyde - 13C, 2H2 (
13C2H2O), N-ethylmaleimide (NEM), 
Thiopropyl Sepharose 6B resin, nitro blue tetrazolium chloride (NBT), trypsin from bovine 
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pancreas, anti-rabbit IgG alkaline phosphatase secondary antibody and formic acid were purchased 
from Sigma-Aldrich (St. Louis, MO). Iodoacetamide was purchased from Acros (Morris Plains, 
NJ). Sodium cyanoborodeuteride (NaB2H3CN) was obtained from Santa Cruz Biotechnology 
(Dallas, TX). Dithiothreitol (DTT) was purchased from Fisher Scientific (Fair Lawn, NJ). 5-
bromo-4-chloro-3-indolyl phosphate (BCIP), spin column and BCA assay kit were purchased from 
Pierce Thermo (Rockford, IL). Deionized water was produced by a nanopure water system from 
Thermo (Rockford, IL). Protein carbonylation (PCO) measurement kit was from Millipore 
(Temecula, CA). All other chemicals were of analytical reagent grade. 
5.2.2 Tissue Homogenization, Protein Digestion and Stable-isotope Dimethyl Labeling 
Liver tissues were homogenized in an ice-cold phosphate buffer saline (PBS, pH = 7.2) 
solution containing 8 M urea and 5 mM NEM. After BCA determination of protein concentration, 
each sample (100 µg protein) was diluted to a final concentration of 1 µg/µL with PBS (pH = 7.2) 
containing 8 M urea, 1% SDS and 50 mM NEM. Samples were incubated for two hours at room 
temperature in the dark. Excess reagents were depleted by acetone precipitation. The following 
procedures are similar to previous studies38. Briefly, proteins were dissolved in 50 mM Tris buffer 
with 8 M urea (pH = 8.2), reduced by 10 mM DTT for one hour at 37°C, and digested by adding 
4% trypsin with overnight incubation at 37°C. After cleanup by Waters Oasis HLB C18 cartridges, 
samples were lyophilized and enriched by Thiopropyl Sepharose 6B resin with one hour incubation 
at room temperature. Next, 11.2 µL of 4% CH2O/
13C2H2O and 11.2 µL of 0.6 M 
NaBH3CN/NaB
2H3CN were added to WT and AD samples for light and heavy dimethylation 
labeling, respectively. After one hour incubation, 0.2% (v/v) concentration of ammonia was added 
to quench the reaction. 20 mM DTT was used to elute peptides, and 80 mM IAM was added to 
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alkylate sulfhydryl groups. Isotopically labeled WT and AD samples were randomly combined, 
and desalted using C18 cartridges for LC-MS/MS analysis.  
5.2.3 LC-MS/MS Analysis 
Online desalting and reversed-phase chromatography was performed with a Nano-LC 
system equipped with an autosampler (Eksigent; Dublin, CA). Mobile phases A and B were 3% 
(v/v) acetonitrile with 0.1% formic acid and 100% (v/v) acetonitrile with 0.1% formic acid, 
respectively. Sample (5 µL) was loaded onto a trapping column (100 µm i.d. × 2 cm), which was 
packed in-house with C18 200 Å 5 μm stationary phase material (Michrom Bioresource Inc.; 
Auburn, CA) at 3 µL/min in 3% mobile phase B for 3 min. The sample was loaded onto an 
analytical column (75 µm i.d. × 13.2 cm), which was packed in-house with C18 100 Å 5 µm 
stationary phase material (Michrom Bioresource Inc.; Auburn, CA). The following gradient was 
used: 0-5 min, 10% mobile phase B; 5-40 min, 10-15% B; 40-90 min, 15-25% B; 90-115 min, 25-
30% B; 115-130 min, 30-60% B; 130-135 min, 60-80% B; 135-145 min, 80% B; 145-150 min, 
80-10%B; 150-180 min, 10%B. The LC eluent was analyzed with positive ion nanoflow 
electrospray using a LTQ-Orbitrap Velos mass spectrometer (Thermo-Fisher Scientific; Waltham, 
MA).  
OxcysDML samples were analyzed by employing gas phase fractionation (GPF). 
Specifically, each sample was injected six times and subjected to different mass spectrometry (MS) 
scans: the first to third injection) precursor scan over the m/z range 400-1700, fourth to sixth 
injections) m/z 400-777, m/z 762-902 and m/z 887-1700, respectively. The following data-
dependent acquisition (DDA) parameters were used in each injection: the MS survey scan in the 
Orbitrap was 60 000 resolution; the top 15 most intense peaks in the MS survey scan were isolated 
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and fragmented with CID at an isolation width of 3 m/z; CID was performed in the ion trap with 
normalized collision energy 35%.  
5.2.4 Data Analysis and Statistics 
RAW files were analyzed using the SEQUEST HT search engine with Proteome 
Discoverer 1.4 software (Thermo-Fisher Scientific; Waltham, MA) and searched against the 
Uniprot mouse database (Jan 7, 2015; 52639 sequences). SEQUEST HT search parameters of 
OxcysDML data are as follows: precursor mass tolerance 15 ppm; fragment mass tolerance 1 Da; 
static modifications light dimethyl/+28.031 Da (Lys) or heavy dimethyl/+36.076 Da (Lys); 
dynamic modifications light dimethyl/+28.031 Da (N-terminal) or heavy dimethyl/+36.076 Da (N-
terminal), carbamidomethyl modification/+57.021 Da (Cys), N-ethylmaleimide/+125.048 Da 
(Cys), oxidation/+15.995 Da (Met). Decoy database searching was employed to generate medium 
(p < 0.05) and high (p < 0.01) confidence peptide lists. Only peptides containing cysteine residues 
with medium and high confidence were used further. Proteome Discoverer 1.4 provided peak area 
information for light and heavy labeled peptides and peptide ratio calculations. Peptide ratios were 
normalized based on the peptide median ratio in each biological replicate experiment. The 
resulting AD/WT cysteinyl peptide ratios were further normalized using the protein expression 
ratios 325 measured in an independent cysDML experiment38. The final peptide ratios were log2 
transformed and subjected to permutation in MATLAB R2014a38 to calculate the p-values. In 
addition to p-values, the average log2 ratios and the log2 standard deviations were calculated by 
EXCEL 2013 for each quantified peptide. Peptides measured in at least three biological replicates 
were further processed. From an independent experiment, we evaluated error of this method using 
an equimolar 1:1 light and heavy dimethylated liver tissue sample and analyzed by a single LC-
MS/MS run. Based on these measurements, the overall CV of fold-change ratios (heavy/light) is 
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~ 30% (standard deviation = 0.38 on log2 scale, see Figure 5.1). This standard deviation level was 
used to perform FDR by generating a series of normal random numbers. First a stringent p-value 
of less than 0.01 was set as the p-value cutoff for the simulated peptides with different biological 
replicates (N). The calculated FDRs were 18%, 8%, 8% and 2% for N = 3, 4, 5 and 6, respectively. 
By adding criteria that also includes a log2 ratio cutoff of 0.38, the FDRs were 5%, 1%, 1% and 
0.3% for N = 3, 4, 5 and 6, respectively. By increasing the log2 ratio cutoff from 0.38 to 0.50, the 
FDR is lowered to 1% for N = 3. For the analysis of AD liver tissue, we fixed the FDR to 1%, so 
that the ratio cutoff was 0.50 (for N = 3), 0.38 (for N = 4, 5 and 6), and a p-value cutoff (0.01) was 
required to determine redox-sensitive peptides. In addition, a standard deviation cutoff (0.70) was 
applied to filter out measurements with extreme variances as most of the standard deviations from 
repeated measurements do not exceed 0.70 from the simulation data (Table 5.1).  
5.2.5 Oxidative Stress Measurement 
For protein carbonylation (PCO) measurement, five µL of each liver protein sample from 
WT (N = 6) and AD (N = 6) mice was incubated with 12% SDS and 20 mM 2,4-
Dinitrophenylhydrazine (DNPH) solution for 20 min at room temperature. A neutralization 
solution was added to stop the reaction. Derivatized proteins (250 ng) were loaded onto a 
nitrocellulose membrane with a slot blot apparatus. The membranes were blocked with 3% (w/v) 
BSA solution overnight at 4℃ and incubated with a 1:2000 dilution of anti-DNP antibody for 2 
hours. After rinsing the membrane, anti-rabbit IgG alkaline phosphatase secondary antibody was 
added with the dilution factor 1:5000 and incubated with the membrane for 1 hour. The membrane 
was washed in wash blot and developed using 5-bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro 
blue tetrazolium chloride (NBT) colorimetric development. The blot was dried, scanned and slot  
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Figure 5.1 Scatter plot of log2 peptide ratios measured in OxcysDML 1:1 experiment. Three horizontal 
lines represent average+1.95×standard deviation (upper 95% c.i.), average, and average-1.95×standard 
deviation (lower 95% c.i.), respectively. The quantified peptides within each region is labeled. 
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Table 5.1 Summary of p-value, ratio and standard deviation (S.D.) cutoff used to determine redox-sensitive 
peptides. 
N(Replicates)a 3 4 5 6 
FDR (p<0.01 & w/o ratio cutoff)b 18% 8% 8% 2% 
Average log2 ratio cutoffc >0.50 or <-0.50 >0.38 or <-0.38 >0.38 or <-0.38 >0.38 or <-0.38 
Log2 S.D. cutoffd <0.7 
FDR (p<0.01 & ratio cutoff)e 1% 1% 1% 0.3% 
aReplicates of simulation performed to mimic peptides quantified in different number of biological replicates. bFDR if only p 
< 0.01 filter is applied. cRatio cutoff that is used. dStandard deviation cutoff based on the maximal standard deviation from the 
simulation data. eFDR if both p < 0.01 and ratio cutoff are applied. 
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profiles quantified using Scion Image. Statistical testing (student’s t-test) was performed in Origin 
8.0. The entire experiment was repeated twice. 
5.3 RESULTS AND DISCUSSION 
5.3.1 OxcysDML Methodology 
The three major steps in OxcysDML are reduction, isolation and dimethylation, as shown 
in Figure 5.2. Mouse liver tissues (N = 6 for WT and AD) were homogenized in the presence of 
NEM (5 mM) to briefly block free thiols and minimize possible exchange between free thiols and 
oxidized thiols during protein extraction326. Next, a high dose of NEM (50 mM) was applied to 
each sample to further block all free thiols (buffer pH 7.2) and to minimize side reactions. Excess 
reagent was removed and proteins were treated with DTT to reduce any cysteine reversible 
modifications, such as disulfide bonds, S-sulfenylation, SNO, SSG and sulfenic acid. Here we 
applied a strong reducing reagent (i.e., DTT) to help capture multiple cysteine reversible 
modifications in order to gain global insight into cysteine oxidation status in AD. By using other 
reduction conditions, specific types of cysteine modifications (e.g., SNO, SSG) can be analyzed 
with OxcysDML119. Next proteins were digested with trypsin and the peptides containing newly-
formed sulfhydryl groups were enriched by Thiopropyl Sepharose 6B resin and dimethylated38. 
WT and AD samples were labeled with light (–C2H6) or heavy (–13C22H6) dimethyl tags, 
respectively. Peptides were eluted from the resin by DTT and alkylated by IAM. WT and AD 
samples were mixed and six samples were analyzed by LC-MS/MS. To improve proteome 
coverage with limited sample amount (estimated as ~24 µg in total), we used gas phase 
fractionation (GPF)38,291. In the dimethylation step, only two sample channels are labeled, which 
could be expanded to incorporate more samples by using sodium cyanoborohydride and  
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Figure 5.2 Schematic representation of the oxidized cysteine-selective dimethylation (OxcysDML) redox 
proteomics workflow. Mouse liver proteins are treated with 50 mM NEM to block free sulfhydryl groups, 
then reduced with 10 mM DTT and digested. Reduced peptides containing newly-formed sulfhydryl groups 
are enriched by a thiol-affinity resin. WT and AD samples are labeled with light (-C2H6) and heavy (-
13C22H6) dimethyl tags respectively on the affinity resin. Peptides are eluted from the resin with 20 mM 
DTT and free cysteines are alkylated by iodoacetamide. WT and AD samples are combined, desalted and 
analyzed by LC-MS/MS. 
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formaldehyde containing different heavy atoms40 or isobaric tagging methods119. 
The overall tagging efficiency and enrichment efficiency of OxcysDML is 97% and 99% 
(calculated by PSM), respectively. The flow through after enrichment consists of the cysteine-
containing peptides that were NEM tagged (98.5% by PSM). The integration of the dimethylation 
reaction with peptide enrichment on the solid phase resin results in shortened sample handing 
time109 and minimal sample loss. We have previously shown that our dimethylation labeling 
condition is sufficient for labeling all cysteinyl peptides isolated from 200 µg protein digest38. It 
is estimated that ~15% of total thiols are oxidized in vivo64, therefore ~150 µg of oxidized cysteine-
containing proteins can be isolated from 1 mg of tissue and tagged by OxcysDML. OxcysDML 
also has significant cost savings (<$1 US) due to the use of inexpensive isotopic reagents (13C2H2O 
and NaB2H3CN).  
5.3.2 Application of OxcysDML to an AD Mouse Model 
To demonstrate the capability of cysteine redox quantification by OxcysDML method, we 
applied it to the liver proteome of an AD mouse model to gain insights into redox chemistry in 
AD. Based on cysteine occurrence (~14% of all in silico tryptic peptides) in the mouse proteome, 
it is estimated that only ~2% of tryptic peptides (~4 µg for each sample) are enriched and analyzed 
in OxcysDML.  
Figure 5.3 displays some examples of MS and MS/MS spectra. The top panel shows a full 
scan of a triply charged peptide pair (light m/z = 818.754, heavy m/z = 821.435) that upon isolation 
of each peak and generated fragment ions is assigned to the sequence 
S(dimethyl)TEPC(IAM)AHLLVSSIGVVGTAEQNR from D-dopachrome decarboxylase. 
Independent MS/MS spectra of the light (black) and heavy (red) peaks are overlaid on the same 
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Figure 5.3 Example OxcysDML MS and MS/MS spectra for: (a) pair of light (m/z = 818.754) and heavy 
(m/z = 821.435) peaks assigned to the triply charged peptide S(dimethyl)TEPC(IAM)AHLLVSSIGVVGT 
AEQNR from D-dopachrome decarboxylase. MS/MS spectra of light (black) and heavy (red) peaks are 
overlaid. A zoomed-in spectra shows a mass shift of 8 Da for the b162+ peaks representing the isotopic 
dimethylation on the N-terminus; (b) pair of light (m/z = 803.956) and heavy (m/z = 816.023) peaks assigned 
to the doubly charged peptide S(dimethyl)LVANLAAANC(IAM)YK(dimethyl)K(dimethyl) from isoform 
short of adenosine kinase. A zoomed-in spectra shows a mass shift of 8 Da for the b6 peaks, representing 
isotopic dimethylation on the N-terminus.   
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spectrum. The isotopic dimethylation of the peptide N-terminus is indicated by an 8 Da mass shift 
between the pair. The cysteine residue labeled with IAM (Cys57) is reversibly oxidized in vivo. In 
order to determine if oxidation status changes with disease or external stimuli, it is required that 
the oxidative cysteine PTMs are normalized to total protein abundance levels. Our previously 
reported CysDML analysis of AD liver proteome (Chapter 4) was used to determine total protein 
abundance in WT and AD liver by focusing on cysteine-containing peptides (Appendix C Table 
5.1)38. For the example shown in Figure 5.3a, peptide ratio data indicated no significant change of 
this modification in AD (log2(AD/WT) = 0.11, p = 0.1785). However after normalization by the 
total protein abundance ratio, a significant increase is observed (log2(AD/WT) = 0.41, p = 0.0001). 
Another peptide, S(dimethyl)LVANLAAANC(IAM)YK(dimethyl)K(dimethyl) from isoform 
short of adenosine kinase (Figure 5.3b), was quantified as not significant in AD liver tissue 
(log2(AD/WT) = -0.22, p = 0.0139), and this significance was enhanced after normalizing to the 
total protein ratio (log2(AD/WT) = -0.47, p = 0.0006). It must be noted that individual cysteine 
sites exhibit different oxidation status depending on sequence structure, solvent exposure, 
enzymatic function and cellular environment. This difference can be discriminated by quantifying 
cysteine oxidation at the peptide level, as most peptides contain only one cysteine residue.  
In total, 808 peptides containing 828 reversibly oxidized cysteine residues from 527 
proteins were identified in this work and they are listed in Appendix C Table 5.2. The most 
abundant oxidized cysteine site is Cys591 of serum albumin, a disulfide bond site identified by 
638 MS/MS spectral counts. A large portion of proteins (192 out of 527) are identified by only 
one peptide (one spectral count), 211 one peptide (at least two spectral counts), and 124 two or 
more peptides, respectively (see Appendix C Table 5.2), which are consistent with other cysteine- 
redox proteomic studies107,109. Without using multi-dimensional separation techniques, 
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OxcysDML has comparable proteome coverage compared to ICAT101 and iTRAQ-based 
methods109 that used biotin as an enriching reagent and significantly higher proteome coverage in 
comparison to iodoTMT-based methods113,118.  
Quantitative analysis of the entire dataset involved a total of 323 peptides. These peptides 
were quantified by at least three biological replicates and were also measured with CysDML (see 
Chapter 4)38, allowing us to obtain total protein abundance information (Appendix C Table 5.1). 
A major limitation of this work is that the relative quantification is mostly based on a single peptide 
for most proteins109,116,118 whereas other applications have multiple peptides38,54. Because 
OxcysDML is evaluating low abundant in vivo oxidized cysteine modifications, it is critical to 
ensure that suitable criterion are employed to manage over interpretation of biologically 
insignificant results. So we applied the following stringent criteria to control the quality of the data: 
1) we assessed the overall error of this method by an independent experiment, and the error was 
taken into consideration for determining appropriate ratio cutoff; 2) a strict p-value cutoff was 
applied; 3) FDR after using the above statistical criteria was verified using mathematical 
simulation; 4) six biological replicates were employed, and each peptide in Table 6.1 has at least 
four biological replicates and ten spectral identifications from multiple technical replicates; 5) 
protein ratios were used to normalize peptide ratios for unbiased quantification. This resulted in 
seventeen redox-sensitive peptides that have statistically significant (p < 0.01) different cysteine 
oxidation levels in AD mice compared to WT by at least 30% (Table 5.2 and Figure 5.4). A subset 
of these peptides have very small p-values (p < 0.0001) (Figure 5.4). Permutation test is an ideal 
statistical test for quantitative proteomic data to provide p-values without further adjustment327. 
However the p-value only indicates the mathematical probability of the null hypothesis (H0: μ= 0, 
no significant change), regardless of the degree of change. In an independent experiment, we 
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Table 5.2 Redox-sensitive cysteine identified in AD and WT mouse liver tissues. 
Sequencea Acc. No.b Protein Name 
# 
PSMg 
Log2 
(AD/WT)c 
S.D.d p-vale Nf Modificationh 
SLVANLAAANC(159)YKK P55264-2 
Isoform Short of Adenosine 
kinase 
102 -0.47 0.26 0.0006 6  
LC(119)EAIC(123)PAQAITIEAEPR Q8K3J1 
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
8, mitochondrial 
67 -0.80 0.45 0.0001 6 
Metal binding; 
Iron-sulfur 1 
(Cys119) & 2 
(Cys123) 
AIAQSSVIFNPC(254)LFGR Q8VCC2 Liver carboxylesterase 1 53 0.53 0.35 0.0001 6  
LLQLAC(168)PGTGEADAR Q8K1B3 Gltpd2 protein 35 -1.26 0.58 0.0003 6  
ADHQPLTEASYVNLPTIALC(148)NTDSPLR P14206 40S ribosomal protein SA 31 0.39 0.23 0.0010 6  
STEPC(57)AHLLVSSIGVVGTAEQNR O35215 D-dopachrome decarboxylase 29 0.41 0.21 0.0001 6  
TLTQC(85)SWLLDGFPR Q9WTP7 
GTP:AMP phosphotransferase 
AK3, mitochondrial 
28 0.39 0.24 0.0002 6 
 
MTNGFSGADLTEIC(691)QR Q01853 
Transitional endoplasmic 
reticulum ATPase 
26 -0.41 0.25 0.0001 5 
 
NQEAMGAFQEFPQVEAC(107)R D3YZ54 2-hydroxyacyl-CoA lyase 1 22 0.54 0.49 0.0001 5  
SAFEYGGQKC(347)SAC(350)SR Q8CHT0 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial 
22 -0.52 0.55 0.0001 5 
Active site; 
Nucleophile 
(Cys347) 
GALVTVGQLSC(180)YDQAK Q9QZD8 
Mitochondrial dicarboxylate 
carrier 
17 -1.46 0.17 0.0001 4  
NNPAIVVIGNNGQINYDHQNDGATQALA
SC(182)QR 
D3Z5B9 Protein ERGIC-53 (Fragment) 16 -0.84 0.49 0.0001 6 Disulfide 
NILGGTVFREPIIC(154)K P54071 
Isocitrate dehydrogenase 
[NADP], mitochondrial 
16 0.66 0.30 0.0011 4  
LC(88)LTGQWEAAQELQHR E9Q1R2 
4-hydroxy-2-oxoglutarate 
aldolase, mitochondrial 
14 1.59 0.38 0.0001 6  
DC(177)LIPMGITSENVAER Q8VCH0 
3-ketoacyl-CoA thiolase B, 
peroxisomal 
10 0.58 0.51 0.0078 4  
LADIGAC(171)AQIVHK Q8VCN5 Cystathionine gamma-lyase 10 -0.67 0.13 0.0001 4  
TAC(377)YGHFGRSEFPWEVPK Q91X83 
S-adenosylmethionine synthase 
isoform type-1 
10 0.55 0.28 0.0001 4  
aPeptides are grouped by sequence. bAccession number provided from the Uniprot mouse database (Jan 7, 2015; 52639 sequences). cAverage AD/WT ratior on 
log2 scale. dStandard deviation of log2(AD/WT). ep-value calculated from permutation test. fNumber of biological replicates quantified. gNumber of peptide 
spectra matchings. hModification information is obtained from Uniprot database. 
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Figure 5.4 Volcano plot displaying the difference in the levels of peptides containing oxidized cysteine 
between AD and WT liver. Log2 peptide ratios are plotted against negative log10 p-values. The accession 
numbers of proteins containing redox-sensitive cysteine are labeled. Because permutation operation was 
repeated 10000 times in the statistical algorithm, all probabilities less than 1/10000 would not be 
discriminated, and the p-value of them would be 0.0001, resulting in a horizontal line in the volcano plot. 
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evaluated the error of this method using an equimolar 1:1 light and heavy dimethylated liver tissue 
sample and analyzed by a single LC-MS/MS run. Based on this measurement, the overall CV of 
fold-change values was ~30%, which is slightly larger than most quantitative proteomic 
approaches (~20 - 25%)297. We believe this larger variation is a result of OxcysDML quantification 
on single peptides in most cases, instead of many peptides as in global protein analyses. We found 
that using 30% change as the ratio cutoff is sufficient for peptides quantified by four, five and six 
biological replicates to determine biological significance (FDR ≤ 1%). However a higher ratio 
cutoff is needed for peptides with three biological replicates (Table 5.1) in order to keep the FDR 
≤ 1%. This restriction resulted in no redox-sensitive peptides with statistically significant 
differences in oxidization level being reported for N = 3 (Table 5.2). By using the combination of 
p-value and ratio cutoff, the FDR is no more than 1% for all peptides (Table 5.1). The seventeen 
redox-sensitive peptides with statistical significance are listed in Table 5.2, in which nine peptides 
have higher levels of oxidized cysteine in AD mice, whereas the other eight peptides have lower 
levels of oxidized cysteine in AD mice relative to WT. In comparison with other cysteine-redox 
proteomic studies101,109, the number of redox-sensitive peptides obtained by OxcysDML are fewer, 
this is because: 1) no oxidizing reagent (e.g. hydrogen peroxide) is used for enhancing protein 
oxidation; 2) stringent criterion is utilized to determine redox-sensitive peptides. The most 
abundant redox-sensitive peptide in the list is SLVANLAAANC(159)YKK from isoform short of 
adenosine kinase, and it was observed and quantified in all six biological replicates. The least 
abundant redox-sensitive peptides are DC(177)LIPMGITSENVAER from 3-ketoacyl-CoA thiolase 
B, LADIGAC(171)AQIVHK from Cystathionine gamma-lyase and TAC(377)YGHFGRSEFPWEV 
PK from S-adenosylmethionine synthase isoform type-1, in which we detected ten PSMs for each 
across four biological replicates. This data indicates that we measured redox-sensitive peptides 
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with a dynamic range of abundance over ~ two orders of magnitude. This result is also consistent 
with our previous investigation of the dynamic range in cysDML approach38, however experiments 
to measure the dynamic range in OxcysDML would be necessary. On the other hand, the highest 
and lowest log2 ratios in Table 6.1 are 1.59 and -1.46 (3.01 and 0.36 on normal scale, respectively), 
indicating the capability of measuring changes up to 3-fold in in vivo AD tissues.  
The REACTOME database was employed to categorize the identified proteins with regard 
to biological pathways (Figure 5.5). Approximately 39% of the identified proteins belong to the 
metabolic pathway (139 out of 358, see Figure 5.5a), a proportion that is consistent with the mouse 
liver proteome300. A redox proteomic study of mouse liver mitochondria under Cadmium exposure 
indicates the broad involvement of cysteine redox chemistries in liver enzymatic pathways328, 
which is consistent with our finding that metabolism is the most prominent pathway associated 
with cysteine reversible modifications in mouse liver. Proteins belonging to metabolism are further 
categorized (Figure 5.5b), in which energy-related metabolic pathways, including metabolism of 
amino acid and derivatives, metabolism of carbohydrates, metabolism of lipids and lipoproteins, 
the citric acid cycle and respiratory electron transport as well as biological oxidation are the 
predominant pathways (Appendix C Table 5.3). Network analysis using STRING (version 10) also 
shows that the identified proteins cover several basic molecular pathways in liver, e.g. amino acid 
metabolism, pyruvate metabolism, citrate cycle, glycolysis/gluconeogenesis and fatty acid 
degradation (p < 0.05, n > 5) (Figure 5.6). Redox-sensitive proteins in AD (Table 5.2) classify to 
metabolic pathways of amino acid, carbohydrates and lipids (Figure 5.5b) indicating the potential 
alteration of energy production and utilization in AD mouse liver tissue. This is consistent with: 1) 
dysregulated metabolic processes such as β-oxidation, pyruvate metabolism and glucose 
regulation in AD liver54; 2) alterations in carbohydrate metabolism, lipid metabolism and amino 
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Figure 5.5 Histogram plot of a) biological pathways and b) metabolism pathways associated with identified 
proteins (N = 827) obtained from the REACTOME database. Redox-sensitive protein levels are indicated 
in b) with blue color. 
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Figure 5.6 Interaction network of identified Mus Musculus liver proteins containing modified cysteine in 
vivo by OxcysDML approach. Zoom-in details represent example pathways significantly enriched in the 
dataset (p-value < 0.05, n > 5). Red dots indicate the identified proteins by OxcysDML. Uniprot accession 
numbers were uploaded to STRING (version 10) and returned as gene symbols. Network analysis was 
performed using STRING (version 10) with confidence view and confidence score of 0.700, no text mining 
was used. Examples of proteins containing redox-sensitive cysteine as well as the direction of change in 
AD are highlighted. 
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acid metabolism38; and 3) differential SNO of proteins involved in energy metabolism and 
oxidative phosphorylation176. Further examination of redox-sensitive cysteine residues in 
Uniprot329 was used to help with biological interpretation of changes in cysteine status. For 
example, Cys347 of delta-1-pyrroline-5-carboxylate dehydrogenase is an active site for catalysis330, 
Cys119 and Cys123 of NADH dehydrogenase [ubiquinone] iron-sulfur protein 8 are sites for iron 
metal binding to form two 4Fe-4S clusters [55]) (Table 5.2). A rare situation is that a single peptide 
may contain multiple modified cysteine sites, in which the OxcysDML method is not able to 
differentiate their individual redox status, e.g., modified Cys119 and Cys123 of NADH 
dehydrogenase [ubiquinone] iron-sulfur protein 8 are identified from the same peptide. In this case 
we assigned the potentially oxidized cysteine sites based on MS/MS sequencing data individually, 
and we treat the peptide as a whole for quantitative analysis176. 
5.3.3 Proteins Containing Redox-sensitive Cysteine in AD Mouse Liver Tissue 
AD is a progressive neurodegenerative disorder and the most common form of dementia331. 
Our previous studies of peripheral organs and cells in an AD mouse model indicated dysregulated 
metabolic pathways in liver tissue38,54 and elevated oxidative stress in T cells189. Although 
oxidative stress-induced cysteine PTMs (e.g. SNO, SSG) in AD have been reported, most of these 
studies were focused on brain tissue and used gel-based methods123,124,147,176,324,332. The role of 
peripheral organs involved in AD is still not clear. Liver is an organ with known metabolic, 
biosynthetic and detoxification functions and some studies have linked the liver to AD 
pathogenesis. For example, the neuroprotective fatty acid docosahexaenoic acid (DHA), is 
synthesized in liver and is helpful for decreasing amyloid beta (Aβ) deposition333. Liver may 
involve the clearance of Aβ deposition by expressing liver low-density lipoprotein receptor-related 
protein (LRP)334. Characterization of cysteine reversible oxidations in liver proteins facilitates 
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understanding of global processes involving cysteine redox switching, and the role that oxidative 
stress plays systemically in AD. 
Interestingly, half of the proteins (eight out of seventeen) listed in Table 6.1 belong to 
metabolism, which is consistent with our previous work of liver proteome quantification using 
CysDML and cPILOT (Chapter 4)38,54. Among various metabolic processes, lipid metabolism, 
including ketone bodies synthesis and β-oxidation, is considered as a major source of reactive 
oxygen species (ROS). Two proteins involved in lipid metabolism, including peroxisomal 3-
ketoacyl-CoA thiolase B and 2-hydroxyacyl-CoA lyase 1, are found to be in a more oxidized state 
in AD, which may be due to the overwhelmed oxidative stress associated with lipid metabolism. 
To further explore this, we measured the relative abundance of protein carbonylation (PCO) levels 
in liver proteins from WT and AD mice. PCO is a widely used biomarker for protein oxidative 
stress (Chapter 2). Our data (Figure 5.7) indicates there is a significantly elevated PCO level in 
AD mouse liver compared with WT (p < 0.01). Oxidative stress plays an important role in the AD 
pathogenesis as it has been demonstrated in brain186, plasma187, heart188 and the immune 
system188,189. The liver is an organ that is susceptible to oxidative stress due to its high nature of 
metabolic activities335. The dysregulated metabolic processes, such as β-oxidation as we identified 
before54, may contribute to the increased oxidative stress in AD liver. This is especially true for 
the β-oxidation occurred in peroxisomes, in which high-potential electrons generated by oxidative 
reaction are transferred to oxygen molecules and result in hydrogen peroxide336. Hydrogen 
peroxide is a well-known ROS species in cellular environment. 3-ketoacyl-CoA thiolase B is a 
peroxisomal enzyme catalyzing the fourth step of β-oxidation to cleave β-ketoacyl CoA and 
shorten the carbon chain. Our data indicates that Cys177 of 3-ketoacyl-CoA thiolase B has an ~ 
50% elevated oxidation in AD liver compared with WT, which may suggest that a dysregulated 
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Figure 5.7 Histogram plot of protein carbonylation (PCO) levels in liver proteins isolated from WT (N = 
6) and AD (N = 6) mice. Intensities are normalized to WT. Error bar: ±standard deviation. P-values are 
provided. Replicates 1 and 2 are technical replicates. 
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lipid metabolism in AD liver is accompanied by oxidative stress. 
5.4 CONCLUSIONS 
This work described the OxcysDML method, which uses on-resin enrichment and isotopic 
dimethylation labeling. We demonstrated this method using liver from an AD mouse model, 
however it can be applied to many other biological samples (e.g. cell lysates, serum, brain etc.). 
The simple, efficient, and inexpensive nature of the OxcysDML method makes it amenable for 
studies involving comparisons of two conditions. The sample processing steps involved in the 
OxcysDML method, include reduction and dimethylation, and can be modified to accommodate 
the investigation of specific types of oxidative cysteine PTMs by varying the reducing reagent. 
Oxidized cysteinyl peptide ratios were corrected with global protein expression changes using 
independent cysDML data. Redox-sensitive proteins in the AD liver proteome widely participate 
in metabolic processes of glucose, lipids and amino acids, which provides additional evidence for 
dysfunctional metabolism in AD. The contributions of these changes in the liver to AD 
pathogenesis requires further investigation. Future directions include the incorporation of 
additional isotopic channels into the OxcysDML workflow to obtain oxidation level and total 
abundance data in a single run and comparing stoichiometries of cysteine status across 
modification types. In addition, it would be more helpful to isolate and quantify a specific type of 
cysteine modification from tissue samples. For example, SNO is an important cysteine PTM in 
redox signaling and shows both neuroprotective and neurodestructive effects in AD. In Chapter 
6 an enhanced multiplexing approach to characterize endogenous SNO from AD model mouse is 
discussed.  
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6.0 HIGH-THROUGHPUT ENDOGENEOUS MEASUREMENT OF S-
NITROSYLATION IN ALZHEIMER’S DISEASE USING OXIDIZED 
CYSTEINE-SELECTIVE CPILOT 
(Note that information in this chapter is written based on a published research paper141, Gu, L.; 
Robinson, R. A. S. Analyst 2016, DOI: 10.1039/c6an00417b) 
6.1 INTRODUCTION 
Cysteine is an important amino acid in biology as it can be endogenously oxidized into a 
number of oxidative post-translational modifications (PTMs) and these modifications are widely 
involved in  biological activities such as cellular redox status, signaling and  enzymatic 
catalysis64,68,83,96,320 (see Chapter 2). Among them, S-nitrosylation (SNO) is key to cellular 
signaling processes similar to other majors PTMs such as phosphorylation337,338 and can influence 
protein conformation, activity, protein-protein interactions, transcription, autophagy, apoptosis 
and DNA repair339,340. As opposed to some oxidative modifications that may occur sporadically to 
proteins, SNO is believed to be highly regulated and occur at specific cysteine sites76. SNO is 
critical in disease pathogenesis339, especially in the context of neurodegenerative diseases63,340.  
SNO has been linked to protein aggregation and misfolding, mitochondrial dysfunction, synaptic 
injury, neuronal loss, impaired metabolism and autophagy in Alzheimer’s disease (AD)63.  While 
these are detrimental consequences of SNO that likely occur with high concentrations of NO 
derived from environmental toxins, this PTM can be neuroprotective AD and has been used as a 
therapeutic target341. Many proteins have been S-nitrosylated in tissues of AD patients or models, 
including: cyclin-dependent-like kinase 5 (Cdk5), apolipoprotein E (ApoE), tubulin, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), voltage-dependent anion-selective 
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channel protein (VDAC), superoxide dismutase [Mn] (SOD2) and heat shock protein HSP 90 
(HSP90)63.  
There are noted challenges to studying SNO on a global scale, which include its reversible 
nature as it can be denitrosylated/transnitrosylated enzymatically, its low abundance, and its 
potential occurrence at multiple cysteine sites in a protein96,342. Redox proteomics however, 
provides tools with which SNO can be studied for individual proteins or globally in an entire 
proteome. Several approaches, which use different techniques of affinity purification, chemical 
derivatization and mass spectrometry (MS)43,98,100,113,116,118,123,126,137, been developed and have 
been recently reviewed74,82,83,96,343 (see Chapter 2 for more details). Among all available methods, 
isobaric tagging such as iodoTMT, TMT, or the inclusion of iTRAQ100 allow greater sample 
multiplexing capabilities (i.e., up to eight samples can be analyzed simultaneously). In Chapter 5, 
we developed a simple, straightforward, and robust approach to measure oxidized cysteine in 
global proteome experiments, through coupling on-resin capture of cysteines and isotopic 
dimethylation reactions39. This approach, called OxcysDML, could be readily modified to study 
SNO by exchanging the dithiothreitol reducing agent with ascorbate. Ours and other methods118,138 
however, require additional experiments in order to normalize the SNO modification levels to total 
protein abundance and have limited sample throughput (i.e., can only multiplex two to six samples).  
In order to help improve the sample multiplexing capability of measuring SNO in a global 
fashion and the sensitivity to measure endogenous levels of SNO in biological tissues, we 
developed an oxidized cysteine-selective combined precursor isotopic labeling and isobaric 
tagging (OxcyscPILOT) strategy. OxcyscPILOT, is based on global cPILOT for quantifying 
proteomes36,54 and total cysteine proteome (Chapter 4)38 detection. While we use TMT6 reagents 
to multiplex 12 samples in a single analysis, the method is amenable to 20 samples by using 
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TMT10-plex reagents286. A primary advantage of having enhanced multiplexing is the ability to 
analyze several biological replicates which minimizes false-positive detection of biologically 
relevant SNO modifications and methodological error. Additionally, because there are 12 channels 
available for measurement, total cysteine abundance levels can be obtained alongside SNO 
modification levels. As a biologically relevant demonstration of OxcyscPILOT, the strategy was 
applied to brain homogenates from an APP/PS-1 transgenic mouse model54,344 of AD. SNO 
modification in AD has been reported in the literature63,123,171,176 including, specific SNO-
modification sites and proteins. In a single analysis, OxcyscPILOT allows unbiased quantification 
of SNO-modified protein levels in wild-type and APP/PS-1 mice across biological replicates. Also, 
SNO levels for specific cysteine sites and the relative amount of SNO compared to total cysteine 
levels are obtained. Among 520 identified proteins, 135 are SNO-modified proteins, and are 
mainly involved in metabolism and signal transduction pathways. After conservative criteria were 
applied, eleven SNO sites were statistically different in expression levels in the AD mice. 
OxcyscPILOT is a versatile and flexible redox proteomics method, and can be applied to study 
other oxidative PTMs of cysteine in addition to SNO.  
6.2 EXPERIMENTAL 
6.2.1 Animal Husbandry 
Fourteen-month old APP/PS-1 male mice [B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, 
stock number 005864, genetic background C57BL/6J express the chimeric mouse/human (Mo/Hu) 
APP695swe (i.e., K595N and M596L) and a mutant human PS1-dE9] and the genetically 
heterogeneous wild type (WT) (stock number 000664, genetic background C57BL/6J) were 
purchased from Jackson Laboratory. Mice were housed in the Division of Laboratory Animal 
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Resources at the University of Pittsburgh and fed standard Purina rodent laboratory chow ad 
libitum on a 12 hour light/dark cycle. APP/PS-1 (hereafter referred to as AD) and WT mice (N = 
4 for each genotype) were euthanized using CO2. Brain tissues were harvested immediately and 
stored at -80°C until further experiments. Animal protocols were approved by the Institutional 
Animal Care and Use Committee at the University of Pittsburgh.    
6.2.2 Brain Homogenization and Protein Digestion 
Brain tissues were homogenized in an ice-cold phosphate buffer saline (PBS) solution 
containing 8 M urea with 100 passes of a Wheaton homogenizer for total cysteine enrichment. For 
SNO cysteine enrichment, the same homogenization procedure was utilized except 5 mM N-
ethylmaleimide (NEM) and 5 mM EDTA were added into the buffer. Homogenate solution was 
collected, sonicated, and centrifuged at 13000 rpm for 10 minutes (4°C) to collect supernatant. For 
total cysteine samples, WT or AD proteins (100 µg, two aliquots for each genotype) containing 
equimolar mixing of four biological replicates were digested according to previously reported 
procedures (Chapter 4)38. Briefly, proteins were denatured and reduced in 50 mM Tris buffer (pH 
= 8.2), 8 M urea, and 10 mM dithiothreitol (DTT) for 1 hour at 37°C. The resulting protein mixture 
was diluted 10-fold with 20 mM Tris buffer (pH = 8.2). TPCK-treated trypsin from bovine 
pancreas (Sigma) was added to each sample in a 4% w/w enzyme/protein ratio and incubated at 
37°C overnight. For SNO samples, WT or AD proteins (four biological replicates for each 
genotype) were incubated with 50 mM NEM for two hours at room temperature in the dark 
followed by acetone precipitation. After BCA determination of protein concentrations, each 
sample (1 mg) was digested by adding 4% trypsin in 20 mM Tris buffer (pH = 8.2). Digests were 
acidified with 0.5% formic acid, cleaned using Waters Oasis HLB C18 cartridges, and lyophilized.  
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6.2.3 SNO Measurement by Slot Blot 
Brain tissues from WT (N = 4) and AD (N = 4) mice were homogenized with the presence 
of NEM and incubated with 5% SDS for 0.5 h at room temperature. BCA assay was used to 
determine protein concentrations. An aliquot of 250 µL PBS containing 0.5 µg protein was loaded 
onto a nitrocellulose membrane with a slot blot apparatus (Bio-Rad). The membranes were blocked 
with 3% (w/v) BSA solution and 5 mM NEM overnight at 4℃ and incubated with a 1:2500 dilution 
of anti-SNO antibody produced by mouse (Sigma) for 2 hours. After rinsing the membrane, anti-
mouse IgG alkaline phosphatase secondary antibody (Sigma) was added with the dilution factor 
1:5000 and incubated with the membrane for 1 hour. The membrane was washed in wash blot 
(PBS with 0.1% Tween 20) and developed using 5-bromo-4-chloro-3-indolyl phosphate (BCIP) 
(Thermo Fisher)/nitro blue tetrazolium chloride (NBT) (Sigma) colorimetric development. The 
blot was dried, scanned and slot profiles quantified using Scion Image. Statistical testing (student’s 
t-test) was performed in Origin 8.0. The entire experiment was repeated twice. 
6.2.4 Total Cysteine and SNO-cysteine Enrichment 
Enrichment of total cysteine-containing peptides were performed as previously described 
(Chapter 4)38. Briefly, tryptic digests were reduced with 5 mM DTT for 1 hour at 37°C, after 
which the samples were diluted five-fold to lower the concentration of DTT. After dilution, resin 
was largely in excess, and the concentration of DTT (< 1 mM) was lower than the minimum level 
required for efficient reduction of disulfide bonds345. Any remaining DTT, did not appear to 
significantly affect the resin’s enriching capacity, based on no observable changes to the resin’s 
physical properties after enrichment295 and previous experiments by our laboratory38. For SNO-
cysteine enrichment, tryptic mixtures were reconstituted by HEPES buffer (pH = 7.7) and 20 mM 
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sodium ascorbate was added to selectively reduce SNO. All samples were immediately mixed with 
pretreated 35 mg Thiopropyl Sepharose 6B thiol-affinity resin (Sigma) for 1.5 h incubation at room 
temperature. Unbound portion was removed by centrifugation, and the resin was washed by Tris 
buffer (pH = 8.0), 2 M NaCl, 80% acetonitrile/0.1% TFA and 1% acetic acid (pH = 2.5). 
6.2.5 On-Resin Low pH Stable-Isotope Dimethyl Labeling  
Extensively washed resin was mixed with 100 µL of 1% acetic acid solution. After that 8 
µL of 4% CH2O/
13C2H2O (98% 
2H and 99% 13C) and 8 µL of 0.6 M NaBH3CN/NaB
2H3CN (96% 
2H) were added to the sample for light and heavy labeling. The following samples were subject to 
light (i.e., (-CH3)2) dimethylation: one total cysteine sample from WT, one total cysteine sample 
from AD, two SNO samples from WT, and two SNO samples from AD. The remaining samples 
were subject to heavy dimethylation (i.e., (-13C2H3)2). Samples were incubated for 10 min while 
mixing, and terminated by adding ammonia to a final 0.2% (v/v) concentration. After 
centrifugation, the resin was washed by tetraethylammonium bromide (TEAB). 
6.2.6 On-Resin High pH TMT Tagging 
Purified resin was mixed with 75 µL TEAB, and tagged with TMT6 reagents (Thermo Scientific) 
individually according to the manufacturer’s protocol. TMT reagents 126 and 127 were used to tag total 
cysteine samples from WT and AD, respectively. SNO samples from WT were tagged with TMT6 reagents 
128 and 130, and SNO samples from AD were tagged with TMT6 reagents 129 and 131. Tagging reactions 
were quenched by 1% hydroxylamine, and the resin washed by Tris buffer (pH = 8.0). 
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6.2.7 Elution, Alkylation and Strong Cation Exchange Fractionation 
The captured and labeled cysteinyl-peptides were released by incubating the resin with 20 
mM DTT. Each elution was reacted with 80 mM iodoacetamide for 1 hour at room temperature in 
the dark. Samples were pooled into a single mixture, purified by HLB C18 cartridges, dried and 
dissolved by SCX reconstitution buffer. The pooled peptide sample was separated by a SCX spin 
tip (Protea Biosciences) according to manufacturer’s instruction. Four fractions were collected by 
eluting the sample using buffers containing 40 mM, 80 mM, 150 mM and 500 mM ammonia 
acetate (10% ACN, pH = 3). Each fraction was dried by speed-vac and reconstituted in 0.1% 
formic acid solution. 
6.2.8 LC-MS/MS Analysis 
Online desalting and reversed-phase chromatography was performed with a Nano-LC 
system equipped with an autosampler (Eksigent). Mobile phases A and B were 3% (v/v) 
acetonitrile with 0.1% formic acid and 100% (v/v) acetonitrile with 0.1% formic acid, respectively. 
Sample (5 µL) was loaded onto a trapping column (100 µm i.d. × 2 cm), which was packed in-
house with C18 200 Å 5 μm stationary phase material (Michrom Bioresource Inc) at 3 µL/min in 
3% mobile phase B for 3 min. The sample was loaded onto an analytical column (75 µm i.d. × 
13.2 cm), which was packed in-house with C18 100 Å 5 µm stationary phase material (Michrom 
Bioresource Inc.; Auburn, CA). The following gradient was used: 0-5 min, 10% mobile phase B; 
5-40 min, 10-15% B; 40-90 min, 15-25% B; 90-115 min, 25-30% B; 115-130 min, 30-60% B; 
130-135 min, 60-80% B; 135-145 min, 80% B; 145-150 min, 80-10%B; 150-180 min, 10%B. The 
LC eluent was analyzed with positive ion nanoflow electrospray using a LTQ-Orbitrap Velos mass 
spectrometer (Thermo Fisher).  
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Each SCX fraction was injected two times. The MS survey scan in the Orbitrap was 60 000 
resolution over m/z 400-1700. The top seven ions were selected for each DDA cycle. DDA 
parameters were as follows: precursor ions were isolated with a width of 2.8 m/z and normalized 
collision energy of 35%, the most intense CID fragment ion over the m/z range 400-1300 was 
selected for HCD-MS3. The HCD fragment-ion isolation width was set to 3 m/z, the normalized 
collision energy was 60%, and HCD resolution was 7500 in the Orbitrap. The maximum fill time 
for MS, MS/MS and MS3 is 500 ms, 50 ms and 250 ms, respectively. The total duty cycle timing 
is ~4 sec. 
6.2.9 Database Searching and Data Analysis 
RAW files were analyzed using the SEQUEST HT search engine with Proteome 
Discoverer 1.4 software (Thermo Fisher) and searched against the Uniprot mouse database. 
SEQUEST HT search parameters are as follows: precursor mass tolerance 15 ppm; fragment mass 
tolerance 1 Da; dynamic modifications light dimethyl/+28.031 Da (N-terminal) or heavy 
dimethyl/+36.076 Da (N-terminal), dynamic carbamidomethyl modification/+57.021 Da (Cys), 
dynamic ethylmaleimide/+125.048 Da (Cys), dynamic oxidation/+15.995 Da (Met) and dynamic 
TMT-6plex/+229.163 Da (Lys). Decoy database searching was employed to calculate false 
discovery rate and the cutoff was set to 5% to ensure high level of confidence while maintaining 
high proteome coverage287. The reporter ions (i.e., m/z 126-131) were identified with the following 
parameters: centroid with smallest delta mass, 30 ppm for reporter ion mass tolerance. Only 
peptide spectral matchings (PSMs) containing reporter ions of 126 and 127 were used for 
quantification. The median value across an individual reporter ion channel was calculated from all 
extracted PSMs, and used for normalization. SNO channels with missing signal were replaced by 
a minimal signal, and the ratios were calculated based on the summed reporter ion intensities. SNO 
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site occupancy was calculated based on reporter ion intensities of SNO to total cysteine in WT or 
AD (e.g. 128/126, 130/126 for WT and 129/127, 131/127 for AD, see formulas 1 and 2). Protein 
level ratios were used to correct SNO ratios between AD and WT. SNO ratios were then log(2) 
transformed for statistical analysis. For SNO peptides quantified by three or four biological 
replicates, permutation tests were used to calculate p-values. For SNO peptides quantified by two 
biological replicates, relative standard deviation (RSD) was calculated. P-value cutoff and RSD 
cutoff were 0.05 and 30%, respectively. Finally, a fold change cutoff of 25% (log2 (AD/WT) > 0.3 
or < -0.3) was also applied. This cutoff was determined based on the relative error of TMT reporter 
ion signals (Figure 6.1). 
𝑆𝑁𝑂 𝑠𝑖𝑡𝑒 𝑜𝑐𝑐𝑢𝑝𝑎𝑛𝑐𝑦 𝑖𝑛 𝑊𝑇 % =  
𝐼128
𝐼126 × 10
 × 100% 𝑜𝑟 
𝐼130
𝐼126 × 10
 × 100%         (1)  
𝑆𝑁𝑂 𝑠𝑖𝑡𝑒 𝑜𝑐𝑐𝑢𝑝𝑎𝑛𝑐𝑦 𝑖𝑛 𝐴𝐷 % =  
𝐼129
𝐼127 × 10
 × 100% 𝑜𝑟 
𝐼131
𝐼127 × 10
 × 100%          (2)  
6.3 RESULTS AND DISCUSSION 
SNO is a notable PTM in AD and contributes to both neuroprotective346 and 
neurodestructive processes347. In the APP/PS-1 mouse model of AD used in this work, SNO is 
detectable in brain tissue homogenates by immunoblot detection (Figure 6.2). While there is a 
trend towards higher expression levels of SNO in AD animals, there was no statistically significant 
difference based on a student’s t-test (p < 0.05). A moderate number of animals were used (N = 4) 
for this analysis and that SNO is a highly dynamic modification would contribute to this 
observation. Because the immunoblot detection represents changes across many proteins, 
assessment of the individual differences in SNO levels of proteins requires more specific detection 
methods such as immunoprecipitation or MS. 
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Figure 6.1 Correlation of reporter ions of TMT 126 and 127 tags in a) light and b) heavy channels. The 
linearity is indicated by R2 value. The distribution of TMT 126 and 127 ratios is shown in c) with a 
calculated error of 25%. 
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Figure 6.2 Histogram plot of protein S-nitrosylation (SNO) levels in brain proteins isolated from WT (N = 
4) and AD (N = 4) mice. Intensities are normalized to WT. Error bar: ±standard deviation. P-values are 
0.57 and 0.10 for trial one and trial two, respectively. 
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Here we developed an enhanced multiplexing approach “OxcyscPILOT” to detect SNO-
proteins and quantify their levels across multiple biological replicates in a single analysis (Figure 
6.3). This approach is an extension to our cPILOT methodologies36,38,54 and allows more 
specificity and multiplexing than the previously reported OxcysDML approach (Chapter 5) 39. 
Oxidative modifications to cysteine are several and overall occur at low abundance levels 
estimated to be ~1-2% across all tryptic peptides64; and SNO-modified peptides are estimated to 
be even lower. Enrichment methods are extremely valuable for increasing the detection of these 
modifications in complex tissues, such as brain homogenate. Realizing this large difference in 
concentration levels of cysteine-containing peptides and those peptides modified with SNO, we 
varied the amount of protein starting material used to detect total cysteine levels in comparison to 
SNO modifications on peptides. Additionally, to enable normalization of the protein SNO levels 
to the protein abundance, a pooled sample (0.1 mg) of either wild-type or AD tissues across the 
four biological replicates was generated. Pooled samples were subject to DTT (10 mM) in order 
to reduce all thiols, trypsin digestion, and then were enriched using a Thiol Sepharose 6B resin. 
Digested samples were dimethylated (either isotopically labeled light or heavy versions) at low pH 
conditions to tag N-termini and then labeled with TMT reagents 126 or 127 on lysine amines, for 
WT and AD samples respectively. Brain homogenate samples (1 mg) from each individual animal 
were subject to NEM (50 mM) in order to label any free thiols. Next proteins were digested and 
subject to ascorbate to specifically reduce SNO sites. In this manner, the peptides are enriched 
with the thiol resin however we note that SNO-modifications are not directly detected in the mass 
spectrum. These previously SNO-modified peptides were dimethylated (light or heavy) and tagged 
with TMT reagents 128 to 131. This on-resin dual tagging strategy allows 12 samples to be 
multiplexed in a single analysis that enables direct normalization of SNO levels to total protein  
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Figure 6.3 Schematic representation of the oxidized cysteine-selective cPILOT (OxcyscPILOT) redox proteomics workflow. For protein level 
quantification, a pooled sample of 0.1 mg of brain total protein containing an equimolar mixture proteins from four biological replicates of WT or 
AD mouse is made. Proteins are reduced by DTT and digested by trypsin. Cysteine-containing peptides are enriched by a thiol-affinity resin followed 
by on-resin low pH dimethylation using light (-C2H6) or heavy (-13C22H6) tags. After buffer exchange, resin-linked peptides are labeled with TMT 
126 and 127 reagents for WT and AD, respectively. For S-nitrosylation quantification, 1 mg brain proteins from individual WT or AD mice are 
treated with NEM to block free sulfhydryl groups. After tryptic digestion, ascorbate is added to the peptide mixture to selectively reduce SNO. 
Reduced peptides containing newly-formed sulfhydryl groups are enriched by the thiol-affinity resin and subject to similar tagging procedures as 
the total cysteine samples, except TMT 128, TMT 129, TMT 130 and TMT 131 are used for WT and AD samples from different animals, respectively. 
Enriched and tagged peptide samples are eluted from the resin and alkylated by iodoacetamide. The twelve samples are combined to a single mixture. 
This mixture is fractionated by SCX and analyzed using nanoLC-MS/MS3. Protein level ratios, SNO site occupancy in WT or AD, and SNO ratios 
between WT and AD can be calculated by using corresponding reporter ion intensities. 
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abundance and allows comparison across several biological replicates. Strong cation exchange 
fractionation coupled with reversed-phase nanoLC-MS/MS and MS3 in the HCD of the LTQ 
Orbitrap Velos was used for separation and mass analysis.  
The efficiencies of the enrichment, dimethylation, and TMT tagging are higher than 98%, 
97% and 96% based on peptide spectral matches (PSMs), respectively, and are consistent with 
previous reports by our laboratory38,39, which allows us to examine a large number of cysteine-
containing proteins and get quantitative information. The total number of cysteine-containing 
peptides identified in this experiment is 661 (520 proteins) and we detected 138 SNO peptides 
(135 SNO-proteins) (Table 6.1). Compared with the previously demonstrated cysteine-selective 
cPILOT38, OxcyscPILOT identified 170% more cysteinyl peptides with experimental conditions 
that employed half the number of SCX fractions and 2/3 less instrument acquisition time.  The 
number of SNO-modified proteins is comparable to several iodoTMT43,113,118 or label-free176 based 
quantitative studies, and higher than gel-based approaches123. In terms of quantitation, ~ 36% of 
the identified peptide spectra did not have quantitative information via HCD MS3. This is mostly 
due to the tryptic peptides with Arg on C-terminus which lack a TMT tag. In a previous study 
performed by our laboratory whereby trypsin and Lys-C were evaluated. Trypsin resulted in better 
proteome coverage compared with Lys-C36. Trypsin can also generate peptides with missed 
cleavage sites, and these peptides (up to two miscleavages) are included in the quantification for 
individual proteins. In addition, not all peptides modified by TMT can release reporter ions in MS3. 
One reason is the selection of a b-type ion in MS/MS spectra that is fragmented by HCD and 
resulting in no reporter ions. The other reason is the very low abundance of SNO modifications 
present in the samples and the MS3 acquisition is accompanied with significant loss of signal 
intensities. A dramatic increase in SNO-modifications will be possible with instrumentation such 
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Table 6.1 Summary of OxcyscPILOT results in WT and AD brain tissues. 
Total Proteins Identified 520 
Total Cysteinyl Peptides Identified 661 
Light PSMs 6574 
Heavy PSMs 8557 
WT SNO Proteins 115 
AD SNO Proteins 113 
Total SNO Proteins 135 
Total SNO Peptides 138 
Quantified SNO-modified Peptides (N = 4) 43 (6)a 
Quantified SNO-modified Peptides (N = 3) 14 (2)a 
Quantified SNO-modified Peptides (N = 2) 41 (4)b 
Quantified SNO-modified Peptides (N = 1) 40 
aNumber in bracket indicates the significantly changed SNO-modified peptides in AD compared with 
WT. A p-value cutoff (<0.05) and fold change cutoff (>25%) is applied. 
bNumber in bracket indicates the significantly changed SNO-modified peptides in AD compared with 
WT. A RSD cutoff (<30%) and fold change cutoff (>25%) is applied. 
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as the Orbitrap Fusion mass spectrometer equipped with faster MS3 acquisition and synchronous 
precursor selection technology, which takes multiple fragment ions from the MS/MS for HCD-
MS3 and results in enhanced sensitivity of reporter ions348.  
In this particular experiment, it is important to note that not all cysteine-containing peptides 
will generate SNO-related reporter ion signals. For example, the precursor peaks at m/z 617.673 
and 620.354 correspond to the triply-charged peptide G(dimethyl)VLFGVPGAFTPGC(IAM) 
SK(TMT6) of peroxiredoxin-5 (Figure 6.4a). Upon isolation and fragmentation of the y5 fragments, 
the MS3 spectrum shows only reporter ion signal at m/z 126 and 127, for the total WT and AD 
pooled samples. No measurable signal is detected for SNO of this peptide which is consistent with 
likely sulfenic acid modification of Cysteine 96 on this protein349. Because OxcyscPILOT is only 
selective to SNO modification, sulfenic acid modifications are not expected to be reduced, 
enriched and detected. The peptide with Cys96 of peroxiredoxin-5 only shows detectable signals 
in TMT channels 126 and 127. In WT and AD brain tissues, the lack of TMT signals in this peptide 
suggest that Cys96 is not SNO-modified in our experiments, or is at such low concentration and 
not detectable in our experiments, resulting in missing signals in TMT channels 128-131 for this 
peptide. There are several sample preparation steps (i.e., reduction, enrichment, digestion, 
chemical labeling, etc.) in OxcyscPILOT that present opportunities for the introduction of 
experimental error. The intensities of the reporter ions for the WT and AD pooled samples shown 
in Figure 6.4a, are very similar across the light and heavy dimethylated samples. Total TMT signals 
from all peptides detected in the WT or AD pooled samples are heavily correlated in the light (R2 
= 0.9807) and heavy dimethylation samples (R2 = 0.9867) (Figure 6.1). This indicates the 
robustness of this approach and lends to an overall error of ~25%.   
 
  
147 
 
 
Figure 6.4 Example OxcyscPILOT MS spectra. a) Pair of triply charged precursor peaks with m/z = 
617.673 and m/z = 620.354. Both peaks are isolated and fragmented by CID to generate tandem mass spectra 
to sequence the peptide, which is G(dimethyl)VLFGVPGAFTPGC96(IAM)SK(TMT6) of peroxiredoxin-5. 
The most intense peaks within the m/z range of 400-1300 in CID spectra (y5) are further selected and 
fragmented to give the HCD MS3 spectra, which are zoomed-in over the reporter ion region. Reporter ions 
of 126 and 127 represent the level of total cysteine, and the absence of reporter ion 128, 129, 130 and 131 
indicate this site is not modified by SNO. b) Pair of doubly charged precursor peaks with m/z = 619.380 
and m/z = 623.402. Both peaks are isolated and fragmented by CID to generate tandem mass spectra to 
sequence the peptide, which is A(dimethyl)VLC178(IAM)PPPVK(TMT6) of ras-related C3 botulinum toxin 
substrate 3. The most intense peaks within the m/z range of 400-1300 in CID spectra (y5) are further selected 
and fragmented to give the HCD MS3 spectra, which are zoomed-in over the reporter ion region. Reporter 
ions of 126 and 127 represent the level of total cysteine, and the signals of 128, 129, 130 and 131 indicate 
the presence of SNO on this site. 
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Several situations arise in this dataset where the detection of SNO may only exist in 
peptides detected for a single biological replicate (N = 40) or in as many as all four biological 
replicates (N = 43) of WT and AD animals (see Table 6.1 and Appendix D Tables 6.2 and 6.3). 
Stringent criteria were applied and only those peptides that were detected in any two biological 
replicates were considered for further analysis. Ideally, all peptides that are SNO-modified would 
be detected in reporter ion channels 128-131 in both light and heavy dimethylated samples. An 
example of this is shown in Figure 6.4b, for the doubly-charged precursor pair at m/z 619.380 and 
623.402 identified as A(dimethyl)VLC(IAM)PPPVK(TMT6) of the ras-related C3 botulinum toxin 
substrate 3 protein. The MS3 spectra for both light and heavy y5 fragments show low intensity of 
detectable ion signals across reporter ions for all four biological replicates.  
A total of 115 SNO-modified proteins were identified in WT mice and 113 SNO-modified 
proteins were identified in AD mice (Appendix D Table 6.1). Ninety-three proteins had detectable 
SNO-modified peptides in both WT and AD samples, while 22 and 20 SNO- modified proteins 
are exclusive for WT and AD, respectively. A total of 135 SNO-modified proteins are involved in 
a range of biological pathways such as cell cycle, immune system, homeostasis, neuronal system, 
and vesicle-mediated transport (Figure 6.5).  A majority of SNO-modified proteins are involved 
in metabolism (32 proteins) or signal transduction (29 proteins). An interesting example is L-
lactate dehydrogenase, which is only present in WT but not in AD (Appendix D Table 6.1). The 
SNO modification of L-lactate dehydrogenase in WT tissue has been reported for normal 
enzymatic function in metabolism350. The absence of this modification in AD brain may be 
indicative of dysregulated energy metabolism in disease. These results indicate that SNO is a very 
dynamic modification, and are highly consistent with other reports in the literature123,176. A total 
of 56 SNO-modified proteins (Appendix D Table 6.1) were also frequently reported in previous 
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Figure 6.5 Pathway analysis of 135 SNO-proteins identified in WT and AD mouse brain tissues using 
Reactome database (http://www.reactome.org/). The pie chart shows primary pathways that SNO-proteins 
are involved and the number of proteins in each pathway. SNO-proteins involved in metabolism and signal 
transduction are further broken down into categories as shown in histogram plots. 
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AD studies, such as glial fibrillary acidic protein123,171,176, heat shock cognate 71 kDa protein123,176, 
elongation factor 2176, sarcoplasmic/endoplasmic reticulum calcium ATPase 2176, glyceraldehyde-
3-phosphate dehydrogenase123,176, triosephosphate isomerase123,171,176, fructose-bisphosphate 
aldolase A123,176, dynamin-1-like protein351, 2',3'-cyclic-nucleotide 3'-phosphodiesterase176,352, ras-
related C3 botulinum substrate 3176,353 and ADP/ATP translocase 1176,353. In addition 79 SNO-
modified proteins (Appendix D Table 6.1) were identified for the first time in this work. It is 
important to observe the number of cellular signaling pathways, such as Pho GTPases, Wnt, NGF 
that SNO contributes to which suggests this oxidation status of cysteine is critical for normal 
cellular signaling (Figure 6.5). Network analysis of 135 SNO-modified proteins in WT and AD 
brains using STRING (version 10) shows that the modified proteins are enriched in some basic 
molecular pathways such as citrate cycle, 2-oxocarboxylic acid metabolism, oxidative 
phosphorylation, glycolysis/gluconeogenesis, Huntington's disease and axon guidance (Figure 6.6). 
These pathways are zoomed-in to show the differences of the network patterns of SNO-modified 
proteins in WT and AD. Although most of SNO-modified proteins widely participate in both WT 
and AD, some pathways containing abnormal SNO are observed. For example in the pathway of 
glycolysis/gluconeogenesis, triosephosphate isomerase (Tpi1), glucose-6-phosphate isomerase 
(GM1840) and alcohol dehydrogenase 1 (Adha) have SNO modifications in WT but not AD. A 
lower p-value (3.29E-8 v.s. 2.01E-4) and a higher gene number (8 v.s. 5) indicates that SNO is 
more enriched in WT than AD in glycolysis/gluconeogenesis pathway. The different SNO 
involvement in carbohydrate metabolism in AD mice brain was also reported in a previous study176, 
and is consistent with the finding of altered glucose tolerance and metabolic changes in PET 
analyses of AD patients354. While previous studies mainly focused on proteins with only SNO 
modification in AD123,176, our data also suggests the absence of SNO modification may be 
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Figure 6.6 Interaction network of 135 SNO-modified proteins identified in WT and AD mouse brain tissues. 
Some example KEGG pathways are circled by dished ovals and zoomed-in to show the differences of the 
network patterns between WT and AD. The p-value and number of proteins in each pathway are provided. 
Network analysis was performed using STRING (version 10) with confidence view and confidence score 
of 0.700. No text mining was used. Uniprot accession numbers are uploaded to STRING and return as gene 
symbols. 
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important for disease pathogenesis in AD. Generally SNO-modified proteins in this study have a 
trend of increased levels in AD compared to WT (Figure 6.1 and Table 6.2). 
There are several challenges for quantifying SNO-modified proteins in disease. One is 
cysteine PTM levels can be affected by protein expression changes. In order to take this into 
consideration, multiple experiments must be performed. For example, in a redox proteomic study 
using duplex ICAT reagents, because there are no more channels available for protein 
quantification, a separate experiment using isotopic dimethyl labeling is employed to provide 
protein abundance data101. Even in our OxcysDML approach, two experiments were performed to 
obtain total cysteine oxidation levels and protein abundance information based on cysteine-
containing peptides39. Two, there is a large difference (roughly two to three orders of magnitude65) 
between total peptide and SNO-modified peptide abundance. This means non-cysteinyl peptides 
can cause significant matrix effects and suppress the detection of SNO-modified peptides, thus 
decreasing sensitivity. Solutions are to use the total cysteinyl peptides to represent the protein for 
protein abundance information, and to increase the sample starting material of SNO-modified 
samples by a factor of 10. The latter helps facilitate reducing the abundance differences, so that 
both total cysteinyl and SNO-modified peptides can be detected in a single experiment. This design 
was successfully been utilized with iodoTMT118. The throughput of iodoTMT is greater than ICAT 
or OxcysDML methods but still requires multiple experiments to measure across biological 
replicates118. Due to the enhanced multiplexing ability of OxcyscPILOT, the total cysteinyl 
peptides which represent the protein abundance in each genotype and also SNO levels from four 
biological replicates of each genotype can be detected in a single run. After proteins were filtered 
based on having SNO-modifications detectable in at least two biological replicates, the SNO levels 
were normalized to the total protein abundance level (see Experimental). Following normalization, 
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Table 6.2 Quantified SNO sites with significant changes in levels between WT and AD. 
              
Protein Name 
Uniprot 
Acc. No. 
Peptide Sequence 
Modified 
Site 
Protein 
Level 
AD/WT 
Relative 
SNO Site 
Occupanc
y in WTa 
Relative 
SNO Site 
Occupan
cy in ADa 
SNO log(2) Fold Change AD/WT 
in Each Biological Replicate 
Average 
SNO 
log(2)  
Fold 
Change  
AD/WTb 
Statistics Ne 
1 2 3 4 
Septin-5  Q9Z2Q6 ADCLVPSEIRK C193 0.895 0.18% 0.30% 1.868 0.528 0.576 0.246 0.804 
p-
valuec 
0.0001 4 
ADP/ATP translocase 1 P48962 EFNGLGDCLTK C160 0.850 0.73% 1.05% 0.410 0.330 0.176 1.325 0.560 0.0001 4 
Myc box-dependent-
interacting protein 1 
O08539  AAPQWCQGK C186 0.906 0.35% 0.47% 0.979 0.045 0.415 0.341 0.445 0.0050 4 
Isocitrate dehydrogenase 
[NAD] subunit 
Q91VA7 GVIECLK C184 0.936 0.29% 0.38% 0.657 0.123 0.644 0.092 0.379 0.0112 4 
Ras-related C3 botulinum 
toxin substrate 3 
P60764 AVLCPPPVK C178 0.929 0.48% 0.60% 1.073 0.006 0.020 0.362 0.365 0.0099 4 
14-3-3 protein gamma P61982 NCSETQYESK C112 1.152 7.18% 5.00% -0.626 -0.023 -0.967 -0.549 -0.541 0.0001 4 
Glutamine synthetase P15105  TLDCEPK C49 0.911 0.22% 0.29% 0.200 0.742 0.520 N.A. 0.487 0.0001 3 
Myelin proteolipid protein P60202 VCGSNLLSICK C220 1.099 2.29% 0.89% -2.385 -2.091 -0.826 N.A. -1.767 0.0001 3 
Citrate synthase, mitochondrial Q9CZU6  FRGYSIPECQK C101 0.988 0.07% 0.42% 2.658 2.434 N.A. N.A. 2.546 
RSDd 
0.1097 2 
14-3-3 protein zeta/delta P63101 ACSLAK C188 0.515 27.86% 54.41% 0.868 1.072 N.A. N.A. 0.970 0.0998 2 
2',3'-cyclic-nucleotide 3'-
phosphodiesterase 
P16330  TAWRLDCAQLK C157 1.149 0.45% 0.66% 0.515 0.581 N.A. N.A. 0.548 0.0326 2 
Citrate synthase, mitochondrial Q9CZU6 GYSIPECQK C101 0.933 0.21% 0.30% 0.310 0.731 N.A. N.A. 0.520 0.2045 2 
aRelative SNO site occupancy percentage is calculated based on normalized reporter ion intensities of SNO to total cysteine in WT or AD (e.g. 128/126, 130/126 for WT and 129/127, 131/127 for AD, 
see formulas 1 and 2). 
bSNO fold changes are corrected by protein level abundance change. A fold change of at least 25% is applied to determine significance (log2(AD/WT)>0.3 or <-0.30). 
cP-value cutoff (<0.05) is applied for group of N = 4 and 3. 
dRSD cutoff (<30%) is applied for group of N =2 . 
eNumber of biological replicates quantified. 
  
154 
 
permutation testing38,327 was done in order to determine which SNO-modified peptides were 
statistically different between WT and AD samples. Table 6.2 provides a list of 11 proteins that 
were statistically different in SNO modification level in AD compared to WT mice. Most of these 
proteins have SNO site occupancy below 1%, except for 14-3-3 proteins. The high SNO-
modification levels (28-54%) of 14-3-3 proteins may be linked to the binding nature of 14-3-3 
proteins to microtubule-associated protein tau, whose hyperphosphorylation results in the 
formation of amyloid plaques and neurofibrillary tangles in AD355. The low SNO site occupancy 
percentage data in Table 6.2 suggests the room for further improvement. In the sample preparation 
we used a 10-fold higher sample amount for SNO enrichment. However, if the tissue amounts 
permit, our data suggests a 100-fold SNO loading amount would be a better choice. SNO levels 
are variable amongst mice of the same genetic background, leading to differences in the AD/WT 
ratios detected. For some peptides, the measured SNO ratios are highly diverse. We mainly 
attribute this to the dynamic nature of SNO modification across different animals, and used 
permutation testing for statistical analysis. Permutation testing is an ideal statistical test for 
proteomic data to calculate p-values without further adjustment327. However the p-value only 
indicates the mathematical probability of the null hypothesis (H0: μ= 0, no significant change), 
regardless of the degree of change. Thus we also applied a 25% SNO ratio cutoff to look for the 
peptides with the significant changes of SNO modification. As we can see from Table 6.2, most 
of them have increased SNO levels in AD, which is consistent with previous studies123,176. A few 
of these proteins have been previously identified as SNO-modified in AD: ADP/ATP translocase 
1176,353, ras-related C3 botulinum toxin substrate 3176,353, 14-3-3 protein zeta/delta123, glutamine 
synthetase123,176, myelin proteolipid protein176, citrate synthase176 and 2',3'-cyclic-nucleotide 3'-
phosphodiesterase176. Furthermore, specific modification sites such as C160 for ADP/ATP 
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translocase 1 and C178 for ras-related C3 botulinum toxin substrate 3 have been quantified as 
significantly SNO-modified in AD mouse brain tissue over WT, which are consistent with a 
relevant proteomic study176. These two proteins have been linked with AD and reviewed in 
detail356,357. It must be noted that the whole brain tissue is used in this study. This is unlike some 
other studies using specific cell types or brain regions. For example, one report studied the SNO-
modified proteins in different AD brain regions (hippocampus, substantia nigra and cortex)123, and 
another study focused on the synaptosome of APP mouse176. Brain is a highly heterogeneous organ 
and different portions exhibit various changes in AD. Using the entire homogenate of the brain 
may cause misrepresentation of the changes in specific regions or cells in AD. Because there is 
some literature precedence for SNO-modified proteins in brain homogenate123,176, we chose this 
sample to benchmark our novel method. A total of 50 SNO-modified proteins identified by this 
work were also reported in these two studies123,176 (Appendix D Table 6.1). It would be interesting 
to study SNO-modified proteins at the level of different cells (e.g., microglia, neurons) or brain 
regions (e.g., cortex, striatum) and compare to entire homogenate. 
Characterization of specific cysteine reversible modification (e.g., SNO) from complex 
samples is challenging due to its low abundance and labile nature. We believe a desirable redox 
proteomic strategy to study cysteine PTM should be site-specific, sensitive, versatile, unbiased and 
highly multiplexed. OxcyscPILOT is one such strategy. First, unlike gel-based approach, in which 
the site information of cysteine PTM is generally unavailable, OxcyscPILOT is able to localize 
cysteine PTM on the protein primary sequence, and link this information to protein structure and 
function for biological interpretation. This is a limitation however when multiple cysteinse are 
present on the same peptide and it is not possible to determine which site was initially modified. 
Because NEM blocking was employed prior to reduction and enrichment, peptides observed with 
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multiple cysteines (e.g. ACNCLLLK, Appendix D Table 6.2) should have multiple SNO sites. 
Second, OxcyscPILOT has desirable sensitivity in terms of its proteome coverage and its ability 
for isolation and MS3 quantification of SNO-modified peptides with ~1% abundance. We attribute 
this to the efficient enriching ability of the thiol-affinity resin, and the integration of all chemical 
labeling steps on the resin. Although many sample preparation steps are involved in the 
OxcyscPILOT workflow, repeated sample extraction and cleanup steps are not needed. This can 
potentially minimize sample loss and improve sensitivity. Third, we used SNO here to demonstrate 
the application of OxcyscPILOT methodology. In fact this method is versatile to follow other SNO 
modifications. For example, by simply changing the selective reduction reagent, different types of 
cysteine reversible modifications, such as S-glutathionylation or sulfenic acid, can be characterized 
in the same method. Fourth, the number of multiplexing channels can also be expanded by utilizing 
triplex dimethylation or ten-plex TMT reagents. Fifth, OxcyscPILOT is an unbiased proteomic 
approach because protein ratios are simultaneously determined and used for SNO-peptide 
normalization. Sixth, the relative site occupancy of site-specific SNO can be calculated, which is 
helpful to screen the proteins that are susceptible to nitric oxide attack, e.g., 14-3-3 proteins in this 
study.  
6.4 CONCLUSIONS 
A novel quantitative proteomics approach to quantify endogenous SNO from multiple 
complex samples, OxcyscPILOT, is presented in this work. Endogenous levels of SNO are very 
low abundant and require high sample starting amounts or very sensitive detection methods in 
combination with enrichment strategies. This enhanced multiplexing technique for cysteine PTM 
quantification enables enrichment and tagging of twelve samples for unbiased detection of SNO-
modified proteins. This was extremely useful for measuring changes across multiple biological 
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replicates and for measuring total protein abundance levels for data normalization. Because all 
chemical reactions are coupled with affinity purification on the solid phase resin, the entire 
workflow exhibits desirable efficiency in terms of cysteinyl proteome coverage and cysteine PTM 
isolation. We demonstrate this method to study SNO using brain tissues from an AD mouse model, 
and much of the biological changes are consistent with previous findings in AD. In particular, 
SNO-modified proteins are heavily involved in normal cellular signaling processes and 
metabolism, amongst other functions such as axon guidance, vesicle-transport and immune system 
response. We believe this technique can be directly applied to investigate other types of cysteine 
oxidative modifications by simply changing the sample preparation conditions. Furthermore, the 
sensitivity can be improved by employing SPS MS3 acquisition, and the multiplexing capabilities 
can be enhanced to 20 or 24 samples using TMT10-plex or DiLeu isobaric tagging reagents.  
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7.0 CONCLUDING REMARKS AND FUTURE DIRECTIONS 
7.1 SUMMARY 
This dissertation presented mass spectrometry (MS)-based studies of protein oxidative 
modifications. The following is a brief summary for each chapter.  
Chapter 2 reviewed protein post-translational modifications (PTMs) induced by oxidative 
stress, such as cysteine reversible modifications and protein carbonylation. More emphasis was on 
the biological significance of cysteine oxidative PTMs and current proteomic tools for 
investigation, including the widely used enrichment and isotopic labeling techniques. Oxidative 
stress plays important roles in aging and neurodegenerative diseases, and the relevant applications 
of redox proteomics in disease studies were discussed.  
Chapter 3 presented a study of mapping protein oxidative modifications through MS 
techniques. A model protein was oxidized by metal-catalyzed oxidation, and combined top-down 
and bottom-up MS methods were developed and utilized to localize different types of oxidative 
modifications, such as hydroxylation, carbonylation, deamidation and decarboxylation.  
Chapter 4 demonstrated novel multiplexing approaches to isolate and quantify the 
cysteinyl proteome. Because most proteins contain cysteine, cysteine-selective proteomics 
methods can quantify protein expression and also simply the samples. Two different approaches 
were developed in this chapter, cysteine-selective dimethylation (CysDML), a duplex method 
using inexpensive dimethylation and cysteine-selective combined precursor isotopic labeling and 
isobaric tagging (CyscPILOT), a 12-plex technique using combined dimethylation and iodoTMT 
tagging. To facilitate sample processing, dimethylation reactions were performed on the solid 
phase resin. CysDML was accurate over a dynamic range of one order of magnitude with RSD ~ 
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20%. Both methods were used to study the liver proteome of APP/PS-1 mice, an Alzheimer’s 
disease (AD) model mouse. CysDML and CyscPILOT delivered consistent quantitative data, and 
in total more than 2000 proteins were identified. Differentially-expressed proteins in AD liver are 
involved in carbohydrate and lipid metabolism, which correlates well with other AD studies. 
Cysteine-selective proteomics methods provide the ability to study cysteine PTMs due to 
the enriching capability. Chapter 5 demonstrated such one example using oxidized CysDML 
(OxcysDML). OxcysDML was an accurate but inexpensive method for cysteine redox proteomics, 
and was applied to characterize the redox status of liver proteome of APP/PS-1 mice in AD. This 
work discovered dysregulated lipid metabolism in AD liver tissue associated with elevated 
oxidative stress. 
Chapter 6 further developed and optimized the demonstrated CyscPILOT approach 
(Chapter 4) and achieved quantification of S-nitrosylation (SNO) in tissues (e.g., OxcyscPILOT). 
OxcyscPILOT employed ascorbate reduction to capture SNO peptides, and solid-phase TMT 
tagging to improve proteome coverage. By a single run, OxcyscPILOT was able to quantify 
endogenous SNO from four biological replicates. OxcyscPILOT was applied to the brain proteome 
of the APP/PS-1 mice to study the expression of protein SNO in AD. A 24-hour LC-MS/MS3 run 
identified 135 SNO-modified proteins, which mostly participated in metabolism and signal 
transduction. OxcyscPILOT had eight times higher efficiency compared with CyscPILOT method 
(based on the number of identified peptides by the same instrumental time) and had sensitivity to 
isolate endogenous SNO. OxcyscPILOT successfully expanded sample throughput in cysteine 
PTM quantification. 
In summary, novel methods for studying oxidative modifications were presented in this 
dissertation. The utilization of protein enrichment and tagging chemistry created diverse 
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workflows for quantification of total cysteine, oxidized cysteine and specific cysteine PTM by 
multiplexing either two or twelve samples in one experiment. These workflows were built based 
on simple chemical reactions and commercially available reagents, and could be adapted in any 
laboratory to save costs of isotopic materials or instrument time for studying cysteinyl proteome 
and oxidative modifications in different biological systems. 
7.2 FUTURE DIRECTIONS 
7.2.1 Improve the OxcyscPILOT Methodology: Sample Preparation and Data Acquisition 
A typical 12-plex OxcyscPILOT experiment in Chapter 6 requires ~7 days for sample 
preparation. Multiple reaction steps were performed in spin column for each sample. Repeated 
resin washes by flash centrifugation were required before and after reactions to minimize non-
specific binding, which was time-consuming and labor-intensive. It would be even more 
challenging if more samples are multiplexed using TMT 10-plex or DiLeu 12-plex reagents41,286,358. 
This means optimized sample preparation should focus on improving automation and shortening 
sample preparation time. One potential solution is to design a specialized well plate to handle 
samples in a multiplexing manner. This type of well plate has not been commercially available. 
The ideal well plate should contain a top cover and a bottom cover (similar to the spin column’s 
top and bottom cap), so the plate can switch between incubation and washing modes. A collection 
system with different volume capacity under the plate is also needed so flow through can be easily 
collected after centrifugation by a plate spinner (Figure 7.1). This system will provide the ability 
to perform multiple chemical reactions and resin washes without manual handling, incorporating 
more samples in one experiment, and ultimately decreasing sample’s variance and improving 
data’s quality. 
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Figure 7.1 Optimization of OxcyscPILOT sample preparation. a) Current sample preparation used in 
Chapter 6. b) Sample preparation can be improved by using well plate. 
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OxcyscPILOT presented in Chapter 6 utilized MS3 for quantification. In a typical DDA 
scan the most intense ion of MS/MS spectra within an m/z range was isolated and fragmented by 
HCD MS3 to release reporter ions. MS3 was important for better accuracy however with some 
tradeoffs. First, the cPILOT methodology required that TMT tag was only attached to lysine 
residue on peptide C-terminus. This means MS3 spectra may not contain reporter ion signals if it 
was b-type ion that was isolated and fragmented instead of y-type ion. Second, MS3 scan had lower 
reporter ion sensitivity and higher likelihood of missing channels compared to MS/MS. In addition, 
SNO was naturally present at very low abundance (< 1% on peptide level). As a result, a large 
number of empty SNO channels were observed in MS3 spectra. These limitations could be 
potentially solved by employing MultiNotch MS3 method, in which multiple MS/MS fragment 
ions are co-isolated and co-fragmented299. This technique can significantly increase sensitivity, 
dynamic range and ultimately generate more high-quality quantitative data (Figure 7.2). This 
technique is renamed as synchronous precursor selection (SPS) and is equipped on Thermo’s 
recent Orbitrap Fusion Tribrid MS and allows isolation of up to 20 precursor ions for MSn scan348. 
Moreover, compared with Orbitrap Velos MS, Orbitrap Fusion increases solving power and scan  
rate by 5-fold and 20-fold, respectively359. All of these can benefit the high-throughput 
quantification of low abundant PTMs using cPILOT methodology. 
7.2.2 Use OxcyscPILOT to Enrich and Quantify Other Types of PTMs 
Chapter 6 demonstrated OxcyscPILOT, an enhanced approach to quantify SNO from 
tissue samples. This methodology is expected to expand its utility in targeting a broad range of 
PTMs by employing different chemistry.  
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Figure 7.2 Improvement of HCD MS3 data quality by using SPS technique. Compared with standard MS3 
method used in Chapter 6, SPS technique can generate a) more spectra containing reporter ions and b) 
spectra with enhanced reporter ion intensities. 
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As reviewed in Chapter 2, cysteine is subjected to a number of reversible modifications, 
and the modification of interest can be isolated by selective reductions. OxcyscPILOT provides 
the ability to multiplex many samples in a single run, which makes it ideal to investigate several 
cysteine reversible modifications simultaneously. For example, by using TMT 10-plex reagent, 
OxcyscPILOT method is able to quantify four different cysteine PTMs (total cysteine oxidation, 
S-nitrosylation, S-glutathionylation and sulfenic acid) between two biological conditions (e.g., WT 
v.s. AD) (Figure 7.3). Similar to Chapter 6, the enrichment of total cysteinyl peptides enables the 
correction of PTM ratios to protein abundance changes, and more biological replicates can be 
incorporated due to the cPILOT tagging methodology. This study can benefit our understanding 
of the redox status of each cysteine residue in physiological and pathological conditions, and allow 
one to explore the interplay between different cysteine modifications. 
In addition to targeting various cysteine oxidations, OxcyscPILOT can be adapted in 
quantifying some other types of PTMs, such as carbonylation, phosphorylation, and glycosylation. 
As reviewed in Chapter 2, carbonylation is a desirable biomarker of protein oxidative damage, 
and has implicated in various diseases61. Phosphorylation is attachment of a phosphoryl group 
(PO3
2-) on serine or threonine (in most cases) and important for cell signaling360. Glycosylation, 
on the other hand, is a covalent linkage of glycan to protein asparagine, serine or threonine residues. 
Glycoproteins are involved in many physiological functions and potentially important biomarkers 
of disease and therapeutic targets361. Studying these PTMs on the proteome scale by MS has been 
challenging mostly due to the low natural occurrence rate. Although current MS techniques can 
detect biomolecules as low as high-femtomole/low-picomole levels, the complex matrices 
significantly suppress the PTM signals and severely limit the actual sensitivity362. Towards this 
end, many enriching techniques were developed, including biotin hydrazide363, immobilized metal  
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Figure 7.3 Analysis of various types of cysteine modifications using OxcyscPILOT methodology. 
  
m/z
126
127a&b
128a&b
129a&b
130a&b
131
Channel 126 127a, 127b 128a, 128b 129a, 129b 130a, 130b 131
Genotype WT WT, AD WT, AD WT, AD WT, AD AD
Selectivity Total Cysteine
Total Oxidized 
Cysteine
S-nitrosylation S-glutathionylation Sulfenic Acid Total Cysteine
Thiol 
Blocking
N.A. NEM NEM NEM NEM N.A.
Reductant DTT DTT Ascorbate Glutaredoxin Arsenite DTT
m/z
126
127a&b
128a&b
129a&b
130a&b
131
Light Heavy
  
166 
 
affinity chromatography (IMAC)360 and solid hydrazide361 for isolation of protein carbonylation, 
phosphorylation and glycosylation, respectively. These techniques have been coupled with stable 
isotopic labeling techniques (e.g., SILAC, dimethylation, TMT, iTRAQ, see Chapters 1 and 2) to 
quantitatively analyze PTMs on the whole proteome293,325,364,365. The cPILOT methodology 
requires peptide tagging by both isotopic and isobaric tags for enhanced multiplexing, and can be 
utilized for studying protein carbonylation, phosphorylation and glycosylation. The general 
strategies are listed in Table 7.1. Due to the diverse chemical natures of PTMs, there will be some 
differences in sample preparations. For example, carbonylated proteins requires being derivatized 
by biotin tag at the beginning of sample preparations. Also oxidation of glycosylated peptides is 
required before affinity capture. It must be noted that solid phase hydrazide is compatible with 
dimethylation reaction293. This implies that the cPILOT tagging of glycosylated peptides may be 
performed on the solid phase. In Chapter 6 the values of performing solid phase peptide reactions 
have been highlighted. We suggest further testing the possibilities of solid phase tagging in 
isolation and quantification of protein carbonylation, phosphorylation and glycosylation. 
7.2.3 Alzheimer’s Disease and Protein Oxidative Modifications 
Chapters 4 - 6 characterized cysteine and oxidative PTMs in liver and brain tissues in 
APP/PS-1 mouse model and demonstrated the utility of the novel proteomics methods in disease 
study. To summarize, the liver proteome study in Chapters 4 and 5 presented novel findings of 
cysteinyl proteome in the peripheral organ in AD. The dysregulated energy metabolic pathways in 
AD liver result in lowered glucose metabolism and elevated lipid metabolism. Elevated lipid 
metabolism generates more ketone bodies in liver, which enter into the blood, pass the blood-brain 
barrier (BBB) and serve as an alternative energy source for brain in AD. As a result, more radical 
oxygen species (ROS) are produced by β-oxidation of fatty acid molecules and elevated oxidative  
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Table 7.1 General procedures of studying some other PTMs using cPILOT methodology. 
 Carbonylation Phosphorylation Glycosylation 
1. Pre-derivatization Biotin Hydrazide N.A. N.A. 
2. Proteolysis Trypsin Trypsin Trypsin 
3. Isotopic Labeling Dimethylation Dimethylation Dimethylation 
4. Isobaric Tagging TMT TMT TMT 
4. Post-derivatization N.A. N.A. Oxidation 
5. Affinity Capture Avidin Chromatography IMAC Solid Phase Hydrazide 
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stress as well as more oxidized proteins in AD liver are observed. In Chapter 6, novel proteins 
containing differential SNO in AD brain were identified. Therefore, the future directions can focus 
on the following three aspects.  
First, integrate proteomics data with metabolomics data to investigate the larger cellular 
networks in AD. Enzymatic proteins regulate biological processes through the biotransformation 
of specific substrates to products. The incorporation of metabolome data may provide another layer 
of information and provide insights into AD. Gonzalez-Dominguez et. al. have conducted such a 
metabolomics study of liver tissue366 using APP/PS-1 mouse so a deep data analysis is necessary 
to correlate the findings of multi “omics”. For example, the decreased levels of hypotaurine and 
taurine by metabolomics study suggested the lowered level of antioxidants in AD liver tissue, 
which fits well with the following results in Chapters 4 and 5: 1) the level of superoxide dismutase 
in AD was significantly decreased; 2) the overall oxidative stress was elevated in AD liver tissue; 
3) some proteins involved in lipid metabolism were significantly oxidized in AD. These consistent 
conclusions indicate the important roles of oxidative stress in the liver of AD. Also metabolomics 
discovered differential expression of many energy metabolites, which agree with the changes of 
proteins involved in carbohydrate and lipid metabolism.  
Another direction is the determination of the chemical structures that exhibited differential 
cysteine oxidation in Chapter 5. Redox proteomics method (OxycsDML) in Chapter 5 provided 
the ability to screen cysteine oxidations with significant changes in AD liver tissue, however the 
tradeoff was the loss of structural information of cysteine PTM. This problem can be potentially 
solved by applying immunoprecipitation of proteins followed by non-reducing digestion and MS 
identification249,367,368. For example, the peptides containing disulfide bonds can generate b- and 
y-type ions with characteristic mass shifts in MS/MS369. Further validations can also be done by 
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measuring the enzyme activities before and after oxidation to access the effects of cysteine 
oxidations61,107. A series of biophysical characterizations, such as light scattering, circular 
dichroism and surface plasmon resonance are also suggested to examine the potential changes of 
protein structures due to cysteine oxidation370. Protein modeling and simulating programs, which 
predict the oxidation-susceptible cysteine, may be utilized with experiments to identify possible 
oxidation sites371. Cysteine is involved into a number of bioactivities through formation of PTMs 
(reviewed in Chapter 2). Understanding the cysteine biochemical reactions in AD liver may help 
discover the potential redox biomarkers for diagnostics, and identify the novel cellular signaling 
in AD.  
Third, based on the above findings, novel therapeutic treatments of AD may be developed 
by targeting proteins with significant changes of redox status. Due to the important roles of 
oxidative stress in AD, antioxidant such as N-acetylcysteine had been explored as an AD treatment, 
which can increase glutathione levels and scavenge free radicals372. Proteomics studies can identify 
proteins associated with a disease and suggest target therapies for lower side effects and higher 
treating efficiency373. Chapter 6 identified more than 100 SNO-modified proteins in AD brain. 
Some SNO-modified proteins have well demonstrated biological effects in AD. For example, SNO 
of dynamin-1-like proteins and glyceraldehyde-3-phosphate dehydrogenase are related to synaptic 
damage and neuronal cell death, respectively192. These protein targets can be used as a start to 
explore novel treatments. For example the 3D protein structures can provide information so a 
specially designed small molecule can fit the SNO-modified site and inhibit its oxidation374. Also 
biopharmaceutical drugs (e.g., antibody-drug conjugate) can be explored for targeting proteins of 
interest375. Large-scale screening of target proteins as well as drug candidates is the essential. 
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APPENDIX A 
Appendix A Figure 3.1 MS/MS spectra of oxidatively-modified peptides identified in Table 
3.2.…………………………………………………………………………………….Attached CD 
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APPENDIX B 
Appendix B Table 4.1 List of proteins identified in CysDML experiment.…….....….Attached CD 
Appendix B Table 4.2 List of peptides identified in CysDML experiment.……....… Attached CD 
Appendix B Table 4.3 List of proteins identified in cPILOT experiment…….…...… Attached CD 
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APPENDIX C 
Appendix C Table 5.1 Protein ratios used as the normalization factors for OxcysDML 
data.……………………………………………………………………………...…....Attached CD 
Appendix C Table 5.2 Peptides identified in OxcysDML experiment…....…....…… Attached CD 
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APPENDIX D 
Appendix D Table 6.1 List of SNO-modified proteins identified by OxcyscPILOT…Attached CD 
Appendix D Table 6.2 List of SNO-modified peptides that were quantified by four, three or two 
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